HECTRE failed to produce a cdf for the PDF located at /Users/jan535/code/HECTRE/hectre/tests/test_data/292_bissonnette_2019.pdfdata

HECTRE Performance Evaluation Report¶

No description has been provided for this image

297_guttman_2019¶

Control rows matched by test output: 5 of 100

Literature data accuracy: 78.20%

Clinical data accuracy: 4.26%

Clinical data accuracy (drop unmatched): 85.13%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
upadacitinib 30 oncedaily easi90 16 4 c72t4 test Double-Blind TRUE Upadacitinib Janus kinase inhibitor 30 mg Oral Once Daily 42 42 21 ITT NRI NRI 16 WK EASI-90 Percent 50.0 Percent 52 39.9 YR
30.0 qd easi90 16 72 c72t4 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 21.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 90 50.0 percent 95%CI 35.177 64.82300000000001 52.0 39.9 YR
similarity 100 100 100 98 67 100 100 17 0 100 67 67 100 6 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 67 100 100
15 qd easi75 16 0 c57t0 test Double-Blind TRUE Upadacitinib Janus kinase inhibitor 15 mg Oral QD 42 42 32 ITT Cochran-Mantel-Haenszel test, adjusted for stratum (geographic region) NRI 16 WK EASI-75 Percent 76 percent 95% CI 61 87 71 38.5 YR
15.0 qd easi75 16 57 c57t0 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 22.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 75 52.4 percent 95%CI 41.898 67.194 71.0 38.5 YR
similarity 100 100 100 98 67 100 100 100 0 100 67 33 100 59 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 0 100 100 100 25 25 100 100 100 100 100 100 67 100 100
30 oncedaily easi75 16 2 c52t2 test Double-Blind TRUE Upadacitinib Janus kinase inhibitor 30 mg Oral Once Daily 42 42 32 ITT NRI NRI 16 WK EASI-75 Percent 76 Percent 95% CI 61 87 52 39.9 YR
30.0 qd easi75 16 52 c52t2 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 29.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 75 69.0 percent 95%CI 55.336 83.4 52.0 39.9 YR
similarity 100 100 100 98 67 100 100 17 0 100 67 33 100 6 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 33 100 100 100 25 33 100 100 100 100 100 100 67 100 100
15 qd easi50 16 1 c37t1 test Double-Blind TRUE Upadacitinib Janus kinase inhibitor 15 mg Oral QD 42 42 26 ITT Cochran-Mantel-Haenszel test, adjusted for stratum (geographic region) NRI 16 WK EASI-50 Percent 61.9 Percent 95% CI 46.4 75.8 71 38.5 YR
15.0 qd easi50 16 37 c37t1 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 30.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 50 71.4 percent 95%CI 57.708 85.376 71.0 38.5 YR
similarity 100 100 100 98 67 100 100 100 0 100 67 0 100 59 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 100 100 100 20 60 100 100 100 100 100 100 67 100 100
30 oncedaily easi50 16 3 c32t3 test Double-Blind TRUE Upadacitinib Janus kinase inhibitor 30 mg Oral Once Daily 42 42 30 ITT Cochran-Mantel-Haenszel test, adjusted for stratum (geographic region) NRI 16 WK EASI-50 Percent 71.4 percent 95% CI 55.4 84.3 52 39.9 YR
30.0 qd easi50 16 32 c32t3 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 35.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 50 83.3 percent 95%CI 71.937 94.466 52.0 39.9 YR
similarity 100 100 100 98 67 100 100 17 0 100 67 33 100 59 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 100 100 100 20 40 100 100 100 100 100 100 67 100 100
7.5 qd scorad 8 92 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 39.0 ITT ANCOVA LOCF 8 WK SCORAD Mean -35.4 5.53 SE 67.0 41.5 YR
16 93 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 39.0 ITT ANCOVA LOCF 16 WK SCORAD Mean -32.5 5.66 SE 67.0 41.5 YR
0 91 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 ITT ANCOVA LOCF 0 WK SCORAD Mean 0.0 67.0 41.5 YR
easi90 8 80 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 4.0 ITT Cochran Mantel Haenszel Test NRI 8 WK EASI 90 9.5 percent 95%CI 0.198 17.985000000000003 67.0 41.5 YR
4 79 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 5.0 ITT Cochran Mantel Haenszel Test NRI 4 WK EASI 90 11.759 percent 95%CI 1.878 18.874 67.0 41.5 YR
2 78 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 2.0 ITT Cochran Mantel Haenszel Test NRI 2 WK EASI 90 5.089 percent 95%CI -0.84 11.018 67.0 41.5 YR
16 82 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 6.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 90 14.3 percent 95%CI 4.095 24.505 67.0 41.5 YR
12 81 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 5.0 ITT Cochran Mantel Haenszel Test NRI 12 WK EASI 90 11.56 percent 95%CI 2.0749999999999997 21.443 67.0 41.5 YR
easi75 8 60 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 13.0 ITT Cochran Mantel Haenszel Test NRI 8 WK EASI 75 31.0 percent 95%CI 16.996 44.664 67.0 41.5 YR
4 59 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 13.0 ITT Cochran Mantel Haenszel Test NRI 4 WK EASI 75 30.83 percent 95%CI 16.996 44.664 67.0 41.5 YR
2 58 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 6.0 ITT Cochran Mantel Haenszel Test NRI 2 WK EASI 75 13.834 percent 95%CI 6.720000000000001 19.368 67.0 41.5 YR
16 62 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 12.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 75 28.6 percent 95%CI 18.578000000000003 37.155 67.0 41.5 YR
12 61 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 13.0 ITT Cochran Mantel Haenszel Test NRI 12 WK EASI 75 30.435 percent 95%CI 18.578000000000003 44.664 67.0 41.5 YR
easi50 8 40 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 23.0 ITT Cochran Mantel Haenszel Test NRI 8 WK EASI 50 54.8 percent 95%CI 39.526 69.961 67.0 41.5 YR
4 39 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 22.0 ITT Cochran Mantel Haenszel Test NRI 4 WK EASI 50 52.569 percent 95%CI 37.154 67.589 67.0 41.5 YR
2 38 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 12.0 ITT Cochran Mantel Haenszel Test NRI 2 WK EASI 50 28.063 percent 95%CI 15.02 42.293 67.0 41.5 YR
16 42 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 21.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 50 50.0 percent 95%CI 34.783 65.613 67.0 41.5 YR
12 41 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 20.0 ITT Cochran Mantel Haenszel Test NRI 12 WK EASI 50 47.431 percent 95%CI 32.411 62.846 67.0 41.5 YR
easi100 16 1 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 1.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 100 2.4 percent 95%CI 0.0 6.819 67.0 41.5 YR
easi 8 19 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 ITT ANCOVA LOCF 8 WK EASI Mean 31.4 0-72 score 15.8 SD Mean -43.7 6.09 SE 67.0 41.5 YR
4 18 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 ITT ANCOVA LOCF 4 WK EASI Mean 31.4 0-72 score 15.8 SD Mean -51.053 5.527 SE 67.0 41.5 YR
2 17 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 ITT ANCOVA LOCF 2 WK EASI Mean 31.4 0-72 score 15.8 SD Mean -39.474 5.264 SE 67.0 41.5 YR
16 21 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 ITT ANCOVA LOCF 16 WK EASI Mean 31.4 0-72 score 15.8 SD Mean -39.4 6.24 SE 67.0 41.5 YR
12 20 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 ITT ANCOVA LOCF 12 WK EASI Mean 31.4 0-72 score 15.8 SD Mean -40.527 6.316000000000001 SE 67.0 41.5 YR
0 16 control Double-Blind True upadacitinib Janus kinase inhibitors 7.5 MG ORAL QD TAB 42 42.0 ITT ANCOVA LOCF 0 WK EASI Mean 31.4 0-72 score 15.8 SD Mean 0.0 67.0 41.5 YR
30.0 qd scorad 8 98 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 40.0 ITT ANCOVA LOCF 8 WK SCORAD Mean -65.3 5.52 SE 52.0 39.9 YR
16 99 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 40.0 ITT ANCOVA LOCF 16 WK SCORAD Mean -60.4 5.65 SE 52.0 39.9 YR
0 97 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 ITT ANCOVA LOCF 0 WK SCORAD Mean 0.0 52.0 39.9 YR
easi90 8 70 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 19.0 ITT Cochran Mantel Haenszel Test NRI 8 WK EASI 90 45.2 percent 95%CI 30.238 59.881 52.0 39.9 YR
4 69 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 14.0 ITT Cochran Mantel Haenszel Test NRI 4 WK EASI 90 33.498999999999995 percent 95%CI 21.641 47.727 52.0 39.9 YR
2 68 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 4.0 ITT Cochran Mantel Haenszel Test NRI 2 WK EASI 90 9.437 percent 95%CI 0.742 18.132 52.0 39.9 YR
12 71 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 19.0 ITT Cochran Mantel Haenszel Test NRI 12 WK EASI 90 45.157 percent 95%CI 29.744 60.178 52.0 39.9 YR
easi75 8 50 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 34.0 ITT Cochran Mantel Haenszel Test NRI 8 WK EASI 75 81.0 percent 95%CI 69.17 92.886 52.0 39.9 YR
4 49 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 33.0 ITT Cochran Mantel Haenszel Test NRI 4 WK EASI 75 78.65700000000001 percent 95%CI 66.00800000000001 91.305 52.0 39.9 YR
2 48 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 14.0 ITT Cochran Mantel Haenszel Test NRI 2 WK EASI 75 33.202 percent 95%CI 24.111 47.431 52.0 39.9 YR
12 51 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 32.0 ITT Cochran Mantel Haenszel Test NRI 12 WK EASI 75 75.89 percent 95%CI 65.218 89.32900000000001 52.0 39.9 YR
easi50 8 30 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 39.0 ITT Cochran Mantel Haenszel Test NRI 8 WK EASI 50 92.9 percent 95%CI 85.376 100.0 52.0 39.9 YR
4 29 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 36.0 ITT Cochran Mantel Haenszel Test NRI 4 WK EASI 50 85.376 percent 95%CI 75.099 96.443 52.0 39.9 YR
2 28 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 25.0 ITT Cochran Mantel Haenszel Test NRI 2 WK EASI 50 59.289 percent 95%CI 45.059 74.308 52.0 39.9 YR
12 31 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 39.0 ITT Cochran Mantel Haenszel Test NRI 12 WK EASI 50 92.885 percent 95%CI 85.376 100.0 52.0 39.9 YR
easi100 16 3 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 10.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 100 24.0 percent 95%CI 10.607 36.742999999999995 52.0 39.9 YR
easi 8 7 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 ITT ANCOVA LOCF 8 WK EASI Mean 28.2 0-72 score 11.6 SD Mean -82.8 5.98 SE 52.0 39.9 YR
4 6 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 ITT ANCOVA LOCF 4 WK EASI Mean 28.2 0-72 score 11.6 SD Mean -77.895 5.264 SE 52.0 39.9 YR
2 5 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 ITT ANCOVA LOCF 2 WK EASI Mean 28.2 0-72 score 11.6 SD Mean -58.948 4.737 SE 52.0 39.9 YR
16 9 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 ITT ANCOVA LOCF 16 WK EASI Mean 28.2 0-72 score 11.6 SD Mean -74.4 6.13 SE 52.0 39.9 YR
12 8 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 ITT ANCOVA LOCF 12 WK EASI Mean 28.2 0-72 score 11.6 SD Mean -82.632 6.316000000000001 SE 52.0 39.9 YR
0 4 control Double-Blind True upadacitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 42 42.0 ITT ANCOVA LOCF 0 WK EASI Mean 28.2 0-72 score 11.6 SD Mean 0.0 52.0 39.9 YR
15.0 qd scorad 8 95 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 36.0 ITT ANCOVA LOCF 8 WK SCORAD Mean -44.1 5.69 SE 71.0 38.5 YR
16 96 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 36.0 ITT ANCOVA LOCF 16 WK SCORAD Mean -46.9 5.82 SE 71.0 38.5 YR
0 94 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 ITT ANCOVA LOCF 0 WK SCORAD Mean 0.0 71.0 38.5 YR
easi90 8 75 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 11.0 ITT Cochran Mantel Haenszel Test NRI 8 WK EASI 90 26.2 percent 95%CI 12.846 39.328 71.0 38.5 YR
4 74 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 10.0 ITT Cochran Mantel Haenszel Test NRI 4 WK EASI 90 23.617 percent 95%CI 11.76 36.66 71.0 38.5 YR
2 73 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 2.0 ITT Cochran Mantel Haenszel Test NRI 2 WK EASI 90 4.694 percent 95%CI -1.63 11.018 71.0 38.5 YR
16 77 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 11.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 90 26.2 percent 95%CI 13.27 39.129999999999995 71.0 38.5 YR
12 76 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 13.0 ITT Cochran Mantel Haenszel Test NRI 12 WK EASI 90 32.114999999999995 percent 95%CI 19.071 47.53 71.0 38.5 YR
easi75 8 55 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 22.0 ITT Cochran Mantel Haenszel Test NRI 8 WK EASI 75 52.4 percent 95%CI 37.155 67.589 71.0 38.5 YR
4 54 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 18.0 ITT Cochran Mantel Haenszel Test NRI 4 WK EASI 75 42.293 percent 95%CI 27.668 57.708 71.0 38.5 YR
2 53 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 11.0 ITT Cochran Mantel Haenszel Test NRI 2 WK EASI 75 25.297 percent 95%CI 19.368 39.131 71.0 38.5 YR
12 56 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 21.0 ITT Cochran Mantel Haenszel Test NRI 12 WK EASI 75 49.803 percent 95%CI 34.782999999999994 63.242 71.0 38.5 YR
easi50 8 35 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 30.0 ITT Cochran Mantel Haenszel Test NRI 8 WK EASI 50 71.4 percent 95%CI 58.103 85.376 71.0 38.5 YR
4 34 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 31.0 ITT Cochran Mantel Haenszel Test NRI 4 WK EASI 50 72.727 percent 95%CI 60.474 83.795 71.0 38.5 YR
2 33 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 24.0 ITT Cochran Mantel Haenszel Test NRI 2 WK EASI 50 56.127 percent 95%CI 44.664 72.332 71.0 38.5 YR
12 36 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 33.0 ITT Cochran Mantel Haenszel Test NRI 12 WK EASI 50 78.656 percent 95%CI 66.008 85.771 71.0 38.5 YR
easi100 16 2 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 4.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 100 9.5 percent 95%CI 0.379 18.182 71.0 38.5 YR
easi 8 13 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 ITT ANCOVA LOCF 8 WK EASI Mean 31.4 0-72 score 12.3 SD Mean -65.4 5.97 SE 71.0 38.5 YR
4 12 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 ITT ANCOVA LOCF 4 WK EASI Mean 31.4 0-72 score 12.3 SD Mean -65.264 5.0 SE 71.0 38.5 YR
2 11 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 ITT ANCOVA LOCF 2 WK EASI Mean 31.4 0-72 score 12.3 SD Mean -54.737 5.0 SE 71.0 38.5 YR
16 15 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 ITT ANCOVA LOCF 16 WK EASI Mean 31.4 0-72 score 12.3 SD Mean -61.7 6.12 SE 71.0 38.5 YR
12 14 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 ITT ANCOVA LOCF 12 WK EASI Mean 31.4 0-72 score 12.3 SD Mean -66.843 6.053 SE 71.0 38.5 YR
0 10 control Double-Blind True upadacitinib Janus kinase inhibitors 15.0 MG ORAL QD TAB 42 42.0 ITT ANCOVA LOCF 0 WK EASI Mean 31.4 0-72 score 12.3 SD Mean 0.0 71.0 38.5 YR
placebo 0.0 qd scorad 8 89 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 33.0 ITT ANCOVA LOCF 8 WK SCORAD Mean -7.0 5.84 SE 59.0 39.9 YR
16 90 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 33.0 ITT ANCOVA LOCF 16 WK SCORAD Mean -12.4 5.97 SE 59.0 39.9 YR
0 88 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 ITT ANCOVA LOCF 0 WK SCORAD Mean 0.0 59.0 39.9 YR
easi90 8 85 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 0.0 ITT Cochran Mantel Haenszel Test NRI 8 WK EASI 90 0.0 percent 95%CI -13.24 13.24 59.0 39.9 YR
4 84 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 0.0 ITT Cochran Mantel Haenszel Test NRI 4 WK EASI 90 0.296 percent 95%CI -9.188 9.78 59.0 39.9 YR
2 83 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 0.0 ITT Cochran Mantel Haenszel Test NRI 2 WK EASI 90 0.346 percent 59.0 39.9 YR
16 87 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 1.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 90 2.4 percent 95%CI -2.32 7.12 59.0 39.9 YR
12 86 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 2.0 ITT Cochran Mantel Haenszel Test NRI 12 WK EASI 90 4.8420000000000005 percent 59.0 39.9 YR
easi75 8 65 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 3.0 ITT Cochran Mantel Haenszel Test NRI 8 WK EASI 75 7.3 percent 95%CI -1.974999999999998 15.415 59.0 39.9 YR
4 64 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 0.0 ITT Cochran Mantel Haenszel Test NRI 4 WK EASI 75 0.0 percent 59.0 39.9 YR
2 63 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 1.0 ITT Cochran Mantel Haenszel Test NRI 2 WK EASI 75 1.977 percent 95%CI -2.7660000000000005 6.720000000000001 59.0 39.9 YR
16 67 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 4.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 75 9.8 percent 95%CI 4.975 14.625 59.0 39.9 YR
12 66 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 4.0 ITT Cochran Mantel Haenszel Test NRI 12 WK EASI 75 9.882 percent 95%CI 0.791 16.996 59.0 39.9 YR
easi50 8 45 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 9.0 ITT Cochran Mantel Haenszel Test NRI 8 WK EASI 50 22.0 percent 95%CI 9.091 34.783 59.0 39.9 YR
4 44 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 3.0 ITT Cochran Mantel Haenszel Test NRI 4 WK EASI 50 7.115 percent 95%CI -1.1849999999999987 15.415 59.0 39.9 YR
2 43 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 3.0 ITT Cochran Mantel Haenszel Test NRI 2 WK EASI 50 7.115 percent 95%CI -0.7899999999999991 15.02 59.0 39.9 YR
16 47 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 9.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 50 22.0 percent 95%CI 9.486 34.783 59.0 39.9 YR
12 46 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 8.0 ITT Cochran Mantel Haenszel Test NRI 12 WK EASI 50 19.368 percent 95%CI 7.51 31.621 59.0 39.9 YR
easi100 16 0 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 0.0 ITT Cochran Mantel Haenszel Test NRI 16 WK EASI 100 0.0 percent 59.0 39.9 YR
easi 8 25 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 39.0 ITT ANCOVA LOCF 8 WK EASI Mean 32.6 0-72 score 14.5 SD Mean -17.5 6.27 SE 59.0 39.9 YR
4 24 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 ITT ANCOVA LOCF 4 WK EASI Mean 32.6 0-72 score 14.5 SD Mean -11.579 5.527 SE 59.0 39.9 YR
2 23 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 ITT ANCOVA LOCF 2 WK EASI Mean 32.6 0-72 score 14.5 SD Mean -8.948 5.527 SE 59.0 39.9 YR
16 27 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 39.0 ITT ANCOVA LOCF 16 WK EASI Mean 32.6 0-72 score 14.5 SD Mean -23.0 6.42 SE 59.0 39.9 YR
12 26 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 ITT ANCOVA LOCF 12 WK EASI Mean 32.6 0-72 score 14.5 SD Mean -21.053 6.316000000000001 SE 59.0 39.9 YR
0 22 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 41 41.0 ITT ANCOVA LOCF 0 WK EASI Mean 32.6 0-72 score 14.5 SD Mean 0.0 59.0 39.9 YR

299_gooderham_2019¶

Control rows matched by test output: 9 of 240

Literature data accuracy: 87.20%

Clinical data accuracy: 2.98%

Clinical data accuracy (drop unmatched): 79.57%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
abrocitinib 200 oncedaily easi50 12 3 c96t3 test Double-Blind TRUE Abrocitinib Janus Kinase 1 Inhibitor 200 mg Oral Once Daily 48 54 38 FAS Logistic regression model NRI 12 WK EASI-50 Observed response 79.2 percent 50.9 38.7 YR
200.0 qd easi50 12 96 c96t3 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 48.0 38.0 FAS 12 WK EASI 50 79.2 percent 50.9 38.7 YR
similarity 100 100 100 94 75 100 100 17 0 0 33 67 100 0 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
30mg oncedaily easi50 12 5 c78t5 test Double-Blind TRUE Abrocitinib Janus Kinase 1 Inhibitor 30 mg mg Oral Once Daily 51 45 15 FAS Logistic regression model NRI 12 WK EASI-50 Odds ratio 1.36 90% CI 0.65 2.82 43.1 37.6 YR
30.0 qd easi50 12 78 c78t5 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 45.0 15.0 FAS 12 WK EASI 50 33.3 percent 43.1 37.6 YR
similarity 100 100 100 94 44 100 100 17 0 100 67 67 100 0 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 50 0 100 0 0 0 100 100 100 100 100 100 100 100 100
100mg oncedaily easi50 12 7 c69t7 test Double-Blind TRUE Abrocitinib Janus Kinase 1 Inhibitor 100 mg mg Oral Once Daily 54 54 30 FAS Logistic regression model NRI 12 WK EASI-50 Odds ratio 3.28 90% CI 1.66 6.48 55.4 41.1 YR
10.0 qd easi50 12 69 c69t7 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 46.0 12.0 FAS 12 WK EASI 50 26.1 percent 42.9 44.3 YR
similarity 100 100 100 94 40 100 100 17 0 50 33 33 100 0 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 0 100 0 0 0 100 100 100 100 100 100 50 50 100
placebo oncedaily easi50 12 1 c60t1 test Double-Blind TRUE Placebo Oral Once Daily 52 52 14 FAS Logistic regression model NRI 12 WK EASI-50 Odds ratio 0.96 90% CI 0.45 2.03 37.5 42.6 YR
0.0 qd easi50 12 60 c60t1 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 52.0 14.0 FAS 12 WK EASI 50 26.9 percent 37.5 42.6 YR
similarity 100 100 100 0 0 0 100 17 100 50 67 67 100 0 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 50 0 100 0 0 0 100 100 100 100 100 100 100 100 100
abrocitinib 200 oncedaily easi90 12 4 c186t4 test Double-Blind TRUE Abrocitinib Janus Kinase 1 Inhibitor 200 mg Oral Once Daily 48 48 21 FAS Logistic regression model NRI 12 WK EASI-90 Observed response, No. (%) 21 (52.1) percent 50.9 38.7 YR
200.0 qd easi90 12 186 c186t4 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 48.0 25.0 FAS 12 WK EASI 90 52.1 percent 50.9 38.7 YR
similarity 100 100 100 94 75 100 100 17 0 0 67 33 100 0 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 73 100 100 100 100 100 100 100 100 100 100 100 100 100 100
100mg oncedaily easi90 12 8 c159t8 test Double-Blind TRUE Abrocitinib Janus Kinase 1 Inhibitor 100 mg mg Oral Once Daily 54 54 14 FAS Logistic regression model NRI 12 WK EASI-90 Odds ratio 3.18 90% CI 1.29 7.86 55.4 41.1 YR
10.0 qd easi90 12 159 c159t8 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 46.0 5.0 FAS 12 WK EASI 90 10.9 percent 42.9 44.3 YR
similarity 100 100 100 94 40 100 100 17 0 50 33 0 100 0 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 50 0 100 0 0 0 100 100 100 100 100 100 50 50 100
200 oncedaily easi75 12 2 c141t2 test Double-Blind TRUE Abrocitinib Janus Kinase 1 Inhibitor 200 mg Oral Once Daily 48 48 31 FAS Logistic regression model NRI 12 WK EASI-75 Observed response 64.6 percent 50.9 38.7 YR
200.0 qd easi75 12 141 c141t2 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 48.0 31.0 FAS 12 WK EASI 75 64.6 percent 50.9 38.7 YR
similarity 100 100 100 94 75 100 100 17 0 0 67 67 100 0 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
100mg oncedaily easi75 12 6 c114t6 test Double-Blind TRUE Abrocitinib Janus Kinase 1 Inhibitor 100 mg mg Oral Once Daily 54 54 22 FAS Logistic regression model NRI 12 WK EASI-75 Observed response 40.7 percent 55.4 41.1 YR
10.0 qd easi75 12 114 c114t6 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 46.0 8.0 FAS 12 WK EASI 75 17.4 percent 42.9 44.3 YR
similarity 100 100 100 94 40 100 100 17 0 50 33 0 100 0 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 100 100 100 100 100 100 100 100 100 100 100 50 50 100
placebo oncedaily easi75 12 0 c105t0 test Double-Blind TRUE Placebo Oral Once Daily 52 52 8 FAS Logistic regression NRI 12 WK EASI-75 Observed response 15.4 percent 37.5 42.6 YR
0.0 qd easi75 12 105 c105t0 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 52.0 8.0 FAS 12 WK EASI 75 15.4 percent 37.5 42.6 YR
similarity 100 100 100 0 0 0 100 17 100 50 67 50 100 0 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
scorad 8 195 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 41.0 FAS MMRM 8 WK SCORAD Mean 65.0 0-103 score 12.1 SD Mean -19.052 0-103 score 18.574 SD Mean -29.624 30.563 SD 37.5 42.6 YR
6 194 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 44.0 FAS MMRM 6 WK SCORAD Mean 65.0 0-103 score 12.1 SD Mean -19.527 0-103 score 16.787 SD Mean -30.789 27.942 SD 37.5 42.6 YR
4 193 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 50.0 FAS MMRM 4 WK SCORAD Mean 65.0 0-103 score 12.1 SD Mean -14.555 0-103 score 16.641 SD Mean -22.476 26.516 SD 37.5 42.6 YR
2 192 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 55.0 FAS MMRM 2 WK SCORAD Mean 65.0 0-103 score 12.1 SD Mean -10.905 0-103 score 15.416 SD Mean -16.488 23.001 SD 37.5 42.6 YR
16 199 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 28.0 FAS MMRM 16 WK SCORAD Mean 65.0 0-103 score 12.1 SD Mean -19.408 0-103 score 22.174 SD Mean -31.972 36.506 SD 37.5 42.6 YR
14 198 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 32.0 FAS MMRM 14 WK SCORAD Mean 65.0 0-103 score 12.1 SD Mean -17.987 0-103 score 22.089 SD Mean -29.393 36.664 SD 37.5 42.6 YR
13 197 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 30.0 FAS MMRM 13 WK SCORAD Mean 65.0 0-103 score 12.1 SD Mean -16.603 0-103 score 21.385 SD Mean -26.794 34.338 SD 37.5 42.6 YR
12 196 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 35.0 FAS MMRM 12 WK SCORAD Mean 65.0 0-103 score 12.1 SD Mean -18.647 0-103 score 20.019 SD Mean -29.379 31.908 SD 37.5 42.6 YR
50 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 52.0 FAS MMRM 12 WK SCORAD Mean 65.0 0-103 score 12.1 SD LS Mean -29.0 95%CI -36.6 -21.3 37.5 42.6 YR
1 191 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 54.0 FAS MMRM 1 WK SCORAD Mean 65.0 0-103 score 12.1 SD Mean -7.91 0-103 score 12.463 SD Mean -11.547 19.713 SD 37.5 42.6 YR
0 190 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 55.0 FAS MMRM 0 WK SCORAD Mean 65.0 0-103 score 12.1 SD Mean 0.0 0-103 score Mean 0.0 37.5 42.6 YR
easi90 8 149 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 55.0 3.0 FAS 8 WK EASI 90 5.5 percent 37.5 42.6 YR
6 148 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 55.0 4.0 FAS 6 WK EASI 90 7.3 percent 37.5 42.6 YR
4 147 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 55.0 1.0 FAS 4 WK EASI 90 1.8 percent 37.5 42.6 YR
2 146 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 55.0 0.0 FAS 2 WK EASI 90 0.0 percent 37.5 42.6 YR
16 153 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 28.0 4.0 FAS 16 WK EASI 90 14.3 percent 37.5 42.6 YR
14 152 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 32.0 5.0 FAS 14 WK EASI 90 15.6 percent 37.5 42.6 YR
13 151 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 30.0 3.0 FAS 13 WK EASI 90 10.0 percent 37.5 42.6 YR
12 150 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 52.0 5.0 FAS 12 WK EASI 90 9.6 percent 37.5 42.6 YR
1 145 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 54.0 0.0 FAS 1 WK EASI 90 0.0 percent 37.5 42.6 YR
easi75 8 104 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 55.0 11.0 FAS 8 WK EASI 75 20.0 percent 37.5 42.6 YR
6 103 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 55.0 9.0 FAS 6 WK EASI 75 16.4 percent 37.5 42.6 YR
4 102 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 55.0 6.0 FAS 4 WK EASI 75 10.9 percent 37.5 42.6 YR
2 101 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 55.0 3.0 FAS 2 WK EASI 75 5.5 percent 37.5 42.6 YR
16 108 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 28.0 9.0 FAS 16 WK EASI 75 32.1 percent 37.5 42.6 YR
14 107 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 32.0 10.0 FAS 14 WK EASI 75 31.3 percent 37.5 42.6 YR
13 106 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 30.0 8.0 FAS 13 WK EASI 75 26.7 percent 37.5 42.6 YR
1 100 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 54.0 2.0 FAS 1 WK EASI 75 3.7 percent 37.5 42.6 YR
easi50 8 59 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 55.0 17.0 FAS 8 WK EASI 50 30.9 percent 37.5 42.6 YR
6 58 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 55.0 20.0 FAS 6 WK EASI 50 36.4 percent 37.5 42.6 YR
4 57 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 55.0 15.0 FAS 4 WK EASI 50 27.3 percent 37.5 42.6 YR
2 56 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 55.0 15.0 FAS 2 WK EASI 50 27.3 percent 37.5 42.6 YR
16 63 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 28.0 12.0 FAS 16 WK EASI 50 42.9 percent 37.5 42.6 YR
14 62 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 32.0 12.0 FAS 14 WK EASI 50 37.5 percent 37.5 42.6 YR
13 61 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 30.0 13.0 FAS 13 WK EASI 50 43.3 percent 37.5 42.6 YR
1 55 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 56 54.0 5.0 FAS 1 WK EASI 50 9.3 percent 37.5 42.6 YR
easi 8 5 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 FAS MMRM 8 WK EASI Mean 25.4 0-72 score 12.9 SD LS Mean -32.5532 90%CI -43.404 -21.702 37.5 42.6 YR
6 4 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 FAS MMRM 6 WK EASI Mean 25.4 0-72 score 12.9 SD LS Mean -35.3191 90%CI -45.106 -25.532 37.5 42.6 YR
4 3 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 FAS MMRM 4 WK EASI Mean 25.4 0-72 score 12.9 SD LS Mean -22.766 90%CI -30.851 -14.255 37.5 42.6 YR
2 2 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 FAS MMRM 2 WK EASI Mean 25.4 0-72 score 12.9 SD LS Mean -23.4043 90%CI -31.277 -16.17 37.5 42.6 YR
16 9 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 FAS MMRM 16 WK EASI Mean 25.4 0-72 score 12.9 SD LS Mean -32.5532 90%CI -46.17 -18.298 37.5 42.6 YR
14 8 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 FAS MMRM 14 WK EASI Mean 25.4 0-72 score 12.9 SD LS Mean -29.5745 90%CI -42.979 -16.809 37.5 42.6 YR
13 7 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 FAS MMRM 13 WK EASI Mean 25.4 0-72 score 12.9 SD LS Mean -22.766 90%CI -34.681 -10.638 37.5 42.6 YR
12 6 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 52.0 FAS MMRM 12 WK EASI Mean 25.4 0-72 score 12.9 SD LS Mean -35.2 90%CI -46.1 -24.4 37.5 42.6 YR
1 1 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 FAS MMRM 1 WK EASI Mean 25.4 0-72 score 12.9 SD LS Mean -12.9787 90%CI -19.787 -6.17 37.5 42.6 YR
0 0 control Double-Blind True placebo Placebo 0.0 MG ORAL QD 55 55.0 FAS MMRM 0 WK EASI Mean 25.4 0-72 score 12.9 SD LS Mean 0.0 37.5 42.6 YR
abrocitinib 30.0 qd scorad 8 215 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 43.0 FAS MMRM 8 WK SCORAD Mean 62.4 0-103 score 13.0 SD Mean -19.534 0-103 score 18.71 SD Mean -30.48 29.474 SD 43.1 37.6 YR
6 214 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 43.0 FAS MMRM 6 WK SCORAD Mean 62.4 0-103 score 13.0 SD Mean -19.93 0-103 score 17.597 SD Mean -31.276 29.652 SD 43.1 37.6 YR
4 213 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 47.0 FAS MMRM 4 WK SCORAD Mean 62.4 0-103 score 13.0 SD Mean -15.496 0-103 score 16.48 SD Mean -24.866 25.376 SD 43.1 37.6 YR
2 212 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 47.0 FAS MMRM 2 WK SCORAD Mean 62.4 0-103 score 13.0 SD Mean -13.266 0-103 score 14.527 SD Mean -20.613 21.028 SD 43.1 37.6 YR
16 219 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 27.0 FAS MMRM 16 WK SCORAD Mean 62.4 0-103 score 13.0 SD Mean -12.716 0-103 score 15.939 SD Mean -19.794 25.055 SD 43.1 37.6 YR
14 218 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 29.0 FAS MMRM 14 WK SCORAD Mean 62.4 0-103 score 13.0 SD Mean -12.768 0-103 score 13.691 SD Mean -20.072 21.74 SD 43.1 37.6 YR
13 217 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 31.0 FAS MMRM 13 WK SCORAD Mean 62.4 0-103 score 13.0 SD Mean -15.023 0-103 score 16.157 SD Mean -24.232 26.246 SD 43.1 37.6 YR
12 216 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 30.0 FAS MMRM 12 WK SCORAD Mean 62.4 0-103 score 13.0 SD Mean -21.211 0-103 score 17.677 SD Mean -32.535 25.271 SD 43.1 37.6 YR
52 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 45.0 FAS MMRM 12 WK SCORAD Mean 62.4 0-103 score 13.0 SD LS Mean -30.1 95%CI -38.1 -22.1 43.1 37.6 YR
1 211 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 49.0 FAS MMRM 1 WK SCORAD Mean 62.4 0-103 score 13.0 SD Mean -8.388 0-103 score 14.632 SD Mean -13.068 21.075 SD 43.1 37.6 YR
0 210 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 50.0 FAS MMRM 0 WK SCORAD Mean 62.4 0-103 score 13.0 SD Mean 0.0 0-103 score Mean 0.0 43.1 37.6 YR
easi90 8 167 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 4.0 FAS 8 WK EASI 90 8.0 percent 43.1 37.6 YR
6 166 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 7.0 FAS 6 WK EASI 90 14.0 percent 43.1 37.6 YR
4 165 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 4.0 FAS 4 WK EASI 90 8.0 percent 43.1 37.6 YR
2 164 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 2.0 FAS 2 WK EASI 90 4.0 percent 43.1 37.6 YR
16 171 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 27.0 1.0 FAS 16 WK EASI 90 3.7 percent 43.1 37.6 YR
14 170 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 29.0 0.0 FAS 14 WK EASI 90 0.0 percent 43.1 37.6 YR
13 169 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 31.0 1.0 FAS 13 WK EASI 90 3.2 percent 43.1 37.6 YR
12 168 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 45.0 0.0 FAS 12 WK EASI 90 0.0 percent 43.1 37.6 YR
1 163 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 2.0 FAS 1 WK EASI 90 4.0 percent 43.1 37.6 YR
easi75 8 122 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 11.0 FAS 8 WK EASI 75 22.0 percent 43.1 37.6 YR
6 121 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 9.0 FAS 6 WK EASI 75 18.0 percent 43.1 37.6 YR
4 120 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 10.0 FAS 4 WK EASI 75 20.0 percent 43.1 37.6 YR
2 119 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 3.0 FAS 2 WK EASI 75 6.0 percent 43.1 37.6 YR
16 126 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 27.0 1.0 FAS 16 WK EASI 75 3.7 percent 43.1 37.6 YR
14 125 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 29.0 2.0 FAS 14 WK EASI 75 6.9 percent 43.1 37.6 YR
13 124 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 31.0 4.0 FAS 13 WK EASI 75 12.9 percent 43.1 37.6 YR
12 123 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 45.0 6.0 FAS 12 WK EASI 75 13.3 percent 43.1 37.6 YR
1 118 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 3.0 FAS 1 WK EASI 75 6.0 percent 43.1 37.6 YR
easi50 8 77 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 20.0 FAS 8 WK EASI 50 40.0 percent 43.1 37.6 YR
6 76 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 20.0 FAS 6 WK EASI 50 40.0 percent 43.1 37.6 YR
4 75 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 18.0 FAS 4 WK EASI 50 36.0 percent 43.1 37.6 YR
2 74 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 12.0 FAS 2 WK EASI 50 24.0 percent 43.1 37.6 YR
16 81 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 27.0 9.0 FAS 16 WK EASI 50 33.3 percent 43.1 37.6 YR
14 80 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 29.0 11.0 FAS 14 WK EASI 50 37.9 percent 43.1 37.6 YR
13 79 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 31.0 14.0 FAS 13 WK EASI 50 45.2 percent 43.1 37.6 YR
1 73 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 51 50.0 7.0 FAS 1 WK EASI 50 14.0 percent 43.1 37.6 YR
easi 8 25 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 FAS MMRM 8 WK EASI Mean 22.1 0-72 score 10.7 SD LS Mean -35.9574 90%CI -46.383 -22.979 43.1 37.6 YR
6 24 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 FAS MMRM 6 WK EASI Mean 22.1 0-72 score 10.7 SD LS Mean -39.7872 90%CI -49.149 -26.809 43.1 37.6 YR
4 23 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 FAS MMRM 4 WK EASI Mean 22.1 0-72 score 10.7 SD LS Mean -32.9787 90%CI -41.277 -20.0 43.1 37.6 YR
2 22 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 FAS MMRM 2 WK EASI Mean 22.1 0-72 score 10.7 SD LS Mean -25.3191 90%CI -33.617 -17.234 43.1 37.6 YR
16 29 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 FAS MMRM 16 WK EASI Mean 22.1 0-72 score 10.7 SD LS Mean -15.7447 90%CI -29.575 -2.766 43.1 37.6 YR
14 28 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 FAS MMRM 14 WK EASI Mean 22.1 0-72 score 10.7 SD LS Mean -24.2553 90%CI -37.021 -11.064 43.1 37.6 YR
13 27 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 FAS MMRM 13 WK EASI Mean 22.1 0-72 score 10.7 SD LS Mean -33.1915 90%CI -44.894 -20.0 43.1 37.6 YR
12 26 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 45.0 FAS MMRM 12 WK EASI Mean 22.1 0-72 score 10.7 SD LS Mean -40.7 90%CI -52.0 -29.5 43.1 37.6 YR
1 21 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 FAS MMRM 1 WK EASI Mean 22.1 0-72 score 10.7 SD LS Mean -14.8936 90%CI -21.489 -7.234 43.1 37.6 YR
0 20 control Double-Blind True abrocitinib Janus kinase inhibitors 30.0 MG ORAL QD TAB 50 50.0 FAS MMRM 0 WK EASI Mean 22.1 0-72 score 10.7 SD LS Mean 0.0 43.1 37.6 YR
200.0 qd scorad 8 235 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 49.0 FAS MMRM 8 WK SCORAD Mean 62.7 0-103 score 13.7 SD Mean -42.604 0-103 score 13.977 SD Mean -69.736 21.44 SD 50.9 38.7 YR
6 234 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 52.0 FAS MMRM 6 WK SCORAD Mean 62.7 0-103 score 13.7 SD Mean -41.458 0-103 score 14.394 SD Mean -66.971 22.434 SD 50.9 38.7 YR
4 233 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 52.0 FAS MMRM 4 WK SCORAD Mean 62.7 0-103 score 13.7 SD Mean -39.567 0-103 score 14.733 SD Mean -63.97 21.67 SD 50.9 38.7 YR
2 232 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 50.0 FAS MMRM 2 WK SCORAD Mean 62.7 0-103 score 13.7 SD Mean -32.152 0-103 score 14.435 SD Mean -51.384 21.358 SD 50.9 38.7 YR
16 239 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 38.0 FAS MMRM 16 WK SCORAD Mean 62.7 0-103 score 13.7 SD Mean -21.024 0-103 score 18.158 SD Mean -34.995 27.5 SD 50.9 38.7 YR
14 238 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 44.0 FAS MMRM 14 WK SCORAD Mean 62.7 0-103 score 13.7 SD Mean -21.292 0-103 score 17.778 SD Mean -36.519 28.54 SD 50.9 38.7 YR
13 237 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 45.0 FAS MMRM 13 WK SCORAD Mean 62.7 0-103 score 13.7 SD Mean -29.884 0-103 score 19.15 SD Mean -48.428 30.113 SD 50.9 38.7 YR
12 236 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 42.0 FAS MMRM 12 WK SCORAD Mean 62.7 0-103 score 13.7 SD Mean -41.384 0-103 score 15.436 SD Mean -68.537 24.239 SD 50.9 38.7 YR
54 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 48.0 FAS MMRM 12 WK SCORAD Mean 62.7 0-103 score 13.7 SD LS Mean -69.7 95%CI -76.9 -62.5 50.9 38.7 YR
1 231 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 53.0 FAS MMRM 1 WK SCORAD Mean 62.7 0-103 score 13.7 SD Mean -21.326 0-103 score 15.887 SD Mean -34.66 25.084 SD 50.9 38.7 YR
0 230 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 54.0 FAS MMRM 0 WK SCORAD Mean 62.7 0-103 score 13.7 SD Mean 0.0 0-103 score Mean 0.0 50.9 38.7 YR
easi90 8 185 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 53.0 23.0 FAS 8 WK EASI 90 43.4 percent 50.9 38.7 YR
6 184 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 54.0 24.0 FAS 6 WK EASI 90 44.4 percent 50.9 38.7 YR
4 183 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 54.0 21.0 FAS 4 WK EASI 90 38.9 percent 50.9 38.7 YR
2 182 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 52.0 10.0 FAS 2 WK EASI 90 19.2 percent 50.9 38.7 YR
16 189 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 38.0 4.0 FAS 16 WK EASI 90 10.5 percent 50.9 38.7 YR
14 188 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 44.0 8.0 FAS 14 WK EASI 90 18.2 percent 50.9 38.7 YR
13 187 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 45.0 14.0 FAS 13 WK EASI 90 31.1 percent 50.9 38.7 YR
1 181 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 54.0 4.0 FAS 1 WK EASI 90 7.4 percent 50.9 38.7 YR
easi75 8 140 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 53.0 39.0 FAS 8 WK EASI 75 73.6 percent 50.9 38.7 YR
6 139 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 54.0 37.0 FAS 6 WK EASI 75 68.5 percent 50.9 38.7 YR
4 138 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 54.0 31.0 FAS 4 WK EASI 75 57.4 percent 50.9 38.7 YR
2 137 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 52.0 19.0 FAS 2 WK EASI 75 36.5 percent 50.9 38.7 YR
16 144 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 38.0 14.0 FAS 16 WK EASI 75 36.8 percent 50.9 38.7 YR
14 143 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 44.0 20.0 FAS 14 WK EASI 75 45.5 percent 50.9 38.7 YR
13 142 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 45.0 25.0 FAS 13 WK EASI 75 55.6 percent 50.9 38.7 YR
1 136 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 54.0 9.0 FAS 1 WK EASI 75 16.7 percent 50.9 38.7 YR
easi50 8 95 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 53.0 48.0 FAS 8 WK EASI 50 90.6 percent 50.9 38.7 YR
6 94 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 54.0 49.0 FAS 6 WK EASI 50 90.7 percent 50.9 38.7 YR
4 93 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 54.0 46.0 FAS 4 WK EASI 50 85.2 percent 50.9 38.7 YR
2 92 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 52.0 34.0 FAS 2 WK EASI 50 65.4 percent 50.9 38.7 YR
16 99 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 38.0 26.0 FAS 16 WK EASI 50 68.4 percent 50.9 38.7 YR
14 98 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 44.0 29.0 FAS 14 WK EASI 50 65.9 percent 50.9 38.7 YR
13 97 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 45.0 34.0 FAS 13 WK EASI 50 75.6 percent 50.9 38.7 YR
1 91 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 55 54.0 22.0 FAS 1 WK EASI 50 40.7 percent 50.9 38.7 YR
easi 8 45 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 FAS MMRM 8 WK EASI Mean 24.6 0-72 score 13.5 SD LS Mean -81.9149 90%CI -92.128 -72.128 50.9 38.7 YR
6 44 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 FAS MMRM 6 WK EASI Mean 24.6 0-72 score 13.5 SD LS Mean -82.1277 90%CI -91.277 -72.766 50.9 38.7 YR
4 43 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 FAS MMRM 4 WK EASI Mean 24.6 0-72 score 13.5 SD LS Mean -77.234 90%CI -85.319 -69.149 50.9 38.7 YR
2 42 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 FAS MMRM 2 WK EASI Mean 24.6 0-72 score 13.5 SD LS Mean -62.1277 90%CI -70.213 -54.043 50.9 38.7 YR
16 49 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 FAS MMRM 16 WK EASI Mean 24.6 0-72 score 13.5 SD LS Mean -51.0638 90%CI -63.192 -38.723 50.9 38.7 YR
14 48 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 FAS MMRM 14 WK EASI Mean 24.6 0-72 score 13.5 SD LS Mean -55.1064 90%CI -66.383 -42.979 50.9 38.7 YR
13 47 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 FAS MMRM 13 WK EASI Mean 24.6 0-72 score 13.5 SD LS Mean -65.1064 90%CI -76.383 -54.468 50.9 38.7 YR
12 46 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 48.0 FAS MMRM 12 WK EASI Mean 24.6 0-72 score 13.5 SD LS Mean -82.6 90%CI -92.8 -72.4 50.9 38.7 YR
1 41 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 FAS MMRM 1 WK EASI Mean 24.6 0-72 score 13.5 SD LS Mean -41.4894 90%CI -48.085 -34.255 50.9 38.7 YR
0 40 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 54 54.0 FAS MMRM 0 WK EASI Mean 24.6 0-72 score 13.5 SD LS Mean 0.0 50.9 38.7 YR
100.0 qd scorad 8 225 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 47.0 FAS MMRM 8 WK SCORAD Mean 65.4 0-103 score 13.7 SD Mean -30.148 0-103 score 20.789 SD Mean -46.187 32.789 SD 55.4 41.1 YR
6 224 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 48.0 FAS MMRM 6 WK SCORAD Mean 65.4 0-103 score 13.7 SD Mean -29.729 0-103 score 21.612 SD Mean -45.27 34.389 SD 55.4 41.1 YR
4 223 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 52.0 FAS MMRM 4 WK SCORAD Mean 65.4 0-103 score 13.7 SD Mean -28.058 0-103 score 16.678 SD Mean -43.846 26.2 SD 55.4 41.1 YR
2 222 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 53.0 FAS MMRM 2 WK SCORAD Mean 65.4 0-103 score 13.7 SD Mean -20.286 0-103 score 15.24 SD Mean -31.025 23.988 SD 55.4 41.1 YR
16 229 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 36.0 FAS MMRM 16 WK SCORAD Mean 65.4 0-103 score 13.7 SD Mean -17.753 0-103 score 19.184 SD Mean -29.13 33.187 SD 55.4 41.1 YR
14 228 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 40.0 FAS MMRM 14 WK SCORAD Mean 65.4 0-103 score 13.7 SD Mean -20.211 0-103 score 20.292 SD Mean -31.521 34.127 SD 55.4 41.1 YR
13 227 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 38.0 FAS MMRM 13 WK SCORAD Mean 65.4 0-103 score 13.7 SD Mean -24.261 0-103 score 19.491 SD Mean -38.193 32.346 SD 55.4 41.1 YR
12 226 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 43.0 FAS MMRM 12 WK SCORAD Mean 65.4 0-103 score 13.7 SD Mean -33.145 0-103 score 21.422 SD Mean -51.624 33.011 SD 55.4 41.1 YR
53 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 54.0 FAS MMRM 12 WK SCORAD Mean 65.4 0-103 score 13.7 SD LS Mean -49.2 95%CI -56.4 -42.0 55.4 41.1 YR
1 221 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 55.0 FAS MMRM 1 WK SCORAD Mean 65.4 0-103 score 13.7 SD Mean -12.024 0-103 score 12.405 SD Mean -19.185 20.009 SD 55.4 41.1 YR
0 220 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 55.0 FAS MMRM 0 WK SCORAD Mean 65.4 0-103 score 13.7 SD Mean 0.0 0-103 score Mean 0.0 55.4 41.1 YR
easi90 8 176 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 13.0 FAS 8 WK EASI 90 23.6 percent 55.4 41.1 YR
6 175 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 9.0 FAS 6 WK EASI 90 16.4 percent 55.4 41.1 YR
4 174 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 6.0 FAS 4 WK EASI 90 10.9 percent 55.4 41.1 YR
2 173 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 3.0 FAS 2 WK EASI 90 5.5 percent 55.4 41.1 YR
16 180 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 36.0 3.0 FAS 16 WK EASI 90 8.3 percent 55.4 41.1 YR
14 179 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 40.0 7.0 FAS 14 WK EASI 90 17.5 percent 55.4 41.1 YR
13 178 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 38.0 9.0 FAS 13 WK EASI 90 23.7 percent 55.4 41.1 YR
12 177 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 54.0 14.0 FAS 12 WK EASI 90 25.9 percent 55.4 41.1 YR
1 172 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 0.0 FAS 1 WK EASI 90 0.0 percent 55.4 41.1 YR
easi75 8 131 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 22.0 FAS 8 WK EASI 75 40.0 percent 55.4 41.1 YR
6 130 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 21.0 FAS 6 WK EASI 75 38.2 percent 55.4 41.1 YR
4 129 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 15.0 FAS 4 WK EASI 75 27.3 percent 55.4 41.1 YR
2 128 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 7.0 FAS 2 WK EASI 75 12.7 percent 55.4 41.1 YR
16 135 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 36.0 9.0 FAS 16 WK EASI 75 25.0 percent 55.4 41.1 YR
14 134 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 40.0 14.0 FAS 14 WK EASI 75 35.0 percent 55.4 41.1 YR
13 133 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 38.0 14.0 FAS 13 WK EASI 75 36.8 percent 55.4 41.1 YR
12 132 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 54.0 22.0 FAS 12 WK EASI 75 40.7 percent 55.4 41.1 YR
1 127 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 2.0 FAS 1 WK EASI 75 3.6 percent 55.4 41.1 YR
easi50 8 86 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 33.0 FAS 8 WK EASI 50 60.0 percent 55.4 41.1 YR
6 85 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 33.0 FAS 6 WK EASI 50 60.0 percent 55.4 41.1 YR
4 84 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 32.0 FAS 4 WK EASI 50 58.2 percent 55.4 41.1 YR
2 83 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 20.0 FAS 2 WK EASI 50 36.4 percent 55.4 41.1 YR
16 90 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 36.0 15.0 FAS 16 WK EASI 50 41.7 percent 55.4 41.1 YR
14 89 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 40.0 20.0 FAS 14 WK EASI 50 50.0 percent 55.4 41.1 YR
13 88 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 38.0 21.0 FAS 13 WK EASI 50 55.3 percent 55.4 41.1 YR
12 87 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 54.0 30.0 FAS 12 WK EASI 50 55.6 percent 55.4 41.1 YR
1 82 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 56 55.0 7.0 FAS 1 WK EASI 50 12.7 percent 55.4 41.1 YR
easi 8 35 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 FAS MMRM 8 WK EASI Mean 26.7 0-72 score 11.8 SD LS Mean -51.7021 90%CI -62.34 -41.489 55.4 41.1 YR
6 34 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 FAS MMRM 6 WK EASI Mean 26.7 0-72 score 11.8 SD LS Mean -52.3404 90%CI -61.489 -42.979 55.4 41.1 YR
4 33 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 FAS MMRM 4 WK EASI Mean 26.7 0-72 score 11.8 SD LS Mean -53.1915 90%CI -61.489 -45.106 55.4 41.1 YR
2 32 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 FAS MMRM 2 WK EASI Mean 26.7 0-72 score 11.8 SD LS Mean -38.0851 90%CI -45.957 -30.638 55.4 41.1 YR
16 39 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 FAS MMRM 16 WK EASI Mean 26.7 0-72 score 11.8 SD LS Mean -18.7234 90%CI -31.915 -6.596 55.4 41.1 YR
14 38 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 FAS MMRM 14 WK EASI Mean 26.7 0-72 score 11.8 SD LS Mean -34.0426 90%CI -46.596 -22.128 55.4 41.1 YR
13 37 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 FAS MMRM 13 WK EASI Mean 26.7 0-72 score 11.8 SD LS Mean -46.383 90%CI -58.298 -35.532 55.4 41.1 YR
12 36 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 54.0 FAS MMRM 12 WK EASI Mean 26.7 0-72 score 11.8 SD LS Mean -59.0 90%CI -69.3 -48.8 55.4 41.1 YR
1 31 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 FAS MMRM 1 WK EASI Mean 26.7 0-72 score 11.8 SD LS Mean -20.0 90%CI -26.383 -13.192 55.4 41.1 YR
0 30 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 55 55.0 FAS MMRM 0 WK EASI Mean 26.7 0-72 score 11.8 SD LS Mean 0.0 55.4 41.1 YR
10.0 qd scorad 8 205 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 36.0 FAS MMRM 8 WK SCORAD Mean 65.3 0-103 score 13.2 SD Mean -18.853 0-103 score 21.795 SD Mean -28.599 33.146 SD 42.9 44.3 YR
6 204 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 38.0 FAS MMRM 6 WK SCORAD Mean 65.3 0-103 score 13.2 SD Mean -16.667 0-103 score 21.858 SD Mean -25.851 34.295 SD 42.9 44.3 YR
4 203 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 45.0 FAS MMRM 4 WK SCORAD Mean 65.3 0-103 score 13.2 SD Mean -14.116 0-103 score 19.164 SD Mean -20.751 29.085 SD 42.9 44.3 YR
2 202 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 48.0 FAS MMRM 2 WK SCORAD Mean 65.3 0-103 score 13.2 SD Mean -8.795 0-103 score 16.388 SD Mean -12.98 25.52 SD 42.9 44.3 YR
16 209 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 26.0 FAS MMRM 16 WK SCORAD Mean 65.3 0-103 score 13.2 SD Mean -18.925 0-103 score 21.546 SD Mean -30.135 34.236 SD 42.9 44.3 YR
14 208 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 28.0 FAS MMRM 14 WK SCORAD Mean 65.3 0-103 score 13.2 SD Mean -15.842 0-103 score 19.5 SD Mean -25.511 31.199 SD 42.9 44.3 YR
13 207 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 29.0 FAS MMRM 13 WK SCORAD Mean 65.3 0-103 score 13.2 SD Mean -16.895 0-103 score 22.113 SD Mean -26.905 34.188 SD 42.9 44.3 YR
12 206 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 29.0 FAS MMRM 12 WK SCORAD Mean 65.3 0-103 score 13.2 SD Mean -17.986 0-103 score 23.195 SD Mean -27.607 36.502 SD 42.9 44.3 YR
51 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 46.0 FAS MMRM 12 WK SCORAD Mean 65.3 0-103 score 13.2 SD LS Mean -26.7 95%CI -35.0 -18.4 42.9 44.3 YR
1 201 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 48.0 FAS MMRM 1 WK SCORAD Mean 65.3 0-103 score 13.2 SD Mean -5.0 0-103 score 13.331 SD Mean -7.287 20.64 SD 42.9 44.3 YR
0 200 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 FAS MMRM 0 WK SCORAD Mean 65.3 0-103 score 13.2 SD Mean 0.0 0-103 score Mean 0.0 42.9 44.3 YR
easi90 8 158 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 6.0 FAS 8 WK EASI 90 12.2 percent 42.9 44.3 YR
6 157 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 7.0 FAS 6 WK EASI 90 14.3 percent 42.9 44.3 YR
4 156 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 4.0 FAS 4 WK EASI 90 8.2 percent 42.9 44.3 YR
2 155 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 3.0 FAS 2 WK EASI 90 6.1 percent 42.9 44.3 YR
16 162 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 26.0 6.0 FAS 16 WK EASI 90 23.1 percent 42.9 44.3 YR
14 161 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 28.0 4.0 FAS 14 WK EASI 90 14.3 percent 42.9 44.3 YR
13 160 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 29.0 4.0 FAS 13 WK EASI 90 13.8 percent 42.9 44.3 YR
1 154 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 48.0 1.0 FAS 1 WK EASI 90 2.1 percent 42.9 44.3 YR
easi75 8 113 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 11.0 FAS 8 WK EASI 75 22.4 percent 42.9 44.3 YR
6 112 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 9.0 FAS 6 WK EASI 75 18.4 percent 42.9 44.3 YR
4 111 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 9.0 FAS 4 WK EASI 75 18.4 percent 42.9 44.3 YR
2 110 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 6.0 FAS 2 WK EASI 75 12.2 percent 42.9 44.3 YR
16 117 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 26.0 10.0 FAS 16 WK EASI 75 38.5 percent 42.9 44.3 YR
14 116 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 28.0 7.0 FAS 14 WK EASI 75 25.0 percent 42.9 44.3 YR
13 115 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 29.0 8.0 FAS 13 WK EASI 75 27.6 percent 42.9 44.3 YR
1 109 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 48.0 1.0 FAS 1 WK EASI 75 2.1 percent 42.9 44.3 YR
easi50 8 68 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 18.0 FAS 8 WK EASI 50 36.7 percent 42.9 44.3 YR
6 67 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 15.0 FAS 6 WK EASI 50 30.6 percent 42.9 44.3 YR
4 66 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 15.0 FAS 4 WK EASI 50 30.6 percent 42.9 44.3 YR
2 65 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 8.0 FAS 2 WK EASI 50 16.3 percent 42.9 44.3 YR
16 72 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 26.0 11.0 FAS 16 WK EASI 50 42.3 percent 42.9 44.3 YR
14 71 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 28.0 12.0 FAS 14 WK EASI 50 42.9 percent 42.9 44.3 YR
13 70 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 29.0 12.0 FAS 13 WK EASI 50 41.4 percent 42.9 44.3 YR
1 64 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 48.0 4.0 FAS 1 WK EASI 50 8.3 percent 42.9 44.3 YR
easi 8 15 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 FAS MMRM 8 WK EASI Mean 28.1 0-72 score 13.1 SD LS Mean -33.1915 90%CI -44.681 -22.128 42.9 44.3 YR
6 14 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 FAS MMRM 6 WK EASI Mean 28.1 0-72 score 13.1 SD LS Mean -29.7872 90%CI -40.426 -19.362 42.9 44.3 YR
4 13 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 FAS MMRM 4 WK EASI Mean 28.1 0-72 score 13.1 SD LS Mean -28.9362 90%CI -38.085 -20.213 42.9 44.3 YR
2 12 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 FAS MMRM 2 WK EASI Mean 28.1 0-72 score 13.1 SD LS Mean -15.3191 90%CI -23.404 -7.234 42.9 44.3 YR
16 19 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 FAS MMRM 16 WK EASI Mean 28.1 0-72 score 13.1 SD LS Mean -32.9787 90%CI -47.447 -17.872 42.9 44.3 YR
14 18 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 FAS MMRM 14 WK EASI Mean 28.1 0-72 score 13.1 SD LS Mean -29.5745 90%CI -43.83 -15.106 42.9 44.3 YR
13 17 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 FAS MMRM 13 WK EASI Mean 28.1 0-72 score 13.1 SD LS Mean -35.7447 90%CI -48.298 -22.766 42.9 44.3 YR
12 16 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 46.0 FAS MMRM 12 WK EASI Mean 28.1 0-72 score 13.1 SD LS Mean -31.1 90%CI -42.8 -19.4 42.9 44.3 YR
1 11 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 FAS MMRM 1 WK EASI Mean 28.1 0-72 score 13.1 SD LS Mean -14.2553 90%CI -21.277 -7.234 42.9 44.3 YR
0 10 control Double-Blind True abrocitinib Janus kinase inhibitors 10.0 MG ORAL QD TAB 49 49.0 FAS MMRM 0 WK EASI Mean 28.1 0-72 score 13.1 SD LS Mean 0.0 42.9 44.3 YR

290_reich_2020¶

Control rows matched by test output: 4 of 66

Literature data accuracy: 83.33%

Clinical data accuracy: 4.96%

Clinical data accuracy (drop unmatched): 81.89%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
baricitinib 4 oncedaily easi90 16 1 c65t1 test Double-Blind TRUE Baricitinib Janus kinase (JAK) 1/JAK2 inhibitor 4 mg Oral Once daily 111 111 27 ITT Logistic regression NRI 16 WK EASI-90 Percent 24 Percent 66 33.9 YR
4.0 qd easi90 16 65 c65t1 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 27.0 ITT Logistic Regression Model NRI 16 WK EASI 90 24.0 percent 95%CI 17.435 33.554 68.0 33.9 YR
similarity 100 100 100 79 50 100 100 17 0 100 75 67 100 86 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 67 100 100 0 0 0 100 100 100 100 100 100 33 100 100
placebo easi75 16 3 c5t3 test Double-Blind TRUE Placebo Topical Corticosteroids 109 109 25 ITT Logistic regression NRI 16 WK EASI-75 Percent 23 Percent 65 33.7 YR
0.0 qd easi75 16 5 c5t3 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 25.0 ITT Logistic Regression Model NRI 16 WK EASI 75 23.0 percent 95%CI 15.918 31.429 65.0 33.7 YR
similarity 100 100 100 20 0 0 0 0 100 100 75 67 100 86 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 67 100 100 0 0 0 100 100 100 100 100 100 67 100 100
baricitinib 4 oncedaily easi75 16 0 c17t0 test Double-Blind TRUE Baricitinib Janus kinase (JAK) 1/JAK2 inhibitor 4 mg Oral Once daily 111 111 53 ITT Logistic regression NRI 16 WK EASI-75 Percent 48 Percent 66 33.9 YR
4.0 qd easi75 16 17 c17t0 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 53.0 ITT Logistic Regression Model NRI 16 WK EASI 75 48.0 percent 95%CI 38.367 56.735 68.0 33.9 YR
similarity 100 100 100 79 50 100 100 17 0 100 75 67 100 86 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 67 100 100 0 0 0 100 100 100 100 100 100 33 100 100
2mgofbaricitinib 2 oncedaily easi75 16 2 c11t2 test Double-Blind TRUE 2 mg of Baricitinib Janus kinase (JAK) inhibitor 2 mg Oral Once daily 109 109 47 ITT Logistic regression NRI 16 WK EASI-75 Percent 43 Percent 64 33.8 YR
baricitinib 2.0 qd easi75 16 11 c11t2 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 47.0 ITT Logistic Regression Model NRI 16 WK EASI 75 43.0 percent 95%CI 34.286 52.245 64.0 33.8 YR
similarity 100 100 73 90 50 100 100 17 0 100 75 67 100 86 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 67 100 100 0 0 0 100 100 100 100 100 100 67 100 100
placebo 0.0 qd scorad 16 24 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 ITT MMRM 16 WK SCORAD Mean 66.6 0-103 score 13.8 SD LS Mean -21.4 0-103 score 1.9 SE 65.0 33.7 YR
0 21 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 ITT MMRM 0 WK SCORAD Mean 66.6 0-103 score 13.8 SD LS Mean 0.0 0-103 score 65.0 33.7 YR
easi90 8 51 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 5.0 ITT Logistic Regression Model NRI 8 WK EASI 90 4.441 percent 95%CI 2.139 10.691 65.0 33.7 YR
4 50 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 6.0 ITT Logistic Regression Model NRI 4 WK EASI 90 5.345 percent 95%CI 2.385 11.596 65.0 33.7 YR
2 49 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 5.0 ITT Logistic Regression Model NRI 2 WK EASI 90 4.317 percent 65.0 33.7 YR
16 53 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 15.0 ITT Logistic Regression Model NRI 16 WK EASI 90 14.0 percent 95%CI 8.553 21.711 65.0 33.7 YR
12 52 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 9.0 ITT Logistic Regression Model NRI 12 WK EASI 90 8.47 percent 95%CI 4.523 15.708 65.0 33.7 YR
1 48 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 2.0 ITT Logistic Regression Model NRI 1 WK EASI 90 1.995 percent 95%CI -2.281 6.271 65.0 33.7 YR
easi75 8 3 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 16.0 ITT Logistic Regression Model NRI 8 WK EASI 75 14.694 percent 95%CI 9.388 22.449 65.0 33.7 YR
4 2 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 13.0 ITT Logistic Regression Model NRI 4 WK EASI 75 11.837 percent 95%CI 6.939 19.592 65.0 33.7 YR
2 1 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 9.0 ITT Logistic Regression Model NRI 2 WK EASI 75 8.163 percent 95%CI 4.49 15.102 65.0 33.7 YR
12 4 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 22.0 ITT Logistic Regression Model NRI 12 WK EASI 75 20.0 percent 95%CI 13.469 28.571 65.0 33.7 YR
1 0 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 8.0 ITT Logistic Regression Model NRI 1 WK EASI 75 6.939 percent 95%CI 3.673 13.878 65.0 33.7 YR
easi50 16 18 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 45.0 ITT Logistic Regression Model NRI 16 WK EASI 50 41.0 percent 65.0 33.7 YR
easi 8 31 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 ITT MMRM 8 WK EASI Mean 28.5 0-72 score 12.3 SD LS Mean -42.632 3.026 SE 65.0 33.7 YR
4 30 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 ITT MMRM 4 WK EASI Mean 28.5 0-72 score 12.3 SD LS Mean -36.842 2.763 SE 65.0 33.7 YR
2 29 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 ITT MMRM 2 WK EASI Mean 28.5 0-72 score 12.3 SD LS Mean -34.474 2.763 SE 65.0 33.7 YR
16 33 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 ITT MMRM 16 WK EASI Mean 28.5 0-72 score 12.3 SD LS Mean -45.1 3.8 SE 65.0 33.7 YR
12 32 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 ITT MMRM 12 WK EASI Mean 28.5 0-72 score 12.3 SD LS Mean -45.263 3.421 SE 65.0 33.7 YR
1 28 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 ITT MMRM 1 WK EASI Mean 28.5 0-72 score 12.3 SD LS Mean -22.632 2.632 SE 65.0 33.7 YR
0 27 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 109 109.0 ITT MMRM 0 WK EASI Mean 28.5 0-72 score 12.3 SD LS Mean 0.0 65.0 33.7 YR
baricitinib 4.0 qd scorad 16 26 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 ITT MMRM 16 WK SCORAD Mean 68.3 0-103 score 13.2 SD LS Mean -35.8 0-103 score 1.8 SE 68.0 33.9 YR
0 23 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 ITT MMRM 0 WK SCORAD Mean 68.3 0-103 score 13.2 SD LS Mean 0.0 0-103 score 68.0 33.9 YR
easi90 8 63 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 20.0 ITT Logistic Regression Model NRI 8 WK EASI 90 18.257 percent 95%CI 12.007 26.481 68.0 33.9 YR
4 62 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 18.0 ITT Logistic Regression Model NRI 4 WK EASI 90 16.201 percent 95%CI 10.279 24.096 68.0 33.9 YR
2 61 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 7.0 ITT Logistic Regression Model NRI 2 WK EASI 90 6.62 percent 95%CI 3.001 12.213 68.0 33.9 YR
12 64 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 24.0 ITT Logistic Regression Model NRI 12 WK EASI 90 21.627 percent 95%CI 15.05 30.511 68.0 33.9 YR
1 60 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 4.0 ITT Logistic Regression Model NRI 1 WK EASI 90 3.639 percent 95%CI -1.624 8.902 68.0 33.9 YR
easi75 8 15 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 45.0 ITT Logistic Regression Model NRI 8 WK EASI 75 40.816 percent 95%CI 32.653 50.612 68.0 33.9 YR
4 14 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 43.0 ITT Logistic Regression Model NRI 4 WK EASI 75 38.367 percent 95%CI 30.204 47.755 68.0 33.9 YR
2 13 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 29.0 ITT Logistic Regression Model NRI 2 WK EASI 75 26.531 percent 95%CI 18.776 35.102 68.0 33.9 YR
12 16 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 53.0 ITT Logistic Regression Model NRI 12 WK EASI 75 47.755 percent 95%CI 38.367 56.735 68.0 33.9 YR
1 12 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 10.0 ITT Logistic Regression Model NRI 1 WK EASI 75 8.98 percent 95%CI 4.898 15.918 68.0 33.9 YR
easi50 16 20 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 78.0 ITT Logistic Regression Model NRI 16 WK EASI 50 70.0 percent 68.0 33.9 YR
easi 8 45 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 ITT MMRM 8 WK EASI Mean 30.9 0-72 score 12.6 SD LS Mean -67.105 2.895 SE 68.0 33.9 YR
4 44 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 ITT MMRM 4 WK EASI Mean 30.9 0-72 score 12.6 SD LS Mean -67.105 2.763 SE 68.0 33.9 YR
2 43 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 ITT MMRM 2 WK EASI Mean 30.9 0-72 score 12.6 SD LS Mean -56.842 2.632 SE 68.0 33.9 YR
16 47 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 ITT MMRM 16 WK EASI Mean 30.9 0-72 score 12.6 SD LS Mean -67.2 3.7 SE 68.0 33.9 YR
12 46 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 ITT MMRM 12 WK EASI Mean 30.9 0-72 score 12.6 SD LS Mean -68.158 3.289 SE 68.0 33.9 YR
1 42 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 ITT MMRM 1 WK EASI Mean 30.9 0-72 score 12.6 SD LS Mean -38.947 2.632 SE 68.0 33.9 YR
0 41 control Double-Blind True baricitinib Janus kinase inhibitors 4.0 MG ORAL QD TAB 111 111.0 ITT MMRM 0 WK EASI Mean 30.9 0-72 score 12.6 SD LS Mean 0.0 68.0 33.9 YR
2.0 qd scorad 16 25 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 ITT MMRM 16 WK SCORAD Mean 66.8 0-103 score 14.0 SD LS Mean -29.9 0-103 score 1.9 SE 64.0 33.8 YR
0 22 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 ITT MMRM 0 WK SCORAD Mean 66.8 0-103 score 14.0 SD LS Mean 0.0 0-103 score 64.0 33.8 YR
easi90 8 57 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 17.0 ITT Logistic Regression Model NRI 8 WK EASI 90 15.954 percent 95%CI 10.033 23.52 64.0 33.8 YR
4 56 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 11.0 ITT Logistic Regression Model NRI 4 WK EASI 90 10.28 percent 95%CI 5.674 17.189 64.0 33.8 YR
2 55 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 5.0 ITT Logistic Regression Model NRI 2 WK EASI 90 4.647 percent 95%CI 1.686 10.239 64.0 33.8 YR
16 59 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 19.0 ITT Logistic Regression Model NRI 16 WK EASI 90 17.0 percent 95%CI 10.855 24.674 64.0 33.8 YR
12 58 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 20.0 ITT Logistic Regression Model NRI 12 WK EASI 90 18.339 percent 95%CI 12.418 26.892 64.0 33.8 YR
1 54 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 0.0 ITT Logistic Regression Model NRI 1 WK EASI 90 0.02 percent 95%CI -3.271 3.311 64.0 33.8 YR
easi75 8 9 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 37.0 ITT Logistic Regression Model NRI 8 WK EASI 75 33.878 percent 95%CI 25.714 42.857 64.0 33.8 YR
4 8 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 29.0 ITT Logistic Regression Model NRI 4 WK EASI 75 26.531 percent 95%CI 18.776 35.51 64.0 33.8 YR
2 7 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 21.0 ITT Logistic Regression Model NRI 2 WK EASI 75 19.184 percent 95%CI 13.061 27.755 64.0 33.8 YR
12 10 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 44.0 ITT Logistic Regression Model NRI 12 WK EASI 75 40.0 percent 95%CI 31.429 49.388 64.0 33.8 YR
1 6 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 5.0 ITT Logistic Regression Model NRI 1 WK EASI 75 4.49 percent 95%CI 1.633 10.204 64.0 33.8 YR
easi50 16 19 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 70.0 ITT Logistic Regression Model NRI 16 WK EASI 50 64.0 percent 64.0 33.8 YR
easi 8 38 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 ITT MMRM 8 WK EASI Mean 29.3 0-72 score 11.9 SD LS Mean -60.526 2.895 SE 64.0 33.8 YR
4 37 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 ITT MMRM 4 WK EASI Mean 29.3 0-72 score 11.9 SD LS Mean -57.895 2.763 SE 64.0 33.8 YR
2 36 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 ITT MMRM 2 WK EASI Mean 29.3 0-72 score 11.9 SD LS Mean -48.158 2.763 SE 64.0 33.8 YR
16 40 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 ITT MMRM 16 WK EASI Mean 29.3 0-72 score 11.9 SD LS Mean -58.2 3.7 SE 64.0 33.8 YR
12 39 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 ITT MMRM 12 WK EASI Mean 29.3 0-72 score 11.9 SD LS Mean -62.895 3.29 SE 64.0 33.8 YR
1 35 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 ITT MMRM 1 WK EASI Mean 29.3 0-72 score 11.9 SD LS Mean -33.947 2.5 SE 64.0 33.8 YR
0 34 control Double-Blind True baricitinib Janus kinase inhibitors 2.0 MG ORAL QD TAB 109 109.0 ITT MMRM 0 WK EASI Mean 29.3 0-72 score 11.9 SD LS Mean 0.0 64.0 33.8 YR

291_silverberg_2020¶

Control rows matched by test output: 34 of 111

Literature data accuracy: 91.33%

Clinical data accuracy: 24.69%

Clinical data accuracy (drop unmatched): 80.61%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
abrocitinib 200 oncedaily easi75 2 23 c9t23 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 200 mg oral once-daily 155 152 37 PPAS Cochran-Mantel-Haenszel test 2 WK EASI-75 Percentage 24.3 percent 56.8 33.5 YR
200.0 qd easi75 4 9 c9t23 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 153.0 78.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 75 51.0 percent 95%CI 43.1 58.9 56.8 33.5 YR
similarity 100 100 100 77 75 100 100 17 0 100 50 33 57 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 100 100 0 0 0 100 100 100 100 100 100 100 100 100
200 oncedaily easi75 2 22 c8t22 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 200 mg oral once-daily 155 152 37 FAS Cochran-Mantel-Haenszel test 2 WK EASI-75 Percentage 24.3 percent 56.8 33.5 YR
200.0 qd easi75 2 8 c8t22 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 152.0 37.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 75 24.3 percent 95%CI 17.5 31.2 56.8 33.5 YR
similarity 100 100 100 77 75 100 100 17 0 100 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
200 oncedaily easi75 12 25 c80t25 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 200 mg oral once-daily 155 130 81 PPAS Cochran-Mantel-Haenszel test 12 WK EASI-75 Percent 62.3 Percent 56.8 33.5 YR
200.0 qd easi75 12 80 c80t25 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 130 130.0 81.0 PP 12 WK EASI 75 62.3 percent 95%CI 54.0 70.6 56.8 33.5 YR
similarity 100 100 100 77 75 100 100 17 0 33 75 67 67 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
100mg oncedaily easi75 12 2 c7t2 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 100 mg mg oral once-daily 158 155 69 FAS Cochran-Mantel-Haenszel test 12 WK EASI-75 Percentage 44.5 percent 95% CI 37.1 53.3 59.5 37.4 YR
100.0 qd easi75 12 7 c7t2 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 155.0 69.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 75 44.5 percent 95%CI 36.7 52.3 59.5 37.4 YR
similarity 100 100 100 77 55 100 100 17 0 100 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 50 75 100 100 100 100 100 100 100 100 100
100mg oncedaily easi75 12 3 c79t3 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 100 mg mg oral once-daily 158 128 63 PPAS Cochran-Mantel-Haenszel test 12 WK EASI-75 Percent 49.2 Percent 40.0 60.9 59.5 37.4 YR
100.0 qd easi75 12 79 c79t3 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 128 128.0 63.0 PP 12 WK EASI 75 49.2 percent 95%CI 40.6 57.9 59.5 37.4 YR
similarity 100 100 100 77 55 100 100 17 0 67 75 67 67 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 50 50 100 100 100 100 100 100 100 100 100
placebo oncedaily easi75 12 15 c78t15 test Double-Blind TRUE Placebo Oral Once-daily 78 52 7 PPAS Cochran-Mantel-Haenszel test 12 WK EASI-75 Percentage 10.4 percent 60.3 33.4 YR
0.0 qd easi75 12 78 c78t15 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 52 52.0 7.0 PP 12 WK EASI 75 13.5 percent 95%CI 4.2 22.7 60.3 33.4 YR
similarity 100 100 100 0 0 0 100 17 100 0 67 50 67 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 50 100 100 0 0 0 100 100 100 100 100 100 100 100 100
abrocitinib 200 oncedaily easi90 12 33 c62t33 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 200 mg oral once-daily 155 130 58 PPAS Cochran-Mantel-Haenszel test 12 WK EASI-90 Percentage 37.7 percent 56.8 33.5 YR
200.0 qd easi 12 62 c62t33 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 12 WK EASI Mean 29.0 0-72 score 12.4 SD LS Mean -73.3 95%CI -79.7 -66.9 56.8 33.5 YR
similarity 100 100 100 77 75 100 100 17 0 100 25 0 57 12 100 100 100 73 0 0 0 0 0 100 100 100 100 100 100 100 100 100 0 0 0 100 100 100 100 0 0 100 0 0 0 100 100 100
100mg oncedaily easi75 2 1 c5t1 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 100 mg mg oral once-daily 158 157 56 PPAS Cochran-Mantel-Haenszel test 2 WK EASI-75 Percentage 35.7 percent 59.5 37.4 YR
100.0 qd easi75 4 5 c5t1 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 155.0 41.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 75 26.5 percent 95%CI 19.5 33.4 59.5 37.4 YR
similarity 100 100 100 77 55 100 100 17 0 100 50 0 57 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 100 100 0 0 0 100 100 100 100 100 100 100 100 100
100mg oncedaily easi50 12 9 c57t9 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 100 mg mg oral once-daily 158 128 106 PPAS Cochran-Mantel-Haenszel test 12 WK EASI-50 Percentage 68.4 percent 59.5 37.4 YR
100.0 qd easi 12 57 c57t9 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 12 WK EASI Mean 28.4 0-72 score 11.2 SD LS Mean -60.0 95%CI -66.5 -53.6 59.5 37.4 YR
similarity 100 100 100 77 55 100 100 17 0 100 50 0 57 12 100 100 100 73 0 0 0 0 0 100 100 100 100 100 100 100 100 100 0 0 0 100 100 100 100 0 0 100 0 0 0 100 100 100
100mg oncedaily easi50 2 7 c53t7 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 100 mg mg oral once-daily 158 157 56 PPAS Cochran-Mantel-Haenszel test 2 WK EASI-50 Percentage 35.7 percent 59.5 37.4 YR
100.0 qd easi 0 53 c53t7 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 0 WK EASI Mean 28.4 0-72 score 11.2 SD LS Mean 0.0 59.5 37.4 YR
similarity 100 100 100 77 55 100 100 17 0 100 50 0 57 12 100 0 100 73 0 0 0 0 0 100 100 100 100 100 100 100 100 100 0 0 0 100 100 100 100 0 0 100 100 100 100 100 100 100
100mg oncedaily easi75 2 0 c4t0 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 100 mg mg oral once-daily 158 157 16 FAS Cochran-Mantel-Haenszel test 2 WK EASI-75 Percentage 10.2 percent 59.5 37.4 YR
100.0 qd easi75 2 4 c4t0 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 157.0 16.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 75 10.2 percent 95%CI 5.5 14.9 59.5 37.4 YR
similarity 100 100 100 77 55 100 100 17 0 100 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
200 oncedaily easi50 12 29 c47t29 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 200 mg oral once-daily 155 130 123 PPAS Cochran-Mantel-Haenszel test 12 WK EASI-50 Percentage 79.9 percent 56.8 33.5 YR
200.0 qd easi100 12 47 c47t29 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 154.0 11.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 100 7.1 percent 95%CI 3.1 11.2 56.8 33.5 YR
similarity 100 100 100 77 75 100 100 17 0 100 25 29 57 100 100 100 100 80 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 29 100 100 0 0 0 100 100 100 100 100 100 100 100 100
placebo oncedaily easi75 12 14 c3t14 test Double-Blind TRUE Placebo Oral Once-daily 78 77 8 FAS Cochran-Mantel-Haenszel test 12 WK EASI-75 Percentage 10.4 percent 60.3 33.4 YR
0.0 qd easi75 12 3 c3t14 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 77.0 8.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 75 10.4 percent 95%CI 3.6 17.2 60.3 33.4 YR
similarity 100 100 100 0 0 0 100 17 100 100 67 50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
oncedaily easi50 12 19 c39t19 test Double-Blind TRUE Placebo Oral Once-daily 78 52 15 PPAS Cochran-Mantel-Haenszel test 12 WK EASI-50 Percentage 19.5 percent 60.3 33.4 YR
0.0 qd easi100 12 39 c39t19 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 77.0 0.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 100 0.0 percent 95%CI 0.0 4.7 60.3 33.4 YR
similarity 100 100 100 0 0 0 100 17 100 100 0 0 57 100 100 100 100 80 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 29 100 100 0 0 0 100 100 100 100 100 100 100 100 100
abrocitinib 200 oncedaily easi90 12 32 c35t32 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 200 mg oral once-daily 155 154 58 FAS Cochran-Mantel-Haenszel test 12 WK EASI-90 Percentage 37.7 percent 56.8 33.5 YR
200.0 qd easi90 12 35 c35t32 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 154.0 58.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 90 37.7 percent 95%CI 30.0 45.3 56.8 33.5 YR
similarity 100 100 100 77 75 100 100 17 0 100 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
200 oncedaily easi90 2 31 c33t31 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 200 mg oral once-daily 155 152 14 PPAS Cochran-Mantel-Haenszel test 2 WK EASI-90 Percentage 9.2 percent 56.8 33.5 YR
200.0 qd easi90 4 33 c33t31 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 153.0 35.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 90 22.9 percent 95%CI 16.2 29.5 56.8 33.5 YR
similarity 100 100 100 77 75 100 100 17 0 100 50 0 57 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 86 100 100 0 0 0 100 100 100 100 100 100 100 100 100
200 oncedaily easi90 2 30 c32t30 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 200 mg oral once-daily 155 152 14 FAS Cochran-Mantel-Haenszel test 2 WK EASI-90 Percentage 9.2 percent 56.8 33.5 YR
200.0 qd easi90 2 32 c32t30 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 152.0 14.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 90 9.2 percent 95%CI 4.6 13.8 56.8 33.5 YR
similarity 100 100 100 77 75 100 100 17 0 100 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
100mg oncedaily easi90 12 10 c31t10 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 100 mg mg oral once-daily 158 155 37 FAS Cochran-Mantel-Haenszel test 12 WK EASI-90 Percentage 23.9 percent 59.5 37.4 YR
100.0 qd easi90 12 31 c31t10 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 155.0 37.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 90 23.9 percent 95%CI 17.2 30.6 59.5 37.4 YR
similarity 100 100 100 77 55 100 100 17 0 100 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
100mg oncedaily easi90 12 11 c28t11 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 100 mg mg oral once-daily 158 128 37 PPAS Cochran-Mantel-Haenszel test 12 WK EASI-90 Percentage 23.9 percent 59.5 37.4 YR
100.0 qd easi90 2 28 c28t11 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 157.0 4.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 90 2.5 percent 59.5 37.4 YR
similarity 100 100 100 77 55 100 100 17 0 100 25 0 57 100 100 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 57 100 100 100 100 100 100 100 100 100 100 100 100 100 100
placebo oncedaily easi90 12 20 c27t20 test Double-Blind TRUE Placebo Oral Once-daily 78 77 3 FAS Cochran-Mantel-Haenszel test 12 WK EASI-90 Percentage 3.9 percent 60.3 33.4 YR
0.0 qd easi90 12 27 c27t20 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 77.0 3.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 90 3.9 percent 95%CI 0.0 8.2 60.3 33.4 YR
similarity 100 100 100 0 0 0 100 17 100 100 67 50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
oncedaily easi90 12 21 c24t21 test Double-Blind TRUE Placebo Oral Once-daily 78 52 3 PPAS Cochran-Mantel-Haenszel test 12 WK EASI-90 Percentage 3.9 percent 60.3 33.4 YR
0.0 qd easi90 2 24 c24t21 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 76.0 0.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 90 0.0 percent 95%CI -4.7 4.7 60.3 33.4 YR
similarity 100 100 100 0 0 0 100 17 100 100 0 0 57 100 100 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 33 100 100 0 0 0 100 100 100 100 100 100 100 100 100
abrocitinib 200 oncedaily easi50 12 28 c23t28 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 200 mg oral once-daily 155 154 123 FAS Cochran-Mantel-Haenszel test 12 WK EASI-50 Percentage 79.9 percent 56.8 33.5 YR
200.0 qd easi50 12 23 c23t28 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 154.0 123.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 50 79.9 percent 95%CI 73.5 86.2 56.8 33.5 YR
similarity 100 100 100 77 75 100 100 17 0 100 75 75 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
200 oncedaily easi50 2 27 c21t27 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 200 mg oral once-daily 155 152 84 PPAS Cochran-Mantel-Haenszel test 2 WK EASI-50 Percentage 55.3 percent 56.8 33.5 YR
200.0 qd easi50 4 21 c21t27 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 153.0 120.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 50 78.4 percent 95%CI 71.9 84.9 56.8 33.5 YR
similarity 100 100 100 77 75 100 100 17 0 100 50 0 57 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 100 100 0 0 0 100 100 100 100 100 100 100 100 100
200 oncedaily easi50 2 26 c20t26 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 200 mg oral once-daily 155 152 84 FAS Cochran-Mantel-Haenszel test 2 WK EASI-50 Percentage 55.3 percent 56.8 33.5 YR
200.0 qd easi50 2 20 c20t26 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 152.0 84.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 50 55.3 percent 95%CI 47.4 63.2 56.8 33.5 YR
similarity 100 100 100 77 75 100 100 17 0 100 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
placebo oncedaily easi75 2 13 c1t13 test Double-Blind TRUE Placebo Oral Once-daily 78 76 1 PPAS Cochran-Mantel-Haenszel test 2 WK EASI-75 Percentage 1.3 percent 60.3 33.4 YR
0.0 qd easi75 4 1 c1t13 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 77.0 5.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 75 6.5 percent 95%CI 1.0 12.0 60.3 33.4 YR
similarity 100 100 100 0 0 0 100 17 100 100 33 0 57 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 33 100 100 0 0 0 100 100 100 100 100 100 100 100 100
abrocitinib 100mg oncedaily easi50 12 8 c19t8 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 100 mg mg oral once-daily 158 155 106 FAS Cochran-Mantel-Haenszel test 12 WK EASI-50 Percentage 68.4 percent 59.5 37.4 YR
100.0 qd easi50 12 19 c19t8 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 155.0 106.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 50 68.4 percent 95%CI 61.1 75.7 59.5 37.4 YR
similarity 100 100 100 77 55 100 100 17 0 100 75 75 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
100mg oncedaily easi50 4 5 c18t5 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 100 mg mg oral once-daily 158 157 56 PPAS Cochran-Mantel-Haenszel test 4 WK EASI-50 Percentage 35.7 percent 59.5 37.4 YR
100.0 qd easi50 8 18 c18t5 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 157.0 104.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 50 66.2 percent 95%CI 58.8 73.6 59.5 37.4 YR
similarity 100 100 100 77 55 100 100 17 0 100 75 0 57 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 100 100 0 0 0 100 100 100 100 100 100 100 100 100
100mg oncedaily easi50 4 4 c17t4 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 100 mg mg oral once-daily 158 157 56 FAS Cochran-Mantel-Haenszel test 4 WK EASI-50 Percentage 35.7 percent 59.5 37.4 YR
100.0 qd easi50 4 17 c17t4 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 155.0 91.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 50 58.7 percent 95%CI 51.0 66.5 59.5 37.4 YR
similarity 100 100 100 77 55 100 100 17 0 100 50 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 75 100 100 0 0 0 100 100 100 100 100 100 100 100 100
100mg oncedaily easi50 2 6 c16t6 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 100 mg mg oral once-daily 158 157 56 FAS Cochran-Mantel-Haenszel test 2 WK EASI-50 Percentage 35.7 percent 59.5 37.4 YR
100.0 qd easi50 2 16 c16t6 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 157.0 56.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 50 35.7 percent 95%CI 28.2 43.2 59.5 37.4 YR
similarity 100 100 100 77 55 100 100 17 0 100 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
placebo oncedaily easi50 12 18 c15t18 test Double-Blind TRUE Placebo Oral Once-daily 78 77 15 FAS Cochran-Mantel-Haenszel test 12 WK EASI-50 Percentage 19.5 percent 60.3 33.4 YR
0.0 qd easi50 12 15 c15t18 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 77.0 15.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 50 19.5 percent 95%CI 10.6 28.3 60.3 33.4 YR
similarity 100 100 100 0 0 0 100 17 100 100 67 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
oncedaily easi50 2 17 c13t17 test Double-Blind TRUE Placebo Oral Once-daily 78 76 8 PPAS Cochran-Mantel-Haenszel test 2 WK EASI-50 Percentage 10.5 percent 60.3 33.4 YR
0.0 qd easi50 4 13 c13t17 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 77.0 22.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 50 28.6 percent 95%CI 18.5 38.7 60.3 33.4 YR
similarity 100 100 100 0 0 0 100 17 100 100 33 0 57 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 100 100 0 0 0 100 100 100 100 100 100 100 100 100
oncedaily easi50 2 16 c12t16 test Double-Blind TRUE Placebo Oral Once-daily 78 76 8 FAS Cochran-Mantel-Haenszel test 2 WK EASI-50 Percentage 10.5 percent 60.3 33.4 YR
0.0 qd easi50 2 12 c12t16 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 76.0 8.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 50 10.5 percent 95%CI 3.6 17.4 60.3 33.4 YR
similarity 100 100 100 0 0 0 100 17 100 100 67 50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
abrocitinib 200 oncedaily easi75 12 24 c11t24 test Double-Blind TRUE abrocitinib Janus kinase 1 selective inhibitor 200 mg oral once-daily 155 154 94 FAS Cochran-Mantel-Haenszel test 12 WK EASI-75 Percentage 61.0 percent 95% CI 40.0 60.9 56.8 33.5 YR
200.0 qd easi75 12 11 c11t24 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 154.0 94.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 75 61.0 percent 95%CI 53.3 68.7 56.8 33.5 YR
similarity 100 100 100 77 75 100 100 17 0 100 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 25 50 100 100 100 100 100 100 100 100 100
placebo oncedaily easi75 2 12 c0t12 test Double-Blind TRUE Placebo Oral Once-daily 78 76 1 FAS Cochran-Mantel-Haenszel test 2 WK EASI-75 Percentage 1.3 percent 60.3 33.4 YR
0.0 qd easi75 2 0 c0t12 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 76.0 1.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 75 1.3 percent 95%CI 0.0 3.9 60.3 33.4 YR
similarity 100 100 100 0 0 0 100 17 100 100 67 50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
scorad 8 99 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 8 WK SCORAD LS Mean -1.5 0-103 score 95%CI -2.1 -0.9 60.3 33.4 YR
84 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 8 WK SCORAD LS Mean -1.8 0-103 score 95%CI -2.4 -1.2 60.3 33.4 YR
66 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 8 WK SCORAD Mean 64.3 0-103 pt scale 12.4 SD LS Mean -23.1 95%CI -29.2 -17.1 60.3 33.4 YR
4 98 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 4 WK SCORAD LS Mean -1.0 0-103 score 95%CI -1.5 -0.5 60.3 33.4 YR
83 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 4 WK SCORAD LS Mean -1.2 0-103 score 95%CI -1.7 -0.6 60.3 33.4 YR
65 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 4 WK SCORAD Mean 64.3 0-103 pt scale 12.4 SD LS Mean -17.2 95%CI -22.5 -12.0 60.3 33.4 YR
2 97 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 2 WK SCORAD LS Mean -0.5 0-103 score 95%CI -1.0 0.0 60.3 33.4 YR
82 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 2 WK SCORAD LS Mean -0.6 0-103 score 95%CI -1.1 -0.1 60.3 33.4 YR
64 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 2 WK SCORAD Mean 64.3 0-103 pt scale 12.4 SD LS Mean -6.3 95%CI -11.0 -1.6 60.3 33.4 YR
12 100 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 12 WK SCORAD LS Mean -2.1 0-103 score 95%CI -2.7 -1.5 60.3 33.4 YR
85 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 12 WK SCORAD LS Mean -2.1 0-103 score 95%CI -2.7 -1.4 60.3 33.4 YR
67 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 12 WK SCORAD Mean 64.3 0-103 pt scale 12.4 SD LS Mean -22.7 95%CI -30.4 -15.1 60.3 33.4 YR
0 96 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 0 WK SCORAD LS Mean 0.0 0-103 score 60.3 33.4 YR
81 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 0 WK SCORAD LS Mean 0.0 0-103 score 60.3 33.4 YR
63 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 0 WK SCORAD Mean 64.3 0-103 pt scale 12.4 SD LS Mean 0.0 60.3 33.4 YR
easi90 8 26 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 2.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 90 2.6 percent 95%CI 0.0 6.1 60.3 33.4 YR
4 25 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 77.0 0.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 90 0.0 percent 95%CI -4.7 4.7 60.3 33.4 YR
easi75 8 2 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 10.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 75 12.8 percent 95%CI 5.4 20.2 60.3 33.4 YR
easi50 8 14 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 27.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 50 34.6 percent 95%CI 24.1 45.2 60.3 33.4 YR
easi100 8 38 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 0.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 100 0.0 percent 95%CI 0.0 4.6 60.3 33.4 YR
4 37 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 77.0 0.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 100 0.0 percent 95%CI 0.0 4.7 60.3 33.4 YR
2 36 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 76.0 0.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 100 0.0 percent 95%CI 0.0 4.7 60.3 33.4 YR
easi 8 51 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 8 WK EASI Mean 28.0 0-72 score 10.2 SD LS Mean -33.0 95%CI -41.1 -25.0 60.3 33.4 YR
4 50 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 4 WK EASI Mean 28.0 0-72 score 10.2 SD LS Mean -24.4 95%CI -31.1 -17.7 60.3 33.4 YR
2 49 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 2 WK EASI Mean 28.0 0-72 score 10.2 SD LS Mean -9.0 95%CI -15.4 -2.5 60.3 33.4 YR
12 52 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 12 WK EASI Mean 28.0 0-72 score 10.2 SD LS Mean -28.6 95%CI -38.4 -18.8 60.3 33.4 YR
0 48 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD 78 78.0 FAS MMRM 0 WK EASI Mean 28.0 0-72 score 10.2 SD LS Mean 0.0 60.3 33.4 YR
abrocitinib 200.0 qd scorad 8 109 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 8 WK SCORAD LS Mean -3.9 0-103 score 95%CI -4.3 -3.5 56.8 33.5 YR
94 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 8 WK SCORAD LS Mean -4.3 0-103 score 95%CI -4.7 -4.0 56.8 33.5 YR
76 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 8 WK SCORAD Mean 64.1 0-103 pt scale 13.1 SD LS Mean -56.7 95%CI -60.9 -52.6 56.8 33.5 YR
4 108 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 4 WK SCORAD LS Mean -3.9 0-103 score 95%CI -4.3 -3.6 56.8 33.5 YR
93 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 4 WK SCORAD LS Mean -4.3 0-103 score 95%CI -4.6 -3.9 56.8 33.5 YR
75 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 4 WK SCORAD Mean 64.1 0-103 pt scale 13.1 SD LS Mean -53.1 95%CI -56.9 -49.4 56.8 33.5 YR
2 107 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 2 WK SCORAD LS Mean -2.9 0-103 score 95%CI -3.3 -2.5 56.8 33.5 YR
92 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 2 WK SCORAD LS Mean -3.5 0-103 score 95%CI -3.8 -3.1 56.8 33.5 YR
74 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 2 WK SCORAD Mean 64.1 0-103 pt scale 13.1 SD LS Mean -38.5 95%CI -41.8 -35.1 56.8 33.5 YR
12 110 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 12 WK SCORAD LS Mean -3.8 0-103 score 95%CI -4.2 -3.4 56.8 33.5 YR
95 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 12 WK SCORAD LS Mean -4.2 0-103 score 95%CI -4.7 -3.8 56.8 33.5 YR
77 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 12 WK SCORAD Mean 64.1 0-103 pt scale 13.1 SD LS Mean -56.2 95%CI -61.2 -51.1 56.8 33.5 YR
0 106 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 0 WK SCORAD LS Mean 0.0 0-103 score 56.8 33.5 YR
91 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 0 WK SCORAD LS Mean 0.0 0-103 score 56.8 33.5 YR
73 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 0 WK SCORAD Mean 64.1 0-103 pt scale 13.1 SD LS Mean 0.0 56.8 33.5 YR
easi90 8 34 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 154.0 53.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 90 34.4 percent 95%CI 26.9 41.9 56.8 33.5 YR
easi75 8 10 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 154.0 93.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 75 60.4 percent 95%CI 52.7 68.1 56.8 33.5 YR
easi50 8 22 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 154.0 127.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 50 82.5 percent 95%CI 76.5 88.5 56.8 33.5 YR
easi100 8 46 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 154.0 6.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 100 3.9 percent 95%CI 0.8 7.0 56.8 33.5 YR
4 45 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 153.0 6.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 100 3.9 percent 95%CI 0.8 7.0 56.8 33.5 YR
2 44 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 152.0 2.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 100 1.3 percent 95%CI 0.0 3.1 56.8 33.5 YR
easi 8 61 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 8 WK EASI Mean 29.0 0-72 score 12.4 SD LS Mean -73.2 95%CI -78.7 -67.7 56.8 33.5 YR
4 60 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 4 WK EASI Mean 29.0 0-72 score 12.4 SD LS Mean -69.0 95%CI -73.7 -64.2 56.8 33.5 YR
2 59 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 2 WK EASI Mean 29.0 0-72 score 12.4 SD LS Mean -51.3 95%CI -55.9 -46.7 56.8 33.5 YR
0 58 control Double-Blind True abrocitinib Janus kinase inhibitors 200.0 MG ORAL QD TAB 155 155.0 FAS MMRM 0 WK EASI Mean 29.0 0-72 score 12.4 SD LS Mean 0.0 56.8 33.5 YR
100.0 qd scorad 8 104 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 8 WK SCORAD LS Mean -3.1 0-103 score 95%CI -3.5 -2.7 59.5 37.4 YR
89 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 8 WK SCORAD LS Mean -3.4 0-103 score 95%CI -3.8 -3.0 59.5 37.4 YR
71 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 8 WK SCORAD Mean 63.8 0-103 pt scale 11.4 SD LS Mean -42.6 95%CI -46.7 -38.4 59.5 37.4 YR
4 103 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 4 WK SCORAD LS Mean -2.8 0-103 score 95%CI -3.1 -2.4 59.5 37.4 YR
88 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 4 WK SCORAD LS Mean -3.1 0-103 score 95%CI -3.5 -2.7 59.5 37.4 YR
70 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 4 WK SCORAD Mean 63.8 0-103 pt scale 11.4 SD LS Mean -38.798 95%CI -42.6 -35.1 59.5 37.4 YR
2 102 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 2 WK SCORAD LS Mean -1.9 0-103 score 95%CI -2.2 -1.5 59.5 37.4 YR
87 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 2 WK SCORAD LS Mean -2.3 0-103 score 95%CI -2.7 -2.0 59.5 37.4 YR
69 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 2 WK SCORAD Mean 63.8 0-103 pt scale 11.4 SD LS Mean -27.2 95%CI -30.5 -23.9 59.5 37.4 YR
12 105 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 12 WK SCORAD LS Mean -3.0 0-103 score 95%CI -3.4 -2.6 59.5 37.4 YR
90 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 12 WK SCORAD LS Mean -3.5 0-103 score 95%CI -3.9 -3.1 59.5 37.4 YR
72 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 12 WK SCORAD Mean 63.8 0-103 pt scale 11.4 SD LS Mean -45.8 95%CI -50.9 -40.7 59.5 37.4 YR
0 101 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 0 WK SCORAD LS Mean 0.0 0-103 score 59.5 37.4 YR
86 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 0 WK SCORAD LS Mean 0.0 0-103 score 59.5 37.4 YR
68 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 0 WK SCORAD Mean 63.8 0-103 pt scale 11.4 SD LS Mean 0.0 59.5 37.4 YR
easi90 8 30 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 157.0 27.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 90 17.2 percent 95%CI 11.3 23.1 59.5 37.4 YR
4 29 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 155.0 15.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 90 9.7 percent 95%CI 5.0 14.3 59.5 37.4 YR
easi75 8 6 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 157.0 68.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 75 43.3 percent 95%CI 35.6 51.1 59.5 37.4 YR
easi100 8 42 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 157.0 2.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 100 1.3 percent 95%CI 0.0 3.0 59.5 37.4 YR
4 41 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 155.0 2.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 100 1.3 percent 95%CI 0.0 3.1 59.5 37.4 YR
2 40 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 157.0 0.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 100 0.0 percent 95%CI 0.0 2.3 59.5 37.4 YR
12 43 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 155.0 8.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 100 5.2 percent 95%CI 1.7 8.6 59.5 37.4 YR
easi 8 56 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 8 WK EASI Mean 28.4 0-72 score 11.2 SD LS Mean -59.5 95%CI -65.0 -54.0 59.5 37.4 YR
4 55 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 4 WK EASI Mean 28.4 0-72 score 11.2 SD LS Mean -54.3 95%CI -59.1 -49.5 59.5 37.4 YR
2 54 control Double-Blind True abrocitinib Janus kinase inhibitors 100.0 MG ORAL QD TAB 158 158.0 FAS MMRM 2 WK EASI Mean 28.4 0-72 score 11.2 SD LS Mean -39.2 95%CI -43.8 -34.7 59.5 37.4 YR

287_silverberg_2021¶

Control rows matched by test output: 9 of 84

Literature data accuracy: 84.93%

Clinical data accuracy: 9.05%

Clinical data accuracy (drop unmatched): 84.43%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
tralokinumab 300 q2w easi90 16 2 c83t2 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 253 252 83 FAS NRI 16 WK EASI-90 n(%) 32.9 percent 95% CI (2.1-20.7) 2.1 20.7 49.4 37.0 YR
300.0 q2w easi90 16 83 c83t2 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 83.0 FAS NRI 16 WK EASI 90 32.9 percent 49.4 37.0 YR
similarity 100 100 100 36 75 100 100 100 100 67 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
300 q2w easi90 16 5 c78t5 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 252 252 83 FAS Cochran-Mantel-Haenszel test NRI 16 WK EASI-90 Percent 32.9 Percent 95% CI 2.1 20.7 49.4 37.0 YR
300.0 q2w easi90 6 78 c78t5 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 41.0 FAS NRI 6 WK EASI 90 16.1444 percent 49.4 37.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 75 0 100 0 100 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 18 100 100 0 0 0 100 100 100 100 100 100 100 100 100
300 q2w easi50 16 1 c67t1 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 253 252 200 FAS Cochran-Mantel-Haenszel test NRI 16 WK EASI-50 Percent 79.4 Percent 11.3 31.3 49.4 37.0 YR
300.0 q2w easi50 16 67 c67t1 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 200.0 FAS NRI 16 WK EASI 50 79.4 percent 49.4 37.0 YR
similarity 100 100 100 36 75 100 100 100 100 67 75 75 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 0 0 100 100 100 100 100 100 100 100 100
300 q2w easi50 16 4 c62t4 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 252 252 200 FAS Cochran-Mantel-Haenszel test NRI 16 WK EASI-50 Percent 79.4 Percent 11.3 31.3 49.4 37.0 YR
300.0 q2w easi50 6 62 c62t4 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 177.0 FAS NRI 6 WK EASI 50 70.1333 percent 49.4 37.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 75 25 100 0 100 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 36 100 100 100 0 0 100 100 100 100 100 100 100 100 100
placebo q2w easi50 16 8 c59t8 test Double-Blind TRUE Placebo Placebo SC Q2W 126 126 73 FAS Cochran-Mantel-Haenszel test NRI 16 WK EASI-50 Percent 57.9 Percent 66.1 34.0 YR
0.0 q2w easi50 16 59 c59t8 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 73.0 FAS NRI 16 WK EASI 50 57.9 percent 66.1 34.0 YR
similarity 100 100 100 100 0 0 100 100 100 100 75 67 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
tralokinumab 300 q2w easi75 16 0 c33t0 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 253 252 141 FAS Cochran-Mantel-Haenszel test NRI 16 WK EASI-75 Percent 56.0 Percent 95% CI 9.8 30.6 49.4 37.0 YR
300.0 q2w easi75 16 33 c33t0 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 141.0 FAS NRI 16 WK EASI 75 56.0 percent 49.4 37.0 YR
similarity 100 100 100 36 75 100 100 100 100 67 75 75 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
300 q2w easi75 16 3 c28t3 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 252 252 141 FAS Cochran-Mantel-Haenszel test NRI 16 WK EASI-75 Percent 56.0 Percent 95% CI 9.8 30.6 49.4 37.0 YR
300.0 q2w easi75 6 28 c28t3 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 105.0 FAS NRI 6 WK EASI 75 41.679 percent 49.4 37.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 75 25 100 0 100 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 40 100 100 0 0 0 100 100 100 100 100 100 100 100 100
300 every4weeks easi75 32 6 c26t6 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Every 4 weeks 69 69 63 FAS Cochran-Mantel-Haenszel test NRI 32 WK EASI-75 Percent 90.8 percent 95% CI 81.3 95.7
300.0 q2w easi75 2 26 c26t6 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 42.0 FAS NRI 2 WK EASI 75 16.641 percent 49.4 37.0 YR
similarity 100 100 100 36 75 100 100 12 100 0 0 0 100 0 100 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 20 100 100 0 0 0 100 100 100 100 100 100 0 0 0
placebo q2w easi75 16 7 c25t7 test Double-Blind TRUE Placebo Placebo SC Q2W 126 126 45 FAS Cochran-Mantel-Haenszel test NRI 16 WK EASI-75 Percent 35.7 Percent 95% CI 27.3 44.9 66.1 34.0 YR
0.0 q2w easi75 16 25 c25t7 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 45.0 FAS NRI 16 WK EASI 75 35.7 percent 66.1 34.0 YR
similarity 100 100 100 100 0 0 100 100 100 100 75 67 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
tralokinumab 600.0 q2w scorad 0 43 control Double-Blind True tralokinumab Interleukin 13 inhibitors 600.0 MG SC Q2W 252 252.0 FAS MMRM OC 0 WK SCORAD Mean 67.0 0-103 pt scale 13.3 SD LS Mean 0.0 0-103 pt scale Mean 67.0 0-103 pt scale 13.3 SD 49.4 37.0 YR
easi 0 9 control Double-Blind True tralokinumab Interleukin 13 inhibitors 600.0 MG SC Q2W 252 252.0 FAS MMRM OC 0 WK EASI Median 24.7 0-72 score 12.963 SD LS Mean 0.0 0-72 score Mean 0.0 49.4 37.0 YR
300.0 q2w scorad 8 47 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 243.0 FAS MMRM OC 8 WK SCORAD Mean 67.0 0-103 pt scale 13.3 SD LS Mean -34.0 0-103 pt scale 1.03 SE Mean 32.7 0-103 pt scale 16.2 SD 49.4 37.0 YR
6 46 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 247.0 FAS MMRM OC 6 WK SCORAD Mean 67.0 0-103 pt scale 13.3 SD LS Mean -31.1 0-103 pt scale 1.03 SE Mean 35.7 0-103 pt scale 16.2 SD 49.4 37.0 YR
4 45 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 246.0 FAS MMRM OC 4 WK SCORAD Mean 67.0 0-103 pt scale 13.3 SD LS Mean -26.9 0-103 pt scale 1.02 SE Mean 40.1 0-103 pt scale 16.7 SD 49.4 37.0 YR
2 44 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 249.0 FAS MMRM OC 2 WK SCORAD Mean 67.0 0-103 pt scale 13.3 SD LS Mean -20.6 0-103 pt scale 0.93 SE Mean 46.5 0-103 pt scale 16.7 SD 49.4 37.0 YR
16 51 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 235.0 FAS MMRM OC 16 WK SCORAD Mean 67.0 0-103 pt scale 13.3 SD LS Mean -37.7 0-103 pt scale 1.25 SE Mean 29.2 0-103 pt scale 18.7 SD 49.4 37.0 YR
14 50 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 235.0 FAS MMRM OC 14 WK SCORAD Mean 67.0 0-103 pt scale 13.3 SD LS Mean -38.2 0-103 pt scale 1.21 SE Mean 28.5 0-103 pt scale 18.2 SD 49.4 37.0 YR
12 49 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 238.0 FAS MMRM OC 12 WK SCORAD Mean 67.0 0-103 pt scale 13.3 SD LS Mean -37.6 0-103 pt scale 1.16 SE Mean 29.4 0-103 pt scale 17.2 SD 49.4 37.0 YR
10 48 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 236.0 FAS MMRM OC 10 WK SCORAD Mean 67.0 0-103 pt scale 13.3 SD LS Mean -36.4 0-103 pt scale 1.1 SE Mean 30.2 0-103 pt scale 16.8 SD 49.4 37.0 YR
easi90 8 79 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 54.0 FAS NRI 8 WK EASI 90 21.6202 percent 49.4 37.0 YR
4 77 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 25.0 FAS NRI 4 WK EASI 90 10.1056 percent 49.4 37.0 YR
2 76 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 8.0 FAS NRI 2 WK EASI 90 3.08109 percent 49.4 37.0 YR
14 82 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 85.0 FAS NRI 14 WK EASI 90 33.5392 percent 49.4 37.0 YR
12 81 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 77.0 FAS NRI 12 WK EASI 90 30.7398 percent 49.4 37.0 YR
10 80 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 71.0 FAS NRI 10 WK EASI 90 28.363 percent 49.4 37.0 YR
easi75 8 29 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 119.0 FAS NRI 8 WK EASI 75 47.328 percent 49.4 37.0 YR
4 27 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 73.0 FAS NRI 4 WK EASI 75 29.008 percent 49.4 37.0 YR
14 32 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 142.0 FAS NRI 14 WK EASI 75 56.336 percent 49.4 37.0 YR
12 31 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 139.0 FAS NRI 12 WK EASI 75 55.267 percent 49.4 37.0 YR
10 30 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 135.0 FAS NRI 10 WK EASI 75 53.435 percent 49.4 37.0 YR
easi50 8 63 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 185.0 FAS NRI 8 WK EASI 50 73.3333 percent 49.4 37.0 YR
4 61 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 148.0 FAS NRI 4 WK EASI 50 58.6667 percent 49.4 37.0 YR
2 60 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 97.0 FAS NRI 2 WK EASI 50 38.6667 percent 49.4 37.0 YR
14 66 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 199.0 FAS NRI 14 WK EASI 50 78.9333 percent 49.4 37.0 YR
12 65 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 199.0 FAS NRI 12 WK EASI 50 78.9333 percent 49.4 37.0 YR
10 64 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 252.0 190.0 FAS NRI 10 WK EASI 50 75.4667 percent 49.4 37.0 YR
easi 8 13 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 243.0 FAS MMRM OC 8 WK EASI Median 24.7 0-72 score 12.963 SD Mean -68.0 26.3 SD 49.4 37.0 YR
6 12 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 247.0 FAS MMRM OC 6 WK EASI Median 24.7 0-72 score 12.963 SD Mean -62.8 27.5 SD 49.4 37.0 YR
4 11 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 247.0 FAS MMRM OC 4 WK EASI Median 24.7 0-72 score 12.963 SD Mean -54.0 31.0 SD 49.4 37.0 YR
2 10 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 250.0 FAS MMRM OC 2 WK EASI Median 24.7 0-72 score 12.963 SD Mean -40.2 30.6 SD 49.4 37.0 YR
16 17 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 235.0 FAS MMRM OC 16 WK EASI Median 24.7 0-72 score 12.963 SD LS Mean -21.0 0-72 score 0.67 SE Mean -72.3 30.5 SD 49.4 37.0 YR
14 16 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 235.0 FAS MMRM OC 14 WK EASI Median 24.7 0-72 score 12.963 SD Mean -73.5 30.9 SD 49.4 37.0 YR
12 15 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 238.0 FAS MMRM OC 12 WK EASI Median 24.7 0-72 score 12.963 SD Mean -72.3 30.6 SD 49.4 37.0 YR
10 14 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 252 237.0 FAS MMRM OC 10 WK EASI Median 24.7 0-72 score 12.963 SD Mean -70.9 26.8 SD 49.4 37.0 YR
placebo 0.0 q2w scorad 8 38 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 122.0 FAS MMRM OC 8 WK SCORAD Mean 68.9 0-103 pt scale 13.2 SD LS Mean -25.2 0-103 pt scale 1.47 SE Mean 41.9 0-103 pt scale 19.2 SD 66.1 34.0 YR
6 37 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 125.0 FAS MMRM OC 6 WK SCORAD Mean 68.9 0-103 pt scale 13.2 SD LS Mean -24.0 0-103 pt scale 1.48 SE Mean 43.6 0-103 pt scale 20.5 SD 66.1 34.0 YR
4 36 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 FAS MMRM OC 4 WK SCORAD Mean 68.9 0-103 pt scale 13.2 SD LS Mean -21.9 0-103 pt scale 1.44 SE Mean 46.6 0-103 pt scale 20.2 SD 66.1 34.0 YR
2 35 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 124.0 FAS MMRM OC 2 WK SCORAD Mean 68.9 0-103 pt scale 13.2 SD LS Mean -16.4 0-103 pt scale 1.33 SE Mean 51.4 0-103 pt scale 17.1 SD 66.1 34.0 YR
16 42 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 119.0 FAS MMRM OC 16 WK SCORAD Mean 68.9 0-103 pt scale 13.2 SD LS Mean -26.8 0-103 pt scale 1.8 SE Mean 40.9 0-103 pt scale 23.7 SD 66.1 34.0 YR
14 41 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 118.0 FAS MMRM OC 14 WK SCORAD Mean 68.9 0-103 pt scale 13.2 SD LS Mean -28.3 0-103 pt scale 1.75 SE Mean 38.8 0-103 pt scale 22.4 SD 66.1 34.0 YR
12 40 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 119.0 FAS MMRM OC 12 WK SCORAD Mean 68.9 0-103 pt scale 13.2 SD LS Mean -27.3 0-103 pt scale 1.67 SE Mean 39.6 0-103 pt scale 21.6 SD 66.1 34.0 YR
10 39 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 118.0 FAS MMRM OC 10 WK SCORAD Mean 68.9 0-103 pt scale 13.2 SD LS Mean -27.2 0-103 pt scale 1.58 SE Mean 40.4 0-103 pt scale 20.5 SD 66.1 34.0 YR
0 34 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 FAS MMRM OC 0 WK SCORAD Mean 68.9 0-103 pt scale 13.2 SD LS Mean 0.0 0-103 pt scale Mean 68.9 0-103 pt scale 13.2 SD 66.1 34.0 YR
easi90 8 71 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 15.0 FAS NRI 8 WK EASI 90 11.7603 percent 66.1 34.0 YR
6 70 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 14.0 FAS NRI 6 WK EASI 90 11.2148 percent 66.1 34.0 YR
4 69 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 9.0 FAS NRI 4 WK EASI 90 7.00694 percent 66.1 34.0 YR
2 68 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 3.0 FAS NRI 2 WK EASI 90 2.37686 percent 66.1 34.0 YR
16 75 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 27.0 FAS NRI 16 WK EASI 90 21.4 percent 66.1 34.0 YR
14 74 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 23.0 FAS NRI 14 WK EASI 90 17.9053 percent 66.1 34.0 YR
12 73 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 21.0 FAS NRI 12 WK EASI 90 16.5144 percent 66.1 34.0 YR
10 72 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 21.0 FAS NRI 10 WK EASI 90 16.5319 percent 66.1 34.0 YR
easi75 8 21 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 40.0 FAS NRI 8 WK EASI 75 31.603 percent 66.1 34.0 YR
6 20 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 36.0 FAS NRI 6 WK EASI 75 28.55 percent 66.1 34.0 YR
4 19 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 30.0 FAS NRI 4 WK EASI 75 23.512 percent 66.1 34.0 YR
2 18 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 14.0 FAS NRI 2 WK EASI 75 10.84 percent 66.1 34.0 YR
14 24 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 45.0 FAS NRI 14 WK EASI 75 35.725 percent 66.1 34.0 YR
12 23 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 44.0 FAS NRI 12 WK EASI 75 34.809 percent 66.1 34.0 YR
10 22 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 40.0 FAS NRI 10 WK EASI 75 31.603 percent 66.1 34.0 YR
easi50 8 55 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 74.0 FAS NRI 8 WK EASI 50 58.9333 percent 66.1 34.0 YR
6 54 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 64.0 FAS NRI 6 WK EASI 50 50.6667 percent 66.1 34.0 YR
4 53 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 60.0 FAS NRI 4 WK EASI 50 47.7333 percent 66.1 34.0 YR
2 52 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 43.0 FAS NRI 2 WK EASI 50 34.4 percent 66.1 34.0 YR
14 58 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 76.0 FAS NRI 14 WK EASI 50 60.5333 percent 66.1 34.0 YR
12 57 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 74.0 FAS NRI 12 WK EASI 50 58.9333 percent 66.1 34.0 YR
10 56 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 77.0 FAS NRI 10 WK EASI 50 61.3333 percent 66.1 34.0 YR
easi 8 4 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 122.0 FAS MMRM OC 8 WK EASI Median 26.5 0-72 score 14.37 SD Mean -56.7 32.1 SD 66.1 34.0 YR
6 3 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 125.0 FAS MMRM OC 6 WK EASI Median 26.5 0-72 score 14.37 SD Mean -51.3 33.7 SD 66.1 34.0 YR
4 2 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 FAS MMRM OC 4 WK EASI Median 26.5 0-72 score 14.37 SD Mean -44.8 37.7 SD 66.1 34.0 YR
2 1 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 124.0 FAS MMRM OC 2 WK EASI Median 26.5 0-72 score 14.37 SD Mean -33.6 32.3 SD 66.1 34.0 YR
16 8 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 120.0 FAS MMRM OC 16 WK EASI Median 26.5 0-72 score 14.37 SD LS Mean -15.6 0-72 score 0.96 SE Mean -54.9 41.3 SD 66.1 34.0 YR
14 7 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 118.0 FAS MMRM OC 14 WK EASI Median 26.5 0-72 score 14.37 SD Mean -57.5 39.4 SD 66.1 34.0 YR
12 6 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 119.0 FAS MMRM OC 12 WK EASI Median 26.5 0-72 score 14.37 SD Mean -58.9 32.5 SD 66.1 34.0 YR
10 5 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 118.0 FAS MMRM OC 10 WK EASI Median 26.5 0-72 score 14.37 SD Mean -56.4 34.5 SD 66.1 34.0 YR
0 0 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 126 126.0 FAS MMRM OC 0 WK EASI Median 26.5 0-72 score 14.37 SD LS Mean 0.0 0-72 score Mean 0.0 66.1 34.0 YR

289_guttman_2020¶

Control rows matched by test output: 11 of 68

Literature data accuracy: 82.73%

Clinical data accuracy: 14.33%

Clinical data accuracy (drop unmatched): 88.60%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
lebrikizumab 250 every4weeks easi50 16 1 c7t1 test Double-Blind TRUE lebrikizumab Interleukin-13 Inhibitor 250 mg SC Every 4 weeks 80 80 62 mITT Cochran-Mantel-Haenszel tests MCMC 16 WK EASI-50 Percent 77.0 Percent 41.2 40.2 YR
125.0 q4w easi50 16 7 c7t1 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 48.0 mITT Cochran Mantel Haenszel Test MCMC 16 WK EASI 50 66.4 percent 37.0 36.7 YR
similarity 100 100 100 98 50 100 100 25 100 0 33 0 100 98 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 100 100 100 100 100 100 100 100 100 100 100 25 25 100
125 every4weeks easi50 16 9 c6t9 test Double-Blind TRUE lebrikizumab Interleukin-13 Inhibitor 125 mg SC Every 4 weeks 73 73 48 mITT Pairwise Cochran-Mantel-Haenszel tests MI 16 wk EASI-50 Percent 66.4 Percent pvalue 37.0 36.7 YR
125.0 q4w easi50 12 6 c6t9 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 50.0 mITT Cochran Mantel Haenszel Test MCMC 12 WK EASI 50 68.153 percent 37.0 36.7 YR
similarity 100 100 100 98 75 100 100 25 100 100 67 0 100 85 33 50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 40 100 100 0 100 100 100 100 100 100 100 100 100 100 100
250 q2w easi90 16 5 c47t5 test Double-Blind TRUE lebrikizumab Interleukin-13 Inhibitor 250 mg SC Q2W 75 75 33 mITT Pairwise Cochran-Mantel-Haenszel tests MCMC 16 wk EASI-90 Percent 44.0 percent pvalue <.001 34.7 38.9 YR
250.0 q2w easi90 16 47 c47t5 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 33.0 mITT Cochran Mantel Haenszel Test MCMC 16 WK EASI 90 44.0 percent 34.7 38.9 YR
similarity 100 100 100 98 75 100 100 100 100 100 67 67 100 85 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100
placebo q2w easi50 16 7 c3t7 test Double-Blind TRUE Placebo SC Q2W 52 52 24 mITT Cochran-Mantel-Haenszel tests MCMC 16 wk EASI-50 Percent 45.8 percent 53.8 42.2 YR
0.0 q2w easi50 16 3 c3t7 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 24.0 mITT Cochran Mantel Haenszel Test MCMC 16 WK EASI 50 45.8 percent 53.8 42.2 YR
similarity 100 100 100 0 0 0 100 100 100 100 67 67 100 98 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
lebrikizumab 250 every4weeks easi90 16 2 c39t2 test Double-Blind TRUE lebrikizumab Interleukin-13 Inhibitor 250 mg SC Every 4 weeks 80 80 29 mITT Pairwise Cochran-Mantel-Haenszel tests MCMC 16 wk EASI-90 Percent 36.1 Percent pvalue two-sided 41.2 40.2 YR
125.0 q4w easi90 16 39 c39t2 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 19.0 mITT Cochran Mantel Haenszel Test MCMC 16 WK EASI 90 26.1 percent 37.0 36.7 YR
similarity 100 100 100 98 50 100 100 25 100 0 33 33 100 85 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 75 100 100 0 100 100 100 100 100 100 100 100 25 25 100
125 every4weeks easi90 16 10 c38t10 test Double-Blind TRUE lebrikizumab Interleukin-13 Inhibitor 125 mg SC Every 4 weeks 73 73 19 mITT Pairwise Cochran-Mantel-Haenszel tests MCMC 16 wk EASI-90 Percent 26.1 percent pvalue two-sided 37.0 36.7 YR
125.0 q4w easi90 12 38 c38t10 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 15.0 mITT Cochran Mantel Haenszel Test MCMC 12 WK EASI 90 20.383 percent 37.0 36.7 YR
similarity 100 100 100 98 75 100 100 25 100 100 67 33 100 85 100 50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 20 100 100 0 100 100 100 100 100 100 100 100 100 100 100
250 q2w easi75 16 3 c31t3 test Double-Blind TRUE lebrikizumab Interleukin-13 Inhibitor 250 mg SC Q2W 75 75 45 mITT Pairwise Cochran-Mantel-Haenszel tests MCMC 16 WK EASI-75 Percent 60.6 Percent pvalue <.001 34.7 38.9 YR
250.0 q2w easi75 16 31 c31t3 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 45.0 mITT Cochran Mantel Haenszel Test MCMC 16 WK EASI 75 60.6 percent 34.7 38.9 YR
similarity 100 100 100 98 75 100 100 100 100 100 67 67 100 85 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100
250 every4weeks easi75 16 0 c23t0 test Double-Blind TRUE lebrikizumab Interleukin-13 Inhibitor 250 mg SC Every 4 weeks 80 80 45 mITT Pairwise Cochran-Mantel-Haenszel tests MCMC 16 WK EASI-75 Percent 56.1 Percent pvalue two-sided 41.2 40.2 YR
125.0 q4w easi75 16 23 c23t0 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 32.0 mITT Cochran Mantel Haenszel Test MCMC 16 WK EASI 75 43.3 percent 37.0 36.7 YR
similarity 100 100 100 98 50 100 100 25 100 0 33 0 100 85 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 100 100 0 100 100 100 100 100 100 100 100 25 25 100
125 every4weeks easi75 16 8 c22t8 test Double-Blind TRUE lebrikizumab Interleukin-13 Inhibitor 125 mg SC Every 4 weeks 73 73 43 mITT Pairwise Cochran-Mantel-Haenszel tests MCMC 16 WK EASI-75 Percent 43.3 Percent pvalue 37.0 36.7 YR
125.0 q4w easi75 12 22 c22t8 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 32.0 mITT Cochran Mantel Haenszel Test MCMC 12 WK EASI 75 43.312999999999995 percent 37.0 36.7 YR
similarity 100 100 100 98 75 100 100 25 100 100 67 33 100 85 100 50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 36 100 100 0 100 100 100 100 100 100 100 100 100 100 100
placebo q2w easi75 16 6 c19t6 test Double-Blind TRUE Placebo SC Q2W 52 52 13 mITT Pairwise Cochran-Mantel-Haenszel tests MCMC 16 wk EASI-75 Percent 24.3 percent pvalue two-sided 53.8 42.2 YR
0.0 q2w easi75 16 19 c19t6 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 13.0 mITT Cochran Mantel Haenszel Test MCMC 16 WK EASI 75 24.3 percent 53.8 42.2 YR
similarity 100 100 100 0 0 0 100 100 100 100 67 67 100 85 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100
lebrikizumab 250 q2w easi50 16 4 c15t4 test Double-Blind TRUE lebrikizumab Interleukin-13 Inhibitor 250 mg SC Q2W 75 75 60 mITT Pairwise Cochran-Mantel-Haenszel tests MCMC 16 wk EASI-50 Percent 81.0 Percent pvalue <.001 34.7 38.9 YR
250.0 q2w easi50 16 15 c15t4 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 61.0 mITT Cochran Mantel Haenszel Test MCMC 16 WK EASI 50 81.0 percent 34.7 38.9 YR
similarity 100 100 100 98 75 100 100 100 100 100 67 33 100 85 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100
placebo 0.0 q2w easi90 8 33 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 2.0 mITT Cochran Mantel Haenszel Test MCMC 8 WK EASI 90 3.822 percent 53.8 42.2 YR
4 32 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 0.0 mITT Cochran Mantel Haenszel Test MCMC 4 WK EASI 90 0.0 percent 53.8 42.2 YR
16 35 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 6.0 mITT Cochran Mantel Haenszel Test MCMC 16 WK EASI 90 11.4 percent 53.8 42.2 YR
12 34 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 3.0 mITT Cochran Mantel Haenszel Test MCMC 12 WK EASI 90 5.096 percent 53.8 42.2 YR
easi75 8 17 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 8.0 mITT Cochran Mantel Haenszel Test MCMC 8 WK EASI 75 15.924 percent 53.8 42.2 YR
4 16 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 1.0 mITT Cochran Mantel Haenszel Test MCMC 4 WK EASI 75 2.548 percent 53.8 42.2 YR
12 18 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 8.0 mITT Cochran Mantel Haenszel Test MCMC 12 WK EASI 75 15.924 percent 53.8 42.2 YR
easi50 8 1 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 18.0 mITT Cochran Mantel Haenszel Test MCMC 8 WK EASI 50 33.758 percent 53.8 42.2 YR
4 0 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 14.0 mITT Cochran Mantel Haenszel Test MCMC 4 WK EASI 50 26.115 percent 53.8 42.2 YR
12 2 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 18.0 mITT Cochran Mantel Haenszel Test MCMC 12 WK EASI 50 34.394999999999996 percent 53.8 42.2 YR
easi 8 50 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 mITT ANCOVA MCMC 8 WK EASI Mean 28.9 0-72 score 11.8 SD Mean -31.3 53.8 42.2 YR
4 49 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 mITT ANCOVA MCMC 4 WK EASI Mean 28.9 0-72 score 11.8 SD Mean -25.4 53.8 42.2 YR
16 52 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 mITT ANCOVA MCMC 16 WK EASI Mean 28.9 0-72 score 11.8 SD Mean -40.6 53.8 42.2 YR
12 51 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 mITT ANCOVA MCMC 12 WK EASI Mean 28.9 0-72 score 11.8 SD Mean -34.0 53.8 42.2 YR
0 48 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 52 52.0 mITT ANCOVA MCMC 0 WK EASI Mean 28.9 0-72 score 11.8 SD Mean 0.0 53.8 42.2 YR
lebrikizumab 500.0 q4w easi 0 58 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 500.0 MG SC Q4W 80 80.0 mITT ANCOVA MCMC 0 WK EASI Mean 26.2 0-72 score 10.1 SD Mean 0.0 41.2 40.2 YR
q2w easi 0 63 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 500.0 MG SC Q2W 75 75.0 mITT ANCOVA MCMC 0 WK EASI Mean 25.5 0-72 score 11.2 SD Mean 0.0 34.7 38.9 YR
250.0 q4w easi90 8 41 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 20.0 mITT Cochran Mantel Haenszel Test MCMC 8 WK EASI 90 25.478 percent 41.2 40.2 YR
4 40 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 6.0 mITT Cochran Mantel Haenszel Test MCMC 4 WK EASI 90 7.644 percent 41.2 40.2 YR
16 43 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 29.0 mITT Cochran Mantel Haenszel Test MCMC 16 WK EASI 90 36.1 percent 41.2 40.2 YR
12 42 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 22.0 mITT Cochran Mantel Haenszel Test MCMC 12 WK EASI 90 28.026 percent 41.2 40.2 YR
easi75 8 25 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 31.0 mITT Cochran Mantel Haenszel Test MCMC 8 WK EASI 75 38.217 percent 41.2 40.2 YR
4 24 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 18.0 mITT Cochran Mantel Haenszel Test MCMC 4 WK EASI 75 22.93 percent 41.2 40.2 YR
16 27 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 45.0 mITT Cochran Mantel Haenszel Test MCMC 16 WK EASI 75 56.1 percent 41.2 40.2 YR
12 26 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 38.0 mITT Cochran Mantel Haenszel Test MCMC 12 WK EASI 75 47.771 percent 41.2 40.2 YR
easi50 8 9 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 54.0 mITT Cochran Mantel Haenszel Test MCMC 8 WK EASI 50 67.516 percent 41.2 40.2 YR
4 8 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 36.0 mITT Cochran Mantel Haenszel Test MCMC 4 WK EASI 50 44.586 percent 41.2 40.2 YR
16 11 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 62.0 mITT Cochran Mantel Haenszel Test MCMC 16 WK EASI 50 77.0 percent 41.2 40.2 YR
12 10 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 59.0 mITT Cochran Mantel Haenszel Test MCMC 12 WK EASI 50 73.88600000000001 percent 41.2 40.2 YR
easi 8 60 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 mITT ANCOVA MCMC 8 WK EASI Mean 26.2 0-72 score 10.1 SD Mean -61.2 41.2 40.2 YR
4 59 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 mITT ANCOVA MCMC 4 WK EASI Mean 26.2 0-72 score 10.1 SD Mean -46.5 41.2 40.2 YR
16 62 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 mITT ANCOVA MCMC 16 WK EASI Mean 26.2 0-72 score 10.1 SD Mean -69.7 41.2 40.2 YR
12 61 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 80 80.0 mITT ANCOVA MCMC 12 WK EASI Mean 26.2 0-72 score 10.1 SD Mean -64.7 41.2 40.2 YR
0 53 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q4W 73 73.0 mITT ANCOVA MCMC 0 WK EASI Mean 29.9 0-72 score 13.5 SD Mean 0.0 37.0 36.7 YR
q2w easi90 8 45 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 22.0 mITT Cochran Mantel Haenszel Test MCMC 8 WK EASI 90 29.3 percent 34.7 38.9 YR
4 44 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 11.0 mITT Cochran Mantel Haenszel Test MCMC 4 WK EASI 90 14.65 percent 34.7 38.9 YR
12 46 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 27.0 mITT Cochran Mantel Haenszel Test MCMC 12 WK EASI 90 35.669 percent 34.7 38.9 YR
easi75 8 29 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 33.0 mITT Cochran Mantel Haenszel Test MCMC 8 WK EASI 75 43.949 percent 34.7 38.9 YR
4 28 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 22.0 mITT Cochran Mantel Haenszel Test MCMC 4 WK EASI 75 29.937 percent 34.7 38.9 YR
12 30 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 49.0 mITT Cochran Mantel Haenszel Test MCMC 12 WK EASI 75 65.60600000000001 percent 34.7 38.9 YR
easi50 8 13 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 52.0 mITT Cochran Mantel Haenszel Test MCMC 8 WK EASI 50 68.79 percent 34.7 38.9 YR
4 12 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 39.0 mITT Cochran Mantel Haenszel Test MCMC 4 WK EASI 50 52.23 percent 34.7 38.9 YR
12 14 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 62.0 mITT Cochran Mantel Haenszel Test MCMC 12 WK EASI 50 82.16600000000001 percent 34.7 38.9 YR
easi 8 65 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 mITT ANCOVA MCMC 8 WK EASI Mean 25.5 0-72 score 11.2 SD Mean -64.1 34.7 38.9 YR
4 64 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 mITT ANCOVA MCMC 4 WK EASI Mean 25.5 0-72 score 11.2 SD Mean -50.4 34.7 38.9 YR
16 67 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 mITT ANCOVA MCMC 16 WK EASI Mean 25.5 0-72 score 11.2 SD Mean -72.8 34.7 38.9 YR
12 66 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 250.0 MG SC Q2W 75 75.0 mITT ANCOVA MCMC 12 WK EASI Mean 25.5 0-72 score 11.2 SD Mean -73.5 34.7 38.9 YR
125.0 q4w easi90 8 37 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 12.0 mITT Cochran Mantel Haenszel Test MCMC 8 WK EASI 90 16.561 percent 37.0 36.7 YR
4 36 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 2.0 mITT Cochran Mantel Haenszel Test MCMC 4 WK EASI 90 3.185 percent 37.0 36.7 YR
easi75 8 21 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 22.0 mITT Cochran Mantel Haenszel Test MCMC 8 WK EASI 75 29.937 percent 37.0 36.7 YR
4 20 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 12.0 mITT Cochran Mantel Haenszel Test MCMC 4 WK EASI 75 16.561 percent 37.0 36.7 YR
easi50 8 5 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 41.0 mITT Cochran Mantel Haenszel Test MCMC 8 WK EASI 50 56.687999999999995 percent 37.0 36.7 YR
4 4 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 30.0 mITT Cochran Mantel Haenszel Test MCMC 4 WK EASI 50 41.402 percent 37.0 36.7 YR
easi 8 55 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 mITT ANCOVA MCMC 8 WK EASI Mean 29.9 0-72 score 13.5 SD Mean -53.9 37.0 36.7 YR
4 54 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 mITT ANCOVA MCMC 4 WK EASI Mean 29.9 0-72 score 13.5 SD Mean -42.4 37.0 36.7 YR
16 57 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 mITT ANCOVA MCMC 16 WK EASI Mean 29.9 0-72 score 13.5 SD Mean -61.5 37.0 36.7 YR
12 56 control Double-Blind True lebrikizumab Interleukin 13 inhibitors 125.0 MG SC Q4W 73 73.0 mITT ANCOVA MCMC 12 WK EASI Mean 29.9 0-72 score 13.5 SD Mean -62.5 37.0 36.7 YR

305_debruin_2018¶

Control rows matched by test output: 8 of 132

Literature data accuracy: 85.40%

Clinical data accuracy: 5.58%

Clinical data accuracy (drop unmatched): 92.04%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
placebo placebo easi75 16 6 c6t6 test Double-Blind TRUE Placebo Placebo SC Placebo 108 108 32 FAS Cochran-Mantel-Haenszel test NRI 16 WK EASI-75 Percent 29.6 Percent 63.0 37.5 YR
0.0 qw easi75 16 6 c6t6 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 32.0 FAS Cochran Mantel Haenszel Test 16 WK EASI 75 29.6 percent 63.0 37.5 YR
similarity 100 100 100 100 0 0 100 0 100 100 75 67 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
dupilumab 300 q2w easi90 16 2 c62t2 test Double-Blind TRUE Dupilumab Monoclonal antibody 300 mg SC Q2W 107 107 49 FAS Nominal P < 0.001 vs. placebo + TCS MI 16 WK EASI-90 Proportion 45.8 Percent Nominal P < 0.001 vs. placebo + TCS 60.7 38.0 YR
300.0 q2w easi90 16 62 c62t2 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 49.0 FAS Cochran Mantel Haenszel Test 16 WK EASI 90 45.8 percent 60.7 38.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 75 67 100 34 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100
300 qw easi90 16 5 c55t5 test Double-Blind TRUE Dupilumab Monoclonal antibody 300 mg SC qw 110 110 41 FAS Nominal P < 0.001 vs. placebo + TCS 16 WK EASI-90 Proportion 37.3 Percent Nominal P < 0.001 vs. placebo + TCS 60.0 38.0 YR
300.0 qw easi90 16 55 c55t5 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 41.0 FAS Cochran Mantel Haenszel Test 16 WK EASI 90 37.3 percent 60.0 38.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 75 67 100 34 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100
300 q2w easi50 16 1 c41t1 test Double-Blind TRUE Dupilumab Monoclonal antibody 300 mg SC Q2W 107 107 91 FAS Cochran-Mantel-Haenszel test 16 WK EASI-50 Percent 85.0 Percent 60.7 38.0 YR
300.0 q2w easi50 16 41 c41t1 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 91.0 FAS Cochran Mantel Haenszel Test 16 WK EASI 50 85.0 percent 60.7 38.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
300 qw easi50 16 4 c34t4 test Double-Blind TRUE Dupilumab Monoclonal antibody 300 mg SC qw 110 110 94 FAS Cochran-Mantel-Haenszel test 16 WK EASI-50 Percent 85.5 Percent 60.0 38.0 YR
300.0 qw easi50 16 34 c34t4 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 94.0 FAS Cochran Mantel Haenszel Test 16 WK EASI 50 85.5 percent 60.0 38.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
placebo placebo easi50 16 7 c27t7 test Double-Blind TRUE Placebo Placebo SC Placebo 108 107 47 FAS Cochran-Mantel-Haenszel test 16 WK EASI-50 Proportion 43.5 Percent 63.0 37.5 YR
0.0 qw easi50 16 27 c27t7 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 47.0 FAS Cochran Mantel Haenszel Test 16 WK EASI 50 43.5 percent 63.0 37.5 YR
similarity 100 100 100 100 0 0 100 0 100 100 50 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
dupilumab 300 q2w easi75 16 0 c20t0 test Double-Blind TRUE Dupilumab Monoclonal antibody 300 mg SC Q2W 107 107 67 FAS Cochran-Mantel-Haenszel test 16 WK EASI-75 Percent 62.6 Percent 60.7 38.0 YR
300.0 q2w easi75 16 20 c20t0 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 67.0 FAS Cochran Mantel Haenszel Test 16 WK EASI 75 62.6 percent 60.7 38.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 75 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
300 qw easi75 16 3 c13t3 test Double-Blind TRUE Dupilumab Monoclonal antibody 300 mg SC qw 110 110 65 FAS Cochran-Mantel-Haenszel test NRI 16 WK EASI-75 Proportion 59.1 Percent 60.0 38.0 YR
300.0 qw easi75 16 13 c13t3 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 65.0 FAS Cochran Mantel Haenszel Test 16 WK EASI 75 59.1 percent 60.0 38.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 75 67 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
placebo 0.0 qw scorad 8 115 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA LOCF 8 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -26.042 2.431 SE 63.0 37.5 YR
92 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA MI 8 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -27.694 2.507 SE 63.0 37.5 YR
6 114 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA LOCF 6 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -23.467 2.315 SE 63.0 37.5 YR
91 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA MI 6 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -25.157 2.381 SE 63.0 37.5 YR
4 113 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA LOCF 4 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -19.734 2.199 SE 63.0 37.5 YR
90 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA MI 4 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -20.614 2.256 SE 63.0 37.5 YR
2 112 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA LOCF 2 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -14.612 1.967 SE 63.0 37.5 YR
89 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA MI 2 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -15.069 2.005 SE 63.0 37.5 YR
16 117 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA LOCF 16 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -26.5 2.546 SE 63.0 37.5 YR
94 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 89.0 FAS ANCOVA MI 16 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -29.5 2.55 SE 63.0 37.5 YR
12 116 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA LOCF 12 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -26.794 2.547 SE 63.0 37.5 YR
93 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA MI 12 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -29.01 2.507 SE 63.0 37.5 YR
1 111 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA LOCF 1 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -9.274 1.505 SE 63.0 37.5 YR
88 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA MI 1 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean -9.038 1.63 SE 63.0 37.5 YR
0 87 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 FAS ANCOVA MI 0 WK SCORAD Mean 67.0 0-103 score 12.2 SD LS Mean 0.0 63.0 37.5 YR
easi90 8 46 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 11.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 90 10.105 percent 63.0 37.5 YR
6 45 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 6.0 FAS Cochran Mantel Haenszel Test 6 WK EASI 90 5.684 percent 63.0 37.5 YR
4 44 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 5.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 90 4.632 percent 63.0 37.5 YR
2 43 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 2.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 90 1.895 percent 63.0 37.5 YR
16 48 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 13.0 FAS Cochran Mantel Haenszel Test 16 WK EASI 90 12.0 percent 63.0 37.5 YR
12 47 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 8.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 90 7.368 percent 63.0 37.5 YR
1 42 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 0.0 FAS Cochran Mantel Haenszel Test 1 WK EASI 90 0.0 percent 63.0 37.5 YR
easi75 8 4 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 25.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 75 22.998 percent 63.0 37.5 YR
6 3 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 18.0 FAS Cochran Mantel Haenszel Test 6 WK EASI 75 16.66 percent 63.0 37.5 YR
4 2 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 14.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 75 13.038 percent 63.0 37.5 YR
2 1 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 9.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 75 8.149 percent 63.0 37.5 YR
12 5 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 26.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 75 24.266 percent 63.0 37.5 YR
1 0 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 3.0 FAS Cochran Mantel Haenszel Test 1 WK EASI 75 2.716 percent 63.0 37.5 YR
easi50 8 25 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 44.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 50 40.601 percent 63.0 37.5 YR
6 24 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 45.0 FAS Cochran Mantel Haenszel Test 6 WK EASI 50 41.981 percent 63.0 37.5 YR
4 23 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 34.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 50 31.734 percent 63.0 37.5 YR
2 22 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 22.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 50 20.518 percent 63.0 37.5 YR
12 26 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 45.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 50 41.715 percent 63.0 37.5 YR
1 21 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 10.0 FAS Cochran Mantel Haenszel Test 1 WK EASI 50 9.484 percent 63.0 37.5 YR
easi 8 68 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA MI 8 WK EASI Mean 32.9 0-72 score 10.8 SD LS Mean -43.257 2.926 SE 63.0 37.5 YR
6 67 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA MI 6 WK EASI Mean 32.9 0-72 score 10.8 SD LS Mean -40.458 2.927 SE 63.0 37.5 YR
4 66 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA MI 4 WK EASI Mean 32.9 0-72 score 10.8 SD LS Mean -33.842 2.799 SE 63.0 37.5 YR
2 65 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA MI 2 WK EASI Mean 32.9 0-72 score 10.8 SD LS Mean -24.428 2.799 SE 63.0 37.5 YR
16 70 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 89.0 FAS ANCOVA MI 16 WK EASI Mean 32.9 0-72 score 10.8 SD LS Mean -46.6 2.76 SE 63.0 37.5 YR
12 69 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA MI 12 WK EASI Mean 32.9 0-72 score 10.8 SD LS Mean -44.784 2.799 SE 63.0 37.5 YR
1 64 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 FAS ANCOVA MI 1 WK EASI Mean 32.9 0-72 score 10.8 SD LS Mean -14.504 2.163 SE 63.0 37.5 YR
0 63 control Double-Blind True placebo Placebo 0.0 MG SC QW 108 108.0 FAS ANCOVA MI 0 WK EASI Mean 32.9 0-72 score 10.8 SD LS Mean 0.0 63.0 37.5 YR
dupilumab 600.0 qw scorad 0 95 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 600.0 MG SC QW 110 110.0 FAS ANCOVA MI 0 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean 0.0 60.0 38.0 YR
easi 0 71 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 600.0 MG SC QW 110 110.0 FAS ANCOVA MI 0 WK EASI Mean 33.1 0-72 score 11.02 SD LS Mean 0.0 60.0 38.0 YR
q2w scorad 0 103 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 600.0 MG SC Q2W 107 107.0 FAS ANCOVA MI 0 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean 0.0 60.7 38.0 YR
easi 0 79 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 600.0 MG SC Q2W 107 107.0 FAS ANCOVA MI 0 WK EASI Mean 33.3 0-72 score 9.93 SD LS Mean 0.0 60.7 38.0 YR
300.0 qw scorad 8 122 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA LOCF 8 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -52.894 2.431 SE 60.0 38.0 YR
100 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA MI 8 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -53.258 2.506 SE 60.0 38.0 YR
6 121 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA LOCF 6 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -47.309 2.431 SE 60.0 38.0 YR
99 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA MI 6 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -47.713 2.381 SE 60.0 38.0 YR
4 120 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA LOCF 4 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -37.79 2.199 SE 60.0 38.0 YR
98 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA MI 4 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -38.158 2.256 SE 60.0 38.0 YR
2 119 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA LOCF 2 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -26.881 2.315 SE 60.0 38.0 YR
97 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA MI 2 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -26.598 2.256 SE 60.0 38.0 YR
16 124 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA LOCF 16 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -57.2 2.663 SE 60.0 38.0 YR
102 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 104.0 FAS ANCOVA MI 16 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -58.3 2.45 SE 60.0 38.0 YR
12 123 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA LOCF 12 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -56.887 2.431 SE 60.0 38.0 YR
101 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA MI 12 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -57.33 2.757 SE 60.0 38.0 YR
1 118 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA LOCF 1 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -12.514 1.621 SE 60.0 38.0 YR
96 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA MI 1 WK SCORAD Mean 66.0 0-103 score 12.7 SD LS Mean -12.297 1.88 SE 60.0 38.0 YR
easi90 8 53 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 34.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 90 30.947 percent 60.0 38.0 YR
6 52 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 21.0 FAS Cochran Mantel Haenszel Test 6 WK EASI 90 18.947 percent 60.0 38.0 YR
4 51 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 7.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 90 6.316 percent 60.0 38.0 YR
2 50 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 1.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 90 0.842 percent 60.0 38.0 YR
12 54 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 43.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 90 38.947 percent 60.0 38.0 YR
1 49 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 0.0 FAS Cochran Mantel Haenszel Test 1 WK EASI 90 0.0 percent 60.0 38.0 YR
easi75 8 11 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 58.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 75 52.515 percent 60.0 38.0 YR
6 10 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 48.0 FAS Cochran Mantel Haenszel Test 6 WK EASI 75 43.642 percent 60.0 38.0 YR
4 9 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 26.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 75 23.541 percent 60.0 38.0 YR
2 8 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 5.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 75 4.346 percent 60.0 38.0 YR
12 12 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 69.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 75 62.656 percent 60.0 38.0 YR
1 7 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 0.0 FAS Cochran Mantel Haenszel Test 1 WK EASI 75 0.0 percent 60.0 38.0 YR
easi50 8 32 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 87.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 50 78.973 percent 60.0 38.0 YR
6 31 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 81.0 FAS Cochran Mantel Haenszel Test 6 WK EASI 50 73.571 percent 60.0 38.0 YR
4 30 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 66.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 50 60.029 percent 60.0 38.0 YR
2 29 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 39.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 50 35.441 percent 60.0 38.0 YR
12 33 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 93.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 50 84.35 percent 60.0 38.0 YR
1 28 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 110.0 13.0 FAS Cochran Mantel Haenszel Test 1 WK EASI 50 11.81 percent 60.0 38.0 YR
easi 8 76 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA MI 8 WK EASI Mean 33.1 0-72 score 11.02 SD LS Mean -72.01 2.799 SE 60.0 38.0 YR
6 75 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA MI 6 WK EASI Mean 33.1 0-72 score 11.02 SD LS Mean -66.921 2.926 SE 60.0 38.0 YR
4 74 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA MI 4 WK EASI Mean 33.1 0-72 score 11.02 SD LS Mean -55.471 2.672 SE 60.0 38.0 YR
2 73 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA MI 2 WK EASI Mean 33.1 0-72 score 11.02 SD LS Mean -39.949 2.672 SE 60.0 38.0 YR
16 78 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 105.0 FAS ANCOVA MI 16 WK EASI Mean 33.1 0-72 score 11.02 SD LS Mean -78.2 2.55 SE 60.0 38.0 YR
12 77 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA MI 12 WK EASI Mean 33.1 0-72 score 11.02 SD LS Mean -77.354 2.545 SE 60.0 38.0 YR
1 72 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC QW 110 FAS ANCOVA MI 1 WK EASI Mean 33.1 0-72 score 11.02 SD LS Mean -20.611 1.909 SE 60.0 38.0 YR
q2w scorad 8 129 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA LOCF 8 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -54.514 2.431 SE 60.7 38.0 YR
108 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA MI 8 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -54.762 2.506 SE 60.7 38.0 YR
6 128 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA LOCF 6 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -49.161 2.315 SE 60.7 38.0 YR
107 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA MI 6 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -49.467 2.381 SE 60.7 38.0 YR
4 127 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA LOCF 4 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -41.725 2.431 SE 60.7 38.0 YR
106 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA MI 4 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -41.667 2.256 SE 60.7 38.0 YR
2 126 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA LOCF 2 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -28.733 1.852 SE 60.7 38.0 YR
105 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA MI 2 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -29.104 2.13 SE 60.7 38.0 YR
16 131 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA LOCF 16 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -61.9 2.662 SE 60.7 38.0 YR
110 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 103.0 FAS ANCOVA MI 16 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -62.4 2.48 SE 60.7 38.0 YR
12 130 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA LOCF 12 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -60.128 2.546 SE 60.7 38.0 YR
109 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA MI 12 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -60.338 2.506 SE 60.7 38.0 YR
1 125 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA LOCF 1 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -13.672 1.505 SE 60.7 38.0 YR
104 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA MI 1 WK SCORAD Mean 68.6 0-103 score 11.91 SD LS Mean -13.55 1.629 SE 60.7 38.0 YR
easi90 8 60 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 29.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 90 26.947 percent 60.7 38.0 YR
6 59 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 15.0 FAS Cochran Mantel Haenszel Test 6 WK EASI 90 14.105 percent 60.7 38.0 YR
4 58 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 8.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 90 7.579 percent 60.7 38.0 YR
2 57 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 1.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 90 0.842 percent 60.7 38.0 YR
12 61 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 38.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 90 35.79 percent 60.7 38.0 YR
1 56 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 0.0 FAS Cochran Mantel Haenszel Test 1 WK EASI 90 0.0 percent 60.7 38.0 YR
easi75 8 18 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 59.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 75 55.05 percent 60.7 38.0 YR
6 17 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 44.0 FAS Cochran Mantel Haenszel Test 6 WK EASI 75 40.926 percent 60.7 38.0 YR
4 16 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 32.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 75 29.698 percent 60.7 38.0 YR
2 15 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 10.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 75 9.054 percent 60.7 38.0 YR
12 19 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 69.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 75 64.467 percent 60.7 38.0 YR
1 14 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 0.0 FAS Cochran Mantel Haenszel Test 1 WK EASI 75 0.0 percent 60.7 38.0 YR
easi50 8 39 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 85.0 FAS Cochran Mantel Haenszel Test 8 WK EASI 50 79.36 percent 60.7 38.0 YR
6 38 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 78.0 FAS Cochran Mantel Haenszel Test 6 WK EASI 50 72.602 percent 60.7 38.0 YR
4 37 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 68.0 FAS Cochran Mantel Haenszel Test 4 WK EASI 50 63.517 percent 60.7 38.0 YR
2 36 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 36.0 FAS Cochran Mantel Haenszel Test 2 WK EASI 50 33.309 percent 60.7 38.0 YR
12 40 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 94.0 FAS Cochran Mantel Haenszel Test 12 WK EASI 50 87.645 percent 60.7 38.0 YR
1 35 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 107.0 8.0 FAS Cochran Mantel Haenszel Test 1 WK EASI 50 7.352 percent 60.7 38.0 YR
easi 8 84 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA MI 8 WK EASI Mean 33.3 0-72 score 9.93 SD LS Mean -73.537 2.799 SE 60.7 38.0 YR
6 83 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA MI 6 WK EASI Mean 33.3 0-72 score 9.93 SD LS Mean -67.176 2.799 SE 60.7 38.0 YR
4 82 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA MI 4 WK EASI Mean 33.3 0-72 score 9.93 SD LS Mean -58.524 2.799 SE 60.7 38.0 YR
2 81 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA MI 2 WK EASI Mean 33.3 0-72 score 9.93 SD LS Mean -39.44 2.799 SE 60.7 38.0 YR
16 86 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 103.0 FAS ANCOVA MI 16 WK EASI Mean 33.3 0-72 score 9.93 SD LS Mean -79.8 2.59 SE 60.7 38.0 YR
12 85 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA MI 12 WK EASI Mean 33.3 0-72 score 9.93 SD LS Mean -78.88 2.672 SE 60.7 38.0 YR
1 80 control Double-Blind True dupilumab Interleukin 4R alpha inhibitors 300.0 MG SC Q2W 107 FAS ANCOVA MI 1 WK EASI Mean 33.3 0-72 score 9.93 SD LS Mean -18.83 2.418 SE 60.7 38.0 YR

544_cefalu_2015¶

Control rows matched by test output: 8 of 8

Literature data accuracy: 75.33%

Clinical data accuracy: 58.71%

Clinical data accuracy (drop unmatched): 58.71%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
dapagliflozin 10mg oncedaily hba1c 24 4 c7t4 test Double-Blind TRUE Dapagliflozin Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor 10 mg mg Oral Once-Daily 455 451 FAS ANCOVA LOCF 24 WK HbA1c Mean 8.18 percent 0.84 SD Adjusted Mean -0.46 percent -0.50 -0.33 Adjusted Mean -0.38 percent -0.46 -0.30 62.8 YR
10 qd hba1c 24.0 7 c7t4 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 220 FAS LOCF 24.0 WK HbA1c Mean 8.05 percent 0.81 SD LS Mean -0.47 percent 95%CI -0.59 -0.36 LS Mean 7.55 percent LS Mean -5.86
similarity 100 100 100 20 57 50 100 17 0 0 0 100 100 0 100 67 100 100 100 50 100 75 100 100 100 60 75 100 100 0 75 75 60 25 100 100 100 0 0 0 0 100 100 100 100 100 0 0
placebo oncedaily hba1c 24 7 c6t7 test Double-Blind TRUE Placebo Once-daily 459 451 FAS ANCOVA LOCF 24 WK HbA1c Mean 8.08 percent 0.80 SD Adjusted Mean 0.08 percent 0.01 0.16 Adjusted Mean 0.08 percent 0.01 0.16 68.6 63.0 YR
0 qd hba1c 24.0 6 c6t7 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 217 FAS LOCF 24.0 WK HbA1c Mean 7.99 percent 0.76 SD LS Mean -0.02 percent 95%CI -0.13 0.1 LS Mean 8.0 percent LS Mean -0.249
similarity 100 100 100 0 0 0 0 17 0 0 33 100 100 0 100 67 100 100 100 25 100 50 100 100 100 60 75 100 100 0 75 86 60 86 100 100 100 0 0 0 0 100 100 100 100 0 0 0
dapagliflozin 10mg oncedaily hba1c 24 3 c5t3 test Double-Blind TRUE Dapagliflozin Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor 10 mg mg Oral Once-Daily 455 451 FAS ANCOVA LOCF 24 WK HbA1c Mean 8.18 percent 0.84 SD Adjusted Mean -0.46 percent -0.50 -0.30 Adjusted Mean -0.38 percent -0.46 -0.30 62.8 YR
10 qd hba1c 24.0 5 c5t3 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 228 FAS LOCF 24.0 WK HbA1c Mean 8.31 percent 0.85 SD LS Mean -0.28 percent 95%CI -0.39 -0.17 LS Mean 7.954 percent LS Mean -3.401
similarity 100 100 100 20 57 50 100 17 0 0 0 100 100 0 100 67 100 100 100 75 100 75 100 100 100 60 50 100 100 0 50 50 60 22 100 100 100 0 0 0 0 100 100 100 100 100 0 0
placebo oncedaily hba1c 24 6 c4t6 test Double-Blind TRUE Placebo Once-daily 459 451 FAS ANCOVA LOCF 24 WK HbA1c Mean 8.08 percent 0.80 SD Adjusted Mean 0.08 percent 0.01 0.16 Adjusted Mean 0.08 percent 0.01 0.16 68.6 63.0 YR
0 qd hba1c 24.0 4 c4t6 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 234 FAS LOCF 24.0 WK HbA1c Mean 8.16 percent 0.83 SD LS Mean 0.19 percent 95%CI 0.08 0.29 LS Mean 8.424 percent LS Mean 2.307
similarity 100 100 100 0 0 0 0 17 0 0 33 100 100 0 100 67 100 100 100 50 100 75 100 100 100 60 50 100 100 0 75 50 60 44 100 100 100 0 0 0 0 100 100 100 100 0 0 0
dapagliflozin 10mg oncedaily hba1c 52 1 c3t1 test Double-Blind TRUE Dapagliflozin Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor 10 mg mg Oral Once-Daily 455 188 FAS ANCOVA LOCF 52 WK HbA1c Mean 8.13 percent 0.81 SD Adjusted Mean -0.66 percent -0.79 -0.53 -27.2 62.8 YR
10 qd hba1c 0.0 3 c3t1 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 220 FAS LOCF 0.0 WK HbA1c Mean 8.05 percent 0.81 SD LS Mean 0.0 percent Mean 8.05 percent 0.81 SD LS Mean 0.0
similarity 100 100 100 20 57 50 100 17 0 0 0 100 100 0 100 0 100 100 100 50 100 100 100 100 100 0 0 0 100 100 100 100 47 50 100 0 0 0 0 0 29 100 100 100 100 100 0 0
10mg oncedaily hba1c 52 2 c2t2 test Double-Blind TRUE Dapagliflozin Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor 10 mg mg Oral Once-Daily 455 188 FAS ANCOVA LOCF 52 WK HbA1c Mean 8.13 percent 0.81 SD Adjusted Mean -0.66 percent -0.79 -0.53 62.8 YR
placebo 0 qd hba1c 0.0 2 c2t2 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 217 FAS LOCF 0.0 WK HbA1c Mean 7.99 percent 0.76 SD LS Mean 0.0 percent Mean 7.99 percent 0.76 SD LS Mean 0.0
similarity 100 100 30 23 33 50 100 17 0 0 33 100 100 0 100 0 100 100 100 25 100 50 100 100 100 0 0 0 100 100 100 100 47 25 100 0 0 0 0 0 0 100 100 100 100 100 0 0
dapagliflozin 10mg oncedaily hba1c 52 0 c1t0 test Double-Blind TRUE Dapagliflozin Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor 10 mg mg Oral Once-Daily 455 188 FAS ANCOVA LOCF 52 WK HbA1c Mean 8.13 percent 0.81 SD Adjusted Mean -0.66 percent -0.79 -0.53 62.8 YR
10 qd hba1c 0.0 1 c1t0 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 228 FAS LOCF 0.0 WK HbA1c Mean 8.31 percent 0.85 SD LS Mean 0.0 percent Mean 8.31 percent 0.85 SD LS Mean 0.0
similarity 100 100 100 20 57 50 100 17 0 0 33 100 100 0 100 0 100 100 100 75 100 75 100 100 100 0 0 0 100 100 100 100 47 25 100 0 0 0 0 0 0 100 100 100 100 100 0 0
placebo oncedaily hba1c 24 8 c0t8 test Double-Blind TRUE Placebo Once-daily 459 451 FAS ANCOVA LOCF 24 WK HbA1c Mean 8.08 percent 0.80 SD Adjusted Mean 0.08 percent 0.01 0.16 Adjusted Mean 0.08 percent 0.01 0.16 68.6 63.0 YR
0 qd hba1c 0.0 0 c0t8 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 234 FAS LOCF 0.0 WK HbA1c Mean 8.16 percent 0.83 SD LS Mean 0.0 percent Mean 8.16 percent 0.83 SD LS Mean 0.0
similarity 100 100 100 0 0 0 0 17 0 0 33 100 100 0 100 0 100 100 100 50 100 75 100 100 100 60 86 100 100 100 0 0 47 50 100 0 0 0 0 0 0 100 100 100 100 0 0 0
dapagliflozin 10mg oncedaily hba1c 24 5 test Double-Blind TRUE Dapagliflozin Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor 10 mg mg Oral Once-Daily 455 451 FAS ANCOVA LOCF 24 WK HbA1c Mean 8.18 percent 0.84 SD Adjusted Mean -0.46 percent 95% CI -0.46 -0.30 Adjusted Mean -0.38 percent 95% CI -0.46 -0.30 62.8 YR

537_jabbour_2014¶

Control rows matched by test output: 18 of 30

Literature data accuracy: 68.60%

Clinical data accuracy: 35.84%

Clinical data accuracy (drop unmatched): 59.73%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
dapagliflozin 10 oncedaily hba1c 24 1 c9t1 test Double-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Once daily 223 223 FAS Longitudinal repeated measures 24 WK HbA1c Mean 7.9 percent 0.8 [mmol/mol] Adjusted mean change -0.4 percent -0.5 -0.3 Adjusted mean -0.4 percent -0.5 -0.3 57.0 54.8 YR
qd hba1c 24.0 9 c9t1 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 94 FAS ANCOVA;Longitudinal Repeated Measure Analysis LOCF 24.0 WK HbA1c Mean 8.65 percent 0.55 SD LS Mean -0.8 percent 95%CI -0.96 -0.65 LS Mean 7.865 percent LS Mean -9.232
similarity 100 100 100 50 100 50 100 17 0 0 0 100 100 77 0 67 100 100 100 29 100 57 0 100 100 44 67 100 100 0 57 57 60 25 100 100 100 0 0 0 0 100 100 100 100 0 0 0
placebo oncedaily hba1c 24 13 c8t13 test Double-Blind TRUE Placebo Oral Once Daily 224 224 FAS Longitudinal repeated measures 24 WK HbA1c Mean 8.0 percent 0.8 [mmol/mol] Adjusted mean change 0.1 percent [1.0 (-0.4 to 2.3) mmol/mol] 0.0 0.2 Adjusted mean 0.1 percent [1.0 (-0.4 to 2.3) mmol/mol] 0.0 0.2 52.7 55.0 YR
0 qd hba1c 24.0 8 c8t13 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 99 FAS ANCOVA;Longitudinal Repeated Measure Analysis LOCF 24.0 WK HbA1c Mean 8.68 percent 0.55 SD LS Mean 0.03 percent 95%CI -0.12 0.18 LS Mean 8.695 percent LS Mean 0.346
similarity 100 100 100 0 0 0 100 17 0 0 0 100 100 77 0 67 100 100 100 57 100 57 0 100 100 44 57 100 100 7 57 57 60 25 100 100 0 0 0 0 0 100 100 100 100 0 0 0
dapagliflozin 10 oncedaily hba1c 48 8 c29t8 test Double-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Once daily 223 110 Stratum 1 (Sitagliptin monotherapy) ANCOVA LOCF 48 WK HbA1c Mean 8.0 percent 0.8 [mmol/mol] Adjusted mean change -0.4 percent [mmol/mol] -0.6 -0.3 Adjusted mean 0.0 percent [mmol/mol] 57.0 54.8 YR
qd hba1c 48.0 29 c29t8 control Double-Blind Extension True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 39 FAS ANCOVA;Longitudinal Repeated Measure Analysis 48.0 WK HbA1c Mean 8.68 percent 0.57 SD LS Mean -1.1 percent LS Mean 7.564 percent LS Mean -12.696
similarity 71 100 100 50 100 50 100 17 0 0 0 100 11 24 0 67 100 100 100 57 100 57 0 100 100 44 33 100 100 0 0 0 60 25 100 100 0 100 100 0 0 100 100 100 100 0 0 0
placebo oncedaily hba1c 48 17 c28t17 test Double-Blind TRUE Placebo Oral Once Daily 224 224 FAS Longitudinal repeated measures 48 WK HbA1c Mean 8.0 percent 0.8 [mmol/mol] Adjusted mean change 0.4 percent 6.8 to 20.2 0.8 to 1.1 Adjusted mean 0.4 percent 0.2 to 0.5 4.2 to 5.9 52.7 55.0 YR
0 qd hba1c 48.0 28 c28t17 control Double-Blind Extension True placebo Placebo 0 MG/DAY ORAL QD TAB 43 FAS ANCOVA;Longitudinal Repeated Measure Analysis 48.0 WK HbA1c Mean 8.65 percent 0.53 SD LS Mean -0.5 percent LS Mean 8.164 percent LS Mean -5.771
similarity 71 100 100 0 0 0 100 17 0 0 40 100 100 77 100 67 100 100 100 57 100 57 0 100 100 44 67 100 100 100 0 0 60 25 100 100 100 0 0 0 0 100 100 100 100 0 0 0
dapagliflozin 10 oncedaily hba1c 48 7 c27t7 test Double-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Once daily 223 223 FAS Longitudinal repeated measures 48 WK HbA1c Mean 7.9 percent 0.8 [mmol/mol] Adjusted mean change -0.4 percent -0.6 -0.3 Adjusted mean -0.3 percent -0.4 -0.2 57.0 54.8 YR
qd hba1c 48.0 27 c27t7 control Double-Blind Extension True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 55 FAS ANCOVA;Longitudinal Repeated Measure Analysis 48.0 WK HbA1c Mean 8.62 percent 0.53 SD LS Mean -1.2 percent LS Mean 7.46 percent LS Mean -13.856
similarity 71 100 100 50 100 50 100 17 0 0 0 100 100 77 100 67 100 100 100 29 100 57 0 100 100 44 33 100 100 100 0 0 60 29 100 100 100 0 0 0 0 100 100 100 100 0 0 0
placebo oncedaily hba1c 48 16 c26t16 test Double-Blind TRUE Placebo Oral Once Daily 224 224 FAS Longitudinal repeated measures 48 WK HbA1c Mean 8.0 percent 0.8 [mmol/mol] Adjusted mean change 0.4 percent 6.8 to 20.2 0.8 to 1.1 Adjusted mean 0.4 percent 0.2 to 0.5 4.2 to 5.9 52.7 55.0 YR
0 qd hba1c 48.0 26 c26t16 control Double-Blind Extension True placebo Placebo 0 MG/DAY ORAL QD TAB 56 FAS ANCOVA;Longitudinal Repeated Measure Analysis 48.0 WK HbA1c Mean 8.7 percent 0.57 SD LS Mean -0.4 percent LS Mean 8.26 percent LS Mean -4.619
similarity 71 100 100 0 0 0 100 17 0 0 0 100 100 77 100 67 100 100 100 67 100 57 0 100 100 44 100 100 100 100 0 0 60 29 100 100 100 0 0 0 0 100 100 100 100 0 0 0
dapagliflozin 10 oncedaily hba1c 48 6 c25t6 test Double-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Once daily 223 223 FAS ANCOVA LOCF 48 WK HbA1c Mean 7.9 percent 0.8 [mmol/mol] Adjusted mean change -0.4 percent -0.6 -0.3 Adjusted mean -0.3 percent -0.4 -0.2 57.0 54.8 YR
qd hba1c 48.0 25 c25t6 control Double-Blind Extension True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 94 FAS ANCOVA;Longitudinal Repeated Measure Analysis 48.0 WK HbA1c Mean 8.65 percent 0.55 SD LS Mean -0.7 percent 95%CI -1.0 -0.5 LS Mean 7.965 percent LS Mean -8.078
similarity 71 100 100 50 100 50 100 17 0 0 0 100 100 24 0 67 100 100 100 29 100 57 0 100 100 44 67 100 100 0 67 67 60 25 100 100 100 0 0 0 0 100 100 100 100 0 0 0
placebo oncedaily hba1c 48 15 c24t15 test Double-Blind TRUE Placebo Oral Once Daily 224 224 FAS ANCOVA LOCF 48 WK HbA1c Mean 8.0 percent 0.8 [mmol/mol] Adjusted mean change 0.4 percent 6.8 to 20.2 0.8 to 1.1 Adjusted mean 0.4 percent 0.2 to 0.5 4.2 to 5.9 52.7 55.0 YR
0 qd hba1c 48.0 24 c24t15 control Double-Blind Extension True placebo Placebo 0 MG/DAY ORAL QD TAB 99 FAS ANCOVA;Longitudinal Repeated Measure Analysis 48.0 WK HbA1c Mean 8.68 percent 0.55 SD LS Mean 0.3 percent 95%CI -0.2 0.7 LS Mean 8.965 percent LS Mean 3.462
similarity 71 100 100 0 0 0 100 17 0 0 0 100 100 24 0 67 100 100 100 57 100 57 0 100 100 44 67 100 100 0 29 31 60 25 100 100 100 0 0 0 0 100 100 100 100 0 0 0
dapagliflozin 10 oncedaily hba1c 48 11 c23t11 test Double-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Once daily 223 113 Stratum 2 (Sitagliptin plus metformin) Longitudinal repeated measures 48 WK HbA1c Mean 56.8 years 10.3 SD Adjusted mean -0.4 percent -0.6 -0.3 Adjusted mean -0.4 percent -0.6 -0.3 57.0 54.8 YR
qd hba1c 24.0 23 c23t11 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 39 FAS ANCOVA;Longitudinal Repeated Measure Analysis 24.0 WK HbA1c Mean 8.68 percent 0.57 SD LS Mean -0.9 percent LS Mean 7.764 percent LS Mean -10.387
similarity 100 100 100 50 100 50 100 17 0 0 40 100 15 77 100 33 100 100 100 75 33 50 100 100 100 60 67 100 100 100 0 0 60 50 100 100 100 0 0 0 0 100 100 100 100 0 0 0
oncedaily hba1c 48 10 c21t10 test Double-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Once daily 223 113 Stratum 2 (Sitagliptin plus metformin) ANCOVA LOCF 48 WK HbA1c Mean 7.8 percent 0.8 [62.0 (8.9)] Adjusted mean change -0.4 percent -0.6 -0.3 Adjusted mean -0.4 percent -0.6 -0.3 57.0 54.8 YR
qd hba1c 24.0 21 c21t10 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 39 FAS ANCOVA;Longitudinal Repeated Measure Analysis LOCF 24.0 WK HbA1c Mean 8.68 percent 0.57 SD LS Mean -0.8 percent 95%CI -1.0 -0.6 LS Mean 7.864 percent LS Mean -9.233
similarity 100 100 100 50 100 50 100 17 0 0 40 100 15 24 100 33 100 100 100 57 100 57 0 100 100 44 67 100 100 0 67 67 60 50 100 100 100 0 0 0 0 100 100 100 100 0 0 0
oncedaily hba1c 24 0 c1t0 test Double-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Once daily 223 223 FAS ANCOVA LOCF 24 WK HbA1c Mean 7.9 percent 0.8 [mmol/mol] LS Mean -0.5 percent [-4.9 mmol/mol] -0.6 -0.4 LS Mean -0.5 percent [-4.9 mmol/mol] -0.6 -0.4 57.0 54.8 YR
qd hba1c 24.0 1 c1t0 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 223.0 223 FAS ANCOVA;Longitudinal Repeated Measure Analysis LOCF 24.0 WK HbA1c Mean 7.9 percent 0.806 SD LS Mean -0.45 percent 95%CI -0.55 -0.35 LS Mean 7.485 percent LS Mean -5.671 57.0 54.8 YR
similarity 100 100 100 50 100 50 100 17 0 75 100 100 100 24 100 67 100 100 100 100 100 75 0 100 100 100 86 100 100 24 57 57 100 25 100 100 0 0 0 0 0 100 100 100 100 100 100 100
oncedaily hba1c 48 9 c19t9 test Double-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Once daily 223 110 Stratum 1 (Sitagliptin monotherapy) Longitudinal repeated measures 48 WK HbA1c Mean 8.0 percent 0.8 [mmol/mol] Adjusted mean change -0.4 percent -0.6 -0.2 Adjusted mean 0.0 percent -0.3 0.3 57.0 54.8 YR
qd hba1c 24.0 19 c19t9 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 113 FAS ANCOVA;Longitudinal Repeated Measure Analysis LOCF 24.0 WK HbA1c Mean 7.8 percent 0.81 SD LS Mean -0.4 percent 95%CI -0.6 -0.3 LS Mean 7.435 percent LS Mean -5.105 59.3 56.8 YR
similarity 100 100 100 50 100 50 100 17 0 0 67 100 11 77 0 33 100 100 100 67 100 86 0 100 100 44 100 100 100 0 100 67 60 25 100 100 100 0 0 0 0 100 100 100 100 50 75 100
oncedaily hba1c 24 5 c17t5 test Double-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Once daily 223 113 Stratum 2 (Sitagliptin plus metformin) Longitudinal repeated measures 24 WK HbA1c Mean 7.9 percent 0.8 [8.2] Adjusted mean change -0.4 percent -0.6 -0.3 Adjusted mean -0.4 percent -0.6 -0.3 57.0 54.8 YR
qd hba1c 24.0 17 c17t5 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 55 FAS ANCOVA;Longitudinal Repeated Measure Analysis 24.0 WK HbA1c Mean 8.62 percent 0.53 SD LS Mean -0.8 percent 95%CI -1.1 -0.5 LS Mean 7.86 percent LS Mean -9.237
similarity 100 100 100 50 100 50 100 17 0 0 0 100 15 77 100 67 100 100 100 29 100 57 0 100 100 44 67 100 100 0 33 67 60 29 100 100 100 0 0 0 0 100 100 100 100 0 0 0
oncedaily hba1c 24 4 c15t4 test Double-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Once daily 223 113 Stratum 2 (Sitagliptin plus metformin) ANCOVA LOCF 24 WK HbA1c Mean 7.9 percent 0.8 [8.2] Adjusted mean change -0.4 percent [-4.4 (-6.3 to -2.5)] -0.6 -0.2 Adjusted mean change -0.4 percent [-4.7 (-6.0 to -3.3)] -0.6 -0.3 57.0 54.8 YR
qd hba1c 24.0 15 c15t4 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 55 FAS ANCOVA;Longitudinal Repeated Measure Analysis LOCF 24.0 WK HbA1c Mean 8.62 percent 0.53 SD LS Mean -0.8 percent 95%CI -1.0 -0.6 LS Mean 7.86 percent LS Mean -9.237
similarity 100 100 100 50 100 50 100 17 0 0 0 100 15 24 100 67 100 100 100 29 100 57 0 100 100 44 67 100 100 21 67 67 44 29 100 100 0 0 0 0 0 100 100 100 100 0 0 0
oncedaily hba1c 24 3 c13t3 test Double-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Once daily 223 110 Stratum 1 (Sitagliptin monotherapy) Longitudinal repeated measures 24 WK HbA1c Mean 8.0 percent 0.8 [mmol/mol] Adjusted mean -0.4 percent -0.6 -0.3 57.0 54.8 YR
qd hba1c 24.0 13 c13t3 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 110 FAS ANCOVA;Longitudinal Repeated Measure Analysis LOCF 24.0 WK HbA1c Mean 7.99 percent 0.8 SD LS Mean -0.5 percent 95%CI -0.6 -0.3 LS Mean 7.53 percent LS Mean -6.227 54.5 52.6 YR
similarity 100 100 100 50 100 50 100 17 0 0 100 100 11 77 0 67 100 100 100 29 100 100 0 100 100 0 0 0 100 0 0 0 60 29 100 100 100 0 0 0 0 100 100 100 100 50 50 100
oncedaily hba1c 24 2 c11t2 test Double-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Once daily 223 110 Stratum 1 (Sitagliptin monotherapy) ANCOVA LOCF 24 WK HbA1c Mean 8.0 percent 0.8 [mmol/mol] LS Mean -0.5 percent [-4.9 mmol/mol] -0.6 -0.3 LS Mean -0.5 percent [-4.9 mmol/mol] -0.6 -0.3 57.0 54.8 YR
qd hba1c 24.0 11 c11t2 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 94 FAS ANCOVA;Longitudinal Repeated Measure Analysis 24.0 WK HbA1c Mean 8.65 percent 0.55 SD LS Mean -0.8 percent 95%CI -1.0 -0.6 LS Mean 7.865 percent LS Mean -9.232
similarity 100 100 100 50 100 50 100 17 0 0 0 100 11 24 0 67 100 100 100 57 100 57 0 100 100 100 67 100 100 24 67 67 100 50 100 100 0 0 0 0 0 100 100 100 100 0 0 0
placebo oncedaily hba1c 24 14 c10t14 test Double-Blind TRUE Placebo Oral Once Daily 224 224 FAS Longitudinal repeated measures 24 WK HbA1c Mean 8.0 percent 0.8 [mmol/mol] Adjusted mean change 0.1 percent [1.0 (-0.4 to 2.3) mmol/mol] 0.0 0.2 Adjusted mean 0.1 percent [1.0 (-0.4 to 2.3) mmol/mol] 0.0 0.2 52.7 55.0 YR
0 qd hba1c 24.0 10 c10t14 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 99 FAS ANCOVA;Longitudinal Repeated Measure Analysis 24.0 WK HbA1c Mean 8.68 percent 0.55 SD LS Mean 0.2 percent 95%CI -0.1 0.4 LS Mean 8.865 percent LS Mean 2.308
similarity 100 100 100 0 0 0 100 17 0 0 0 100 100 77 100 67 100 100 100 57 100 57 0 100 100 44 67 100 100 7 67 67 60 25 100 100 0 0 0 0 0 100 100 100 100 0 0 0
oncedaily hba1c 24 12 c0t12 test Double-Blind TRUE Placebo Oral Once Daily 224 224 FAS ANCOVA LOCF 24 WK HbA1c Mean 8.0 percent 0.8 [mmol/mol] Mean 0.0 percent [-0.1 to 0.1] Mean 0.0 percent [-0.7 to 1.5] 52.7 55.0 YR
0 qd hba1c 24.0 0 c0t12 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 224.0 223 FAS ANCOVA;Longitudinal Repeated Measure Analysis LOCF 24.0 WK HbA1c Mean 7.97 percent 0.778 SD LS Mean 0.04 percent 95%CI -0.06 0.14 LS Mean 7.975 percent LS Mean 0.504 52.7 55.0 YR
similarity 100 100 100 0 0 0 100 17 0 75 67 100 100 24 100 67 100 100 100 29 100 75 0 100 100 73 86 100 100 13 0 0 73 25 100 100 0 100 100 0 0 100 100 100 100 100 100 100
22 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 43 FAS ANCOVA;Longitudinal Repeated Measure Analysis 24.0 WK HbA1c Mean 8.65 percent 0.53 SD LS Mean -0.4 percent LS Mean 8.264 percent LS Mean -4.617
20 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 43 FAS ANCOVA;Longitudinal Repeated Measure Analysis LOCF 24.0 WK HbA1c Mean 8.65 percent 0.53 SD LS Mean 0.0 percent 95%CI -0.2 0.2 LS Mean 8.664 percent LS Mean 0.0
18 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 113 FAS ANCOVA;Longitudinal Repeated Measure Analysis LOCF 24.0 WK HbA1c Mean 7.87 percent 0.75 SD LS Mean 0.0 percent 95%CI -0.2 0.1 LS Mean 7.835 percent LS Mean 0.0 59.3 56.6 YR
16 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 56 FAS ANCOVA;Longitudinal Repeated Measure Analysis 24.0 WK HbA1c Mean 8.7 percent 0.57 SD LS Mean 0.2 percent 95%CI -0.1 0.6 LS Mean 8.86 percent LS Mean 2.309
14 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 56 FAS ANCOVA;Longitudinal Repeated Measure Analysis LOCF 24.0 WK HbA1c Mean 8.7 percent 0.57 SD LS Mean 0.1 percent 95%CI -0.2 0.3 LS Mean 8.76 percent LS Mean 1.155
12 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 111 FAS ANCOVA;Longitudinal Repeated Measure Analysis LOCF 24.0 WK HbA1c Mean 8.07 percent 0.8 SD LS Mean 0.1 percent 95%CI -0.1 0.3 LS Mean 8.13 percent LS Mean 1.245 45.9 53.3 YR
0.0 6 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 43 FAS ANCOVA;Longitudinal Repeated Measure Analysis 0.0 WK HbA1c Mean 8.65 percent 0.53 SD LS Mean 0.0 percent Mean 8.65 percent 0.53 SD LS Mean 0.0
4 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 56 FAS ANCOVA;Longitudinal Repeated Measure Analysis 0.0 WK HbA1c Mean 8.7 percent 0.57 SD LS Mean 0.0 percent Mean 8.7 percent 0.57 SD LS Mean 0.0
2 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD TAB 99 FAS ANCOVA;Longitudinal Repeated Measure Analysis 0.0 WK HbA1c Mean 8.68 percent 0.55 SD LS Mean 0.0 percent Mean 8.68 percent 0.55 SD LS Mean 0.0
dapagliflozin 10 qd hba1c 0.0 7 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 39 FAS ANCOVA;Longitudinal Repeated Measure Analysis 0.0 WK HbA1c Mean 8.68 percent 0.57 SD LS Mean 0.0 percent Mean 8.68 percent 0.57 SD LS Mean 0.0
5 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 55 FAS ANCOVA;Longitudinal Repeated Measure Analysis 0.0 WK HbA1c Mean 8.62 percent 0.53 SD LS Mean 0.0 percent Mean 8.62 percent 0.53 SD LS Mean 0.0
3 control Double-Blind True dapagliflozin SGLT2 10 MG/DAY ORAL QD TAB 94 FAS ANCOVA;Longitudinal Repeated Measure Analysis 0.0 WK HbA1c Mean 8.65 percent 0.55 SD LS Mean 0.0 percent Mean 8.65 percent 0.55 SD LS Mean 0.0

286_wollenberg_2021¶

Control rows matched by test output: 15 of 178

Literature data accuracy: 74.60%

Clinical data accuracy: 6.93%

Clinical data accuracy (drop unmatched): 82.28%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
tralokinumab 300 q2w easi75 52 9 c97t9 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 603 74 38 FAS Cochran -Mantel -Haenszel test, stratified by region and baseline IGA NRI 52 WK EASI-75 Percent 51 Percent 95% CI 13.7 46.4 58.2 37.0 YR
300.0 q2w easi75 2 97 c97t9 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 28.0 FAS Cochran Mantel Haenszel Test NRI 2 WK EASI 75 4.672 percent 60.5 34.0 YR
similarity 100 100 100 36 75 100 100 100 100 33 0 33 100 60 100 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 0 100 100 0 0 0 100 100 100 100 100 100 25 75 100
placebo q2w easi75 16 2 c96t2 test Double-Blind TRUE Placebo SC Q2W 199 197 25 FAS Repeated-measurements model 16 WK EASI-75 Adjusted mean change (SE) -9.0 1.05 SE -8.8 -4.1 61.8 37.0 YR
0.0 q2w easi75 16 96 c96t2 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 23.0 FAS Cochran Mantel Haenszel Test NRI 16 WK EASI 75 11.4 percent 56.7 30.0 YR
similarity 100 100 100 0 0 0 100 100 100 33 25 33 100 40 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 29 0 0 0 0 0 100 100 100 100 100 100 50 75 100
tralokinumab 300 q2w easi75 52 6 c8t6 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 68 47 28 FAS Repeated-measurements model on postbaseline data: change =(Treatment9Week) +(Baseline measure 9Week) +Region +Baseline IGA 52 WK EASI-75 n/N(%) 60 percent 58.2 37.0 YR
300.0 q2w easi75 2 8 c8t6 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 28.0 FAS Cochran Mantel Haenszel Test NRI 2 WK EASI 75 4.672 percent 58.2 37.0 YR
similarity 100 100 100 36 75 100 100 100 100 40 0 67 100 28 0 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 29 100 100 100 100 100 100 100 100 100 100 100 100 100 100
placebo q2w easi75 16 1 c7t1 test Double-Blind TRUE Placebo SC Q2W 199 197 25 FAS Cochran -Mantel -Haenszel test NRI 16 WK EASI-75 Percent 12.7 Percent 95% CI 6.5 17.7 61.8 37.0 YR
0.0 q2w easi75 16 7 c7t1 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 25.0 FAS Cochran Mantel Haenszel Test NRI 16 WK EASI 75 12.7 percent 61.8 37.0 YR
similarity 100 100 100 0 0 0 100 100 100 100 50 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 0 0 0 100 100 100 100 100 100 100 100 100
tralokinumab 300 q2w easi90 16 13 c50t13 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 603 601 87 FAS Cochran -Mantel -Haenszel test, stratified by region and baseline IGA NRI 16 WK EASI-90 n/N(%) 14.5 percent 10.3 14.1 58.2 37.0 YR
300.0 q2w easi90 16 50 c50t13 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 88.0 FAS Cochran Mantel Haenszel Test NRI 16 WK EASI 90 14.512 percent 58.2 37.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 50 33 100 60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 80 100 100 100 0 0 100 100 100 100 100 100 100 100 100
placebo q2w easi90 16 4 c42t4 test Double-Blind TRUE Placebo SC Q2W 199 197 8 FAS Cochran -Mantel -Haenszel test, stratified by region and baseline IGA NRI 16 WK EASI-90 n/N(%) 4.1 percent 61.8 37.0 YR
0.0 q2w easi90 16 42 c42t4 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 8.0 FAS Cochran Mantel Haenszel Test NRI 16 WK EASI 90 4.095 percent 61.8 37.0 YR
similarity 100 100 100 0 0 0 100 100 100 100 50 50 100 60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 50 100 100 100 100 100 100 100 100 100 100 100 100 100 100
tralokinumab 300 q2w easi50 16 11 c34t11 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 603 601 250 FAS Cochran -Mantel -Haenszel test, stratified by region and baseline IGA NRI 16 WK EASI-50 n/N(%) 41.6 percent 13.3 26.8 58.2 37.0 YR
300.0 q2w easi50 16 34 c34t11 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 251.0 FAS Cochran Mantel Haenszel Test NRI 16 WK EASI 50 41.672 percent 58.2 37.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 50 50 100 60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 80 100 100 100 0 0 100 100 100 100 100 100 100 100 100
placebo q2w easi50 16 3 c26t3 test Double-Blind TRUE Placebo SC Q2W 199 197 42 FAS Cochran -Mantel -Haenszel test, stratified by region and baseline IGA NRI 16 WK EASI-50 n/N(%) 21.3 percent 13.3 26.8 61.8 37.0 YR
0.0 q2w easi50 16 26 c26t3 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 42.0 FAS Cochran Mantel Haenszel Test NRI 16 WK EASI 50 21.268 percent 61.8 37.0 YR
similarity 100 100 100 0 0 0 100 100 100 100 50 67 100 60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 60 100 100 100 0 0 100 100 100 100 100 100 100 100 100
tralokinumab 300 every4weeks easi75 52 14 c17t14 test Double-Blind TRUE tralokinumab Monoclonal Antibody 300 mg SC Every 4 Weeks 89 74 38 FAS Cochran -Mantel -Haenszel test, stratified by region and baseline IGA NRI 52 WK EASI-75 Percent 51 Percent 95% CI 17.3 50.0
300.0 q4w easi75 52 17 c17t14 control Open-Label True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q4W 78 57.0 28.0 FAS Cochran Mantel Haenszel Test NRI 52 WK EASI 75 49.0 percent
similarity 45 100 100 36 75 100 100 25 100 50 33 33 100 60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 0 100 100 0 0 0 100 100 100 100 100 100 100 100 100
300 q2w easi75 52 0 c16t0 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 35 30 10 FAS Cochran -Mantel -Haenszel test, stratified by region and baseline IGA NRI 52 WK EASI-75 n/N(%) 33 percent 21.2 42.6 56.7 30.0 YR
300.0 q2w easi75 52 16 c16t0 control Open-Label True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 71 47.0 28.0 FAS Cochran Mantel Haenszel Test NRI 52 WK EASI 75 60.0 percent
similarity 45 100 100 36 75 100 100 100 100 0 33 33 100 60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 0 100 100 100 0 0 100 100 100 100 100 100 0 0 0
300 q2w easi75 16 7 c15t7 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 603 591 196 FAS Cochran -Mantel -Haenszel test, stratified by region and baseline IGA NRI 16 WK EASI-75 Percent 33.2 Percent 95% CI 15.8 27.3 58.2 37.0 YR
300.0 q2w easi75 16 15 c15t7 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 151.0 FAS Cochran Mantel Haenszel Test NRI 16 WK EASI 75 25.0 percent 58.2 37.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 0 25 100 60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 100 100 0 0 0 100 100 100 100 100 100 100 100 100
300 q2w easi75 52 10 c13t10 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 603 74 38 FAS Repeated-measurements model on postbaseline data: change =(Treatment9Week) +(Baseline measure 9Week) +Region +Baseline IGA 52 WK EASI-75 Adjusted mean change (SE) 51.0 percent 58.2 37.0 YR
300.0 q2w easi75 12 13 c13t10 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 163.0 FAS Cochran Mantel Haenszel Test NRI 12 WK EASI 75 27.009 percent 58.2 37.0 YR
similarity 100 100 100 36 75 100 100 100 100 100 0 29 100 28 0 50 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 40 100 100 100 100 100 100 100 100 100 100 100 100 100 100
300 q2w easi50 16 12 c123t12 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 603 601 250 FAS Mantel -Haenszel risk difference, stratified by region and baseline IGA NRI 16 WK EASI-50 Percent 41.6 percent 13.3 26.8 58.2 37.0 YR
300.0 q2w easi50 16 123 c123t12 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 296.0 FAS Cochran Mantel Haenszel Test NRI 16 WK EASI 50 49.971 percent 60.5 34.0 YR
similarity 100 100 100 36 75 100 100 100 100 33 25 25 100 45 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 40 100 100 100 0 0 100 100 100 100 100 100 25 75 100
300 q2w easi75 52 5 c105t5 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 68 77 43 FAS Cochran -Mantel -Haenszel test, stratified by region and baseline IGA NRI 52 WK EASI-75 Percent 56 Percent 95% CI 17.3 50.0 58.2 37.0 YR
300.0 q2w easi75 52 105 c105t5 control Open-Label True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 91 77.0 43.0 FAS Cochran Mantel Haenszel Test NRI 52 WK EASI 75 56.0 percent
similarity 45 100 100 36 75 100 100 100 100 0 67 67 100 60 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 67 100 100 0 0 0 100 100 100 100 100 100 0 0 0
300 q2w easi75 16 8 c104t8 test Double-Blind TRUE Tralokinumab Monoclonal Antibody 300 mg SC Q2W 603 601 150 FAS Repeated-measurements model on postbaseline data: change =(Treatment9Week) +(Baseline measure 9Week) +Region +Baseline IGA 16 WK EASI-75 LSMean 25.0 percent 95% CI 6.5 17.7 58.2 37.0 YR
300.0 q2w easi75 16 104 c104t8 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 197.0 FAS Cochran Mantel Haenszel Test NRI 16 WK EASI 75 33.2 percent 60.5 34.0 YR
similarity 100 100 100 36 75 100 100 100 100 33 25 25 100 28 0 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 25 100 100 0 0 0 100 100 100 100 100 100 25 75 100
600.0 q2w scorad 0 168 control Double-Blind True tralokinumab Interleukin 13 inhibitors 600.0 MG SC Q2W 591 591.0 FAS OC 0 WK SCORAD Mean 70.0 0-103 score 13.4 SD LS Mean 0.0 0-103 score Mean 70.0 0-103 score 13.4 SD 60.5 34.0 YR
79 control Double-Blind True tralokinumab Interleukin 13 inhibitors 600.0 MG SC Q2W 601 601.0 FAS OC 0 WK SCORAD Mean 70.3 0-103 score 13.0 SD LS Mean 0.0 0-103 score Mean 70.3 0-103 score 13.0 SD 58.2 37.0 YR
easi 0 149 control Double-Blind True tralokinumab Interleukin 13 inhibitors 600.0 MG SC Q2W 591 591.0 FAS OC 0 WK EASI Mean 32.1 0-72 score 14.3 SD Mean 0.0 0-72 score LS Mean 0.0 60.5 34.0 YR
60 control Double-Blind True tralokinumab Interleukin 13 inhibitors 600.0 MG SC Q2W 601 601.0 FAS OC 0 WK EASI Mean 32.2 0-72 score 13.7 SD Mean 0.0 0-72 score LS Mean 0.0 58.2 37.0 YR
300.0 q4w easi75 52 106 control Open-Label True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q4W 90 74.0 38.0 FAS Cochran Mantel Haenszel Test NRI 52 WK EASI 75 51.0 percent
q2w scorad 8 172 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 569.0 FAS OC 8 WK SCORAD Mean 70.0 0-103 score 13.4 SD LS Mean -25.0 0-103 score 0.76 SE Mean 44.0 0-103 score 19.8 SD 60.5 34.0 YR
83 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 570.0 FAS OC 8 WK SCORAD Mean 70.3 0-103 score 13.0 SD LS Mean -22.8 0-103 score 0.81 SE Mean 44.4 0-103 score 19.1 SD 58.2 37.0 YR
6 171 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 574.0 FAS OC 6 WK SCORAD Mean 70.0 0-103 score 13.4 SD LS Mean -22.4 0-103 score 0.72 SE Mean 46.9 0-103 score 19.3 SD 60.5 34.0 YR
82 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 579.0 FAS OC 6 WK SCORAD Mean 70.3 0-103 score 13.0 SD LS Mean -21.2 0-103 score 0.73 SE Mean 46.7 0-103 score 18.8 SD 58.2 37.0 YR
4 170 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 574.0 FAS OC 4 WK SCORAD Mean 70.0 0-103 score 13.4 SD LS Mean -18.0 0-103 score 0.62 SE Mean 50.9 0-103 score 18.4 SD 60.5 34.0 YR
81 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 588.0 FAS OC 4 WK SCORAD Mean 70.3 0-103 score 13.0 SD LS Mean -17.0 0-103 score 0.65 SE Mean 51.1 0-103 score 17.8 SD 58.2 37.0 YR
2 169 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 587.0 FAS OC 2 WK SCORAD Mean 70.0 0-103 score 13.4 SD LS Mean -10.8 0-103 score 0.49 SE Mean 58.3 0-103 score 17.2 SD 60.5 34.0 YR
80 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 591.0 FAS OC 2 WK SCORAD Mean 70.3 0-103 score 13.0 SD LS Mean -10.6 0-103 score 0.53 SE Mean 58.2 0-103 score 16.3 SD 58.2 37.0 YR
16 177 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 564.0 FAS OC 16 WK SCORAD Mean 70.0 0-103 score 13.4 SD Mean 41.1 0-103 score 21.9 SD 60.5 34.0 YR
176 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 555.0 FAS OC 16 WK SCORAD Mean 70.0 0-103 score 13.4 SD LS Mean -28.1 0-103 score 0.92 SE Mean 40.9 0-103 score 21.8 SD 60.5 34.0 YR
88 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 561.0 FAS OC 16 WK SCORAD Mean 70.3 0-103 score 13.0 SD Mean 42.2 0-103 score 20.7 SD 58.2 37.0 YR
87 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 547.0 FAS OC 16 WK SCORAD Mean 70.3 0-103 score 13.0 SD LS Mean -25.2 0-103 score 0.94 SE Mean 42.1 0-103 score 20.7 SD 58.2 37.0 YR
14 175 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 549.0 FAS OC 14 WK SCORAD Mean 70.0 0-103 score 13.4 SD LS Mean -29.0 0-103 score 0.87 SE Mean 40.2 0-103 score 20.8 SD 60.5 34.0 YR
86 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 545.0 FAS OC 14 WK SCORAD Mean 70.3 0-103 score 13.0 SD LS Mean -25.9 0-103 score 0.91 SE Mean 41.1 0-103 score 19.7 SD 58.2 37.0 YR
12 174 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 561.0 FAS OC 12 WK SCORAD Mean 70.0 0-103 score 13.4 SD LS Mean -27.7 0-103 score 0.83 SE Mean 41.2 0-103 score 19.9 SD 60.5 34.0 YR
85 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 560.0 FAS OC 12 WK SCORAD Mean 70.3 0-103 score 13.0 SD LS Mean -25.3 0-103 score 0.84 SE Mean 42.1 0-103 score 19.7 SD 58.2 37.0 YR
10 173 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 560.0 FAS OC 10 WK SCORAD Mean 70.0 0-103 score 13.4 SD LS Mean -27.1 0-103 score 0.78 SE Mean 41.5 0-103 score 19.2 SD 60.5 34.0 YR
84 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 564.0 FAS OC 10 WK SCORAD Mean 70.3 0-103 score 13.0 SD LS Mean -24.9 0-103 score 0.83 SE Mean 42.7 0-103 score 19.4 SD 58.2 37.0 YR
easi90 8 135 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 61.0 FAS Cochran Mantel Haenszel Test NRI 8 WK EASI 90 10.345 percent 60.5 34.0 YR
46 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 52.0 FAS Cochran Mantel Haenszel Test NRI 8 WK EASI 90 8.549 percent 58.2 37.0 YR
6 134 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 53.0 FAS Cochran Mantel Haenszel Test NRI 6 WK EASI 90 8.98 percent 60.5 34.0 YR
45 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 38.0 FAS Cochran Mantel Haenszel Test NRI 6 WK EASI 90 6.322 percent 58.2 37.0 YR
4 133 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 27.0 FAS Cochran Mantel Haenszel Test NRI 4 WK EASI 90 4.598 percent 60.5 34.0 YR
44 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 22.0 FAS Cochran Mantel Haenszel Test NRI 4 WK EASI 90 3.592 percent 58.2 37.0 YR
2 132 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 8.0 FAS Cochran Mantel Haenszel Test NRI 2 WK EASI 90 1.293 percent 60.5 34.0 YR
43 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 3.0 FAS Cochran Mantel Haenszel Test NRI 2 WK EASI 90 0.503 percent 58.2 37.0 YR
16 139 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 109.0 FAS Cochran Mantel Haenszel Test NRI 16 WK EASI 90 18.391 percent 60.5 34.0 YR
14 138 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 101.0 FAS Cochran Mantel Haenszel Test NRI 14 WK EASI 90 17.026 percent 60.5 34.0 YR
49 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 71.0 FAS Cochran Mantel Haenszel Test NRI 14 WK EASI 90 11.782 percent 58.2 37.0 YR
12 137 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 86.0 FAS Cochran Mantel Haenszel Test NRI 12 WK EASI 90 14.583 percent 60.5 34.0 YR
48 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 68.0 FAS Cochran Mantel Haenszel Test NRI 12 WK EASI 90 11.207 percent 58.2 37.0 YR
10 136 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 68.0 FAS Cochran Mantel Haenszel Test NRI 10 WK EASI 90 11.422 percent 60.5 34.0 YR
47 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 69.0 FAS Cochran Mantel Haenszel Test NRI 10 WK EASI 90 11.494 percent 58.2 37.0 YR
easi75 8 100 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 155.0 FAS Cochran Mantel Haenszel Test NRI 8 WK EASI 75 26.097 percent 60.5 34.0 YR
11 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 135.0 FAS Cochran Mantel Haenszel Test NRI 8 WK EASI 75 22.336 percent 58.2 37.0 YR
6 99 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 116.0 FAS Cochran Mantel Haenszel Test NRI 6 WK EASI 75 19.487 percent 60.5 34.0 YR
10 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 115.0 FAS Cochran Mantel Haenszel Test NRI 6 WK EASI 75 19.145 percent 58.2 37.0 YR
4 98 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 81.0 FAS Cochran Mantel Haenszel Test NRI 4 WK EASI 75 13.675 percent 60.5 34.0 YR
9 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 73.0 FAS Cochran Mantel Haenszel Test NRI 4 WK EASI 75 12.08 percent 58.2 37.0 YR
14 103 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 193.0 FAS Cochran Mantel Haenszel Test NRI 14 WK EASI 75 32.593 percent 60.5 34.0 YR
14 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 160.0 FAS Cochran Mantel Haenszel Test NRI 14 WK EASI 75 26.553 percent 58.2 37.0 YR
12 102 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 184.0 FAS Cochran Mantel Haenszel Test NRI 12 WK EASI 75 31.111 percent 60.5 34.0 YR
10 101 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 158.0 FAS Cochran Mantel Haenszel Test NRI 10 WK EASI 75 26.667 percent 60.5 34.0 YR
12 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 162.0 FAS Cochran Mantel Haenszel Test NRI 10 WK EASI 75 26.895 percent 58.2 37.0 YR
easi50 8 119 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 269.0 FAS Cochran Mantel Haenszel Test NRI 8 WK EASI 50 45.303 percent 60.5 34.0 YR
30 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 245.0 FAS Cochran Mantel Haenszel Test NRI 8 WK EASI 50 40.634 percent 58.2 37.0 YR
6 118 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 253.0 FAS Cochran Mantel Haenszel Test NRI 6 WK EASI 50 42.709 percent 60.5 34.0 YR
29 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 240.0 FAS Cochran Mantel Haenszel Test NRI 6 WK EASI 50 39.77 percent 58.2 37.0 YR
4 117 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 188.0 FAS Cochran Mantel Haenszel Test NRI 4 WK EASI 50 31.643 percent 60.5 34.0 YR
28 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 199.0 FAS Cochran Mantel Haenszel Test NRI 4 WK EASI 50 33.026 percent 58.2 37.0 YR
2 116 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 104.0 FAS Cochran Mantel Haenszel Test NRI 2 WK EASI 50 17.464 percent 60.5 34.0 YR
27 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 103.0 FAS Cochran Mantel Haenszel Test NRI 2 WK EASI 50 17.118 percent 58.2 37.0 YR
14 122 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 305.0 FAS Cochran Mantel Haenszel Test NRI 14 WK EASI 50 51.355 percent 60.5 34.0 YR
33 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 265.0 FAS Cochran Mantel Haenszel Test NRI 14 WK EASI 50 43.919 percent 58.2 37.0 YR
12 121 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 307.0 FAS Cochran Mantel Haenszel Test NRI 12 WK EASI 50 51.7 percent 60.5 34.0 YR
32 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 266.0 FAS Cochran Mantel Haenszel Test NRI 12 WK EASI 50 44.092 percent 58.2 37.0 YR
10 120 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 593 593.0 301.0 FAS Cochran Mantel Haenszel Test NRI 10 WK EASI 50 50.836 percent 60.5 34.0 YR
31 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 603 603.0 262.0 FAS Cochran Mantel Haenszel Test NRI 10 WK EASI 50 43.401 percent 58.2 37.0 YR
easi 8 153 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 570.0 FAS OC 8 WK EASI Mean 32.1 0-72 score 14.3 SD Mean -16.0 0-72 score 12.4 SD LS Mean -50.122 1.463 SE 60.5 34.0 YR
64 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 570.0 FAS OC 8 WK EASI Mean 32.2 0-72 score 13.7 SD Mean -16.6 0-72 score 13.1 SD LS Mean -47.561 1.555 SE 58.2 37.0 YR
6 152 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 577.0 FAS OC 6 WK EASI Mean 32.1 0-72 score 14.3 SD Mean -14.3 0-72 score 12.2 SD LS Mean -45.0 1.463 SE 60.5 34.0 YR
63 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 579.0 FAS OC 6 WK EASI Mean 32.2 0-72 score 13.7 SD Mean -15.1 0-72 score 12.2 SD LS Mean -44.268 1.463 SE 58.2 37.0 YR
4 151 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 574.0 FAS OC 4 WK EASI Mean 32.1 0-72 score 14.3 SD Mean -11.8 0-72 score 10.9 SD LS Mean -36.585 1.463 SE 60.5 34.0 YR
62 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 588.0 FAS OC 4 WK EASI Mean 32.2 0-72 score 13.7 SD Mean -12.4 0-72 score 11.8 SD LS Mean -35.671 1.372 SE 58.2 37.0 YR
2 150 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 587.0 FAS OC 2 WK EASI Mean 32.1 0-72 score 14.3 SD Mean -7.2 0-72 score 9.6 SD LS Mean -21.951 1.098 SE 60.5 34.0 YR
61 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 593.0 FAS OC 2 WK EASI Mean 32.2 0-72 score 13.7 SD Mean -7.7 0-72 score 10.3 SD LS Mean -21.951 1.281 SE 58.2 37.0 YR
16 157 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 555.0 FAS OC 16 WK EASI Mean 32.1 0-72 score 14.3 SD Mean -17.8 0-72 score 13.0 SD LS Mean -57.073 1.829 SE 60.5 34.0 YR
68 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 547.0 FAS OC 16 WK EASI Mean 32.2 0-72 score 13.7 SD Mean -17.7 0-72 score 13.3 SD LS Mean -51.402 2.012 SE 58.2 37.0 YR
14 156 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 549.0 FAS OC 14 WK EASI Mean 32.1 0-72 score 14.3 SD Mean -18.4 0-72 score 13.1 SD LS Mean -57.805 1.646 SE 60.5 34.0 YR
67 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 546.0 FAS OC 14 WK EASI Mean 32.2 0-72 score 13.7 SD Mean -18.5 0-72 score 13.5 SD LS Mean -52.5 1.646 SE 58.2 37.0 YR
12 155 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 561.0 FAS OC 12 WK EASI Mean 32.1 0-72 score 14.3 SD Mean -18.0 0-72 score 12.5 SD LS Mean -55.976 1.646 SE 60.5 34.0 YR
66 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 561.0 FAS OC 12 WK EASI Mean 32.2 0-72 score 13.7 SD Mean -17.8 0-72 score 13.3 SD LS Mean -52.134 1.646 SE 58.2 37.0 YR
10 154 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 591 560.0 FAS OC 10 WK EASI Mean 32.1 0-72 score 14.3 SD Mean -17.2 0-72 score 12.1 SD LS Mean -54.146 1.646 SE 60.5 34.0 YR
65 control Double-Blind True tralokinumab Interleukin 13 inhibitors 300.0 MG SC Q2W 601 564.0 FAS OC 10 WK EASI Mean 32.2 0-72 score 13.7 SD Mean -17.4 0-72 score 13.0 SD LS Mean -49.939 1.646 SE 58.2 37.0 YR
placebo 0.0 q2w scorad 8 162 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 185.0 FAS OC 8 WK SCORAD Mean 70.5 0-103 score 12.2 SD LS Mean -10.8 0-103 score 1.41 SE Mean 55.9 0-103 score 19.8 SD 56.7 30.0 YR
73 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 185.0 FAS OC 8 WK SCORAD Mean 71.7 0-103 score 12.5 SD LS Mean -12.9 0-103 score 1.52 SE Mean 53.2 0-103 score 19.2 SD 61.8 37.0 YR
6 161 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 187.0 FAS OC 6 WK SCORAD Mean 70.5 0-103 score 12.2 SD LS Mean -9.0 0-103 score 1.31 SE Mean 58.1 0-103 score 17.9 SD 56.7 30.0 YR
72 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 186.0 FAS OC 6 WK SCORAD Mean 71.7 0-103 score 12.5 SD LS Mean -11.4 0-103 score 1.36 SE Mean 55.0 0-103 score 17.8 SD 61.8 37.0 YR
4 160 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 189.0 FAS OC 4 WK SCORAD Mean 70.5 0-103 score 12.2 SD LS Mean -6.9 0-103 score 1.11 SE Mean 60.6 0-103 score 16.9 SD 56.7 30.0 YR
71 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 188.0 FAS OC 4 WK SCORAD Mean 71.7 0-103 score 12.5 SD LS Mean -7.5 0-103 score 1.19 SE Mean 59.9 0-103 score 17.9 SD 61.8 37.0 YR
2 159 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 194.0 FAS OC 2 WK SCORAD Mean 70.5 0-103 score 12.2 SD LS Mean -3.9 0-103 score 0.84 SE Mean 64.8 0-103 score 14.7 SD 56.7 30.0 YR
70 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 193.0 FAS OC 2 WK SCORAD Mean 71.7 0-103 score 12.5 SD LS Mean -5.0 0-103 score 0.92 SE Mean 63.8 0-103 score 17.7 SD 61.8 37.0 YR
16 167 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 181.0 FAS OC 16 WK SCORAD Mean 70.5 0-103 score 12.2 SD Mean 53.3 0-103 score 23.1 SD 56.7 30.0 YR
166 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 175.0 FAS OC 16 WK SCORAD Mean 70.5 0-103 score 12.2 SD LS Mean -14.0 0-103 score 1.79 SE Mean 53.8 0-103 score 23.2 SD 56.7 30.0 YR
78 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 182.0 FAS OC 16 WK SCORAD Mean 71.7 0-103 score 12.5 SD Mean 51.6 0-103 score 18.6 SD 61.8 37.0 YR
77 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 178.0 FAS OC 16 WK SCORAD Mean 71.7 0-103 score 12.5 SD LS Mean -14.7 0-103 score 1.8 SE Mean 51.4 0-103 score 18.6 SD 61.8 37.0 YR
14 165 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 177.0 FAS OC 14 WK SCORAD Mean 70.5 0-103 score 12.2 SD LS Mean -13.5 0-103 score 1.67 SE Mean 52.6 0-103 score 21.9 SD 56.7 30.0 YR
76 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 176.0 FAS OC 14 WK SCORAD Mean 71.7 0-103 score 12.5 SD LS Mean -15.2 0-103 score 1.75 SE Mean 50.6 0-103 score 19.1 SD 61.8 37.0 YR
12 164 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 176.0 FAS OC 12 WK SCORAD Mean 70.5 0-103 score 12.2 SD LS Mean -12.2 0-103 score 1.59 SE Mean 52.2 0-103 score 20.4 SD 56.7 30.0 YR
75 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 177.0 FAS OC 12 WK SCORAD Mean 71.7 0-103 score 12.5 SD LS Mean -16.2 0-103 score 1.62 SE Mean 49.2 0-103 score 17.9 SD 61.8 37.0 YR
10 163 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 182.0 FAS OC 10 WK SCORAD Mean 70.5 0-103 score 12.2 SD LS Mean -12.3 0-103 score 1.47 SE Mean 53.9 0-103 score 21.2 SD 56.7 30.0 YR
74 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 180.0 FAS OC 10 WK SCORAD Mean 71.7 0-103 score 12.5 SD LS Mean -15.9 0-103 score 1.58 SE Mean 50.0 0-103 score 18.9 SD 61.8 37.0 YR
0 158 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 FAS OC 0 WK SCORAD Mean 70.5 0-103 score 12.2 SD LS Mean 0.0 0-103 score Mean 70.5 0-103 score 12.2 SD 56.7 30.0 YR
69 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 197.0 FAS OC 0 WK SCORAD Mean 71.7 0-103 score 12.5 SD LS Mean 0.0 0-103 score Mean 71.7 0-103 score 12.5 SD 61.8 37.0 YR
easi90 8 127 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 4.0 FAS Cochran Mantel Haenszel Test NRI 8 WK EASI 90 2.011 percent 56.7 30.0 YR
38 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 5.0 FAS Cochran Mantel Haenszel Test NRI 8 WK EASI 90 2.514 percent 61.8 37.0 YR
6 126 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 1.0 FAS Cochran Mantel Haenszel Test NRI 6 WK EASI 90 0.575 percent 56.7 30.0 YR
37 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 3.0 FAS Cochran Mantel Haenszel Test NRI 6 WK EASI 90 1.437 percent 61.8 37.0 YR
4 125 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 0.0 FAS Cochran Mantel Haenszel Test NRI 4 WK EASI 90 0.0 percent 56.7 30.0 YR
36 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 4.0 FAS Cochran Mantel Haenszel Test NRI 4 WK EASI 90 1.94 percent 61.8 37.0 YR
2 124 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 0.0 FAS Cochran Mantel Haenszel Test NRI 2 WK EASI 90 0.0 percent 56.7 30.0 YR
35 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 4.0 FAS Cochran Mantel Haenszel Test NRI 2 WK EASI 90 1.94 percent 61.8 37.0 YR
16 131 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 11.0 FAS Cochran Mantel Haenszel Test NRI 16 WK EASI 90 5.46 percent 56.7 30.0 YR
14 130 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 8.0 FAS Cochran Mantel Haenszel Test NRI 14 WK EASI 90 3.879 percent 56.7 30.0 YR
41 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 9.0 FAS Cochran Mantel Haenszel Test NRI 14 WK EASI 90 4.526 percent 61.8 37.0 YR
12 129 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 6.0 FAS Cochran Mantel Haenszel Test NRI 12 WK EASI 90 2.945 percent 56.7 30.0 YR
40 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 7.0 FAS Cochran Mantel Haenszel Test NRI 12 WK EASI 90 3.52 percent 61.8 37.0 YR
10 128 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 6.0 FAS Cochran Mantel Haenszel Test NRI 10 WK EASI 90 2.945 percent 56.7 30.0 YR
39 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 6.0 FAS Cochran Mantel Haenszel Test NRI 10 WK EASI 90 3.017 percent 61.8 37.0 YR
easi75 8 92 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 14.0 FAS Cochran Mantel Haenszel Test NRI 8 WK EASI 75 6.838 percent 56.7 30.0 YR
3 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 25.0 FAS Cochran Mantel Haenszel Test NRI 8 WK EASI 75 12.65 percent 61.8 37.0 YR
6 91 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 9.0 FAS Cochran Mantel Haenszel Test NRI 6 WK EASI 75 4.444 percent 56.7 30.0 YR
2 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 20.0 FAS Cochran Mantel Haenszel Test NRI 6 WK EASI 75 10.143 percent 61.8 37.0 YR
52 107 control Open-Label True placebo Placebo 0.0 MG SC Q2W 46 42.0 9.0 FAS Cochran Mantel Haenszel Test NRI 52 WK EASI 75 21.0 percent
18 control Open-Label True placebo Placebo 0.0 MG SC Q2W 36 30.0 10.0 FAS Cochran Mantel Haenszel Test NRI 52 WK EASI 75 33.0 percent
4 90 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 6.0 FAS Cochran Mantel Haenszel Test NRI 4 WK EASI 75 2.849 percent 56.7 30.0 YR
1 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 15.0 FAS Cochran Mantel Haenszel Test NRI 4 WK EASI 75 7.407 percent 61.8 37.0 YR
2 89 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 2.0 FAS Cochran Mantel Haenszel Test NRI 2 WK EASI 75 0.912 percent 56.7 30.0 YR
0 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 9.0 FAS Cochran Mantel Haenszel Test NRI 2 WK EASI 75 4.558 percent 61.8 37.0 YR
14 95 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 24.0 FAS Cochran Mantel Haenszel Test NRI 14 WK EASI 75 11.966 percent 56.7 30.0 YR
6 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 23.0 FAS Cochran Mantel Haenszel Test NRI 14 WK EASI 75 11.738 percent 61.8 37.0 YR
12 94 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 17.0 FAS Cochran Mantel Haenszel Test NRI 12 WK EASI 75 8.433 percent 56.7 30.0 YR
5 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 29.0 FAS Cochran Mantel Haenszel Test NRI 12 WK EASI 75 14.701 percent 61.8 37.0 YR
10 93 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 18.0 FAS Cochran Mantel Haenszel Test NRI 10 WK EASI 75 8.889 percent 56.7 30.0 YR
4 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 28.0 FAS Cochran Mantel Haenszel Test NRI 10 WK EASI 75 14.131 percent 61.8 37.0 YR
easi50 8 111 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 34.0 FAS Cochran Mantel Haenszel Test NRI 8 WK EASI 50 16.772 percent 56.7 30.0 YR
22 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 42.0 FAS Cochran Mantel Haenszel Test NRI 8 WK EASI 50 21.268 percent 61.8 37.0 YR
6 110 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 34.0 FAS Cochran Mantel Haenszel Test NRI 6 WK EASI 50 16.772 percent 56.7 30.0 YR
21 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 42.0 FAS Cochran Mantel Haenszel Test NRI 6 WK EASI 50 21.095 percent 61.8 37.0 YR
4 109 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 20.0 FAS Cochran Mantel Haenszel Test NRI 4 WK EASI 50 10.029 percent 56.7 30.0 YR
20 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 32.0 FAS Cochran Mantel Haenszel Test NRI 4 WK EASI 50 16.081 percent 61.8 37.0 YR
2 108 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 11.0 FAS Cochran Mantel Haenszel Test NRI 2 WK EASI 50 5.706 percent 56.7 30.0 YR
19 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 19.0 FAS Cochran Mantel Haenszel Test NRI 2 WK EASI 50 9.51 percent 61.8 37.0 YR
16 115 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 40.0 FAS Cochran Mantel Haenszel Test NRI 16 WK EASI 50 20.058 percent 56.7 30.0 YR
14 114 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 39.0 FAS Cochran Mantel Haenszel Test NRI 14 WK EASI 50 19.366 percent 56.7 30.0 YR
25 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 46.0 FAS Cochran Mantel Haenszel Test NRI 14 WK EASI 50 22.997 percent 61.8 37.0 YR
12 113 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 40.0 FAS Cochran Mantel Haenszel Test NRI 12 WK EASI 50 19.712 percent 56.7 30.0 YR
24 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 49.0 FAS Cochran Mantel Haenszel Test NRI 12 WK EASI 50 24.726 percent 61.8 37.0 YR
10 112 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 37.0 FAS Cochran Mantel Haenszel Test NRI 10 WK EASI 50 18.501 percent 56.7 30.0 YR
23 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 199 199.0 53.0 FAS Cochran Mantel Haenszel Test NRI 10 WK EASI 50 26.801 percent 61.8 37.0 YR
easi 8 144 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 185.0 FAS OC 8 WK EASI Mean 32.6 0-72 score 13.9 SD Mean -8.5 0-72 score 12.8 SD LS Mean -19.39 2.927 SE 56.7 30.0 YR
55 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 185.0 FAS OC 8 WK EASI Mean 32.9 0-72 score 13.9 SD Mean -11.6 0-72 score 13.6 SD LS Mean -27.988 2.927 SE 61.8 37.0 YR
6 143 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 187.0 FAS OC 6 WK EASI Mean 32.6 0-72 score 13.9 SD Mean -7.2 0-72 score 12.7 SD LS Mean -16.098 2.744 SE 56.7 30.0 YR
54 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 186.0 FAS OC 6 WK EASI Mean 32.9 0-72 score 13.9 SD Mean -10.1 0-72 score 13.5 SD LS Mean -24.329 2.652 SE 61.8 37.0 YR
4 142 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 189.0 FAS OC 4 WK EASI Mean 32.6 0-72 score 13.9 SD Mean -5.5 0-72 score 10.9 SD LS Mean -10.61 2.561 SE 56.7 30.0 YR
53 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 188.0 FAS OC 4 WK EASI Mean 32.9 0-72 score 13.9 SD Mean -7.8 0-72 score 13.0 SD LS Mean -18.11 2.561 SE 61.8 37.0 YR
2 141 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 194.0 FAS OC 2 WK EASI Mean 32.6 0-72 score 13.9 SD Mean -3.4 0-72 score 9.3 SD LS Mean -7.317 2.012 SE 56.7 30.0 YR
52 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 194.0 FAS OC 2 WK EASI Mean 32.9 0-72 score 13.9 SD Mean -5.0 0-72 score 12.2 SD LS Mean -9.878 2.104 SE 61.8 37.0 YR
16 148 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 176.0 FAS OC 16 WK EASI Mean 32.6 0-72 score 13.9 SD Mean -9.5 0-72 score 14.0 SD LS Mean -22.317 3.476 SE 56.7 30.0 YR
59 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 178.0 FAS OC 16 WK EASI Mean 32.9 0-72 score 13.9 SD Mean -12.3 0-72 score 13.9 SD LS Mean -28.537 3.659 SE 61.8 37.0 YR
14 147 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 177.0 FAS OC 14 WK EASI Mean 32.6 0-72 score 13.9 SD Mean -10.1 0-72 score 14.2 SD LS Mean -21.585 3.293 SE 56.7 30.0 YR
58 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 176.0 FAS OC 14 WK EASI Mean 32.9 0-72 score 13.9 SD Mean -13.0 0-72 score 14.0 SD LS Mean -32.927 3.293 SE 61.8 37.0 YR
12 146 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 176.0 FAS OC 12 WK EASI Mean 32.6 0-72 score 13.9 SD Mean -11.1 0-72 score 13.6 SD LS Mean -21.585 3.11 SE 56.7 30.0 YR
57 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 177.0 FAS OC 12 WK EASI Mean 32.9 0-72 score 13.9 SD Mean -13.5 0-72 score 13.8 SD LS Mean -34.207 3.293 SE 61.8 37.0 YR
10 145 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 182.0 FAS OC 10 WK EASI Mean 32.6 0-72 score 13.9 SD Mean -9.6 0-72 score 13.2 SD LS Mean -21.585 3.11 SE 56.7 30.0 YR
56 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 181.0 FAS OC 10 WK EASI Mean 32.9 0-72 score 13.9 SD Mean -12.5 0-72 score 13.7 SD LS Mean -32.561 3.201 SE 61.8 37.0 YR
0 140 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 201 201.0 FAS OC 0 WK EASI Mean 32.6 0-72 score 13.9 SD Mean 0.0 0-72 score LS Mean 0.0 56.7 30.0 YR
51 control Double-Blind True placebo Placebo 0.0 MG SC Q2W 197 197.0 FAS OC 0 WK EASI Mean 32.9 0-72 score 13.9 SD Mean 0.0 0-72 score LS Mean 0.0 61.8 37.0 YR

1227_list_2009¶

Control rows matched by test output: 7 of 14

Literature data accuracy: 76.27%

Clinical data accuracy: 33.31%

Clinical data accuracy (drop unmatched): 66.61%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
dapagliflozin 20mg oncedaily hba1c 12 5 c9t5 test Double-Blind TRUE Dapagliflozin Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor 20 mg mg Oral Once Daily 54 54 ITT ANCOVA LOCF 12 WK HbA1c Mean 7.9 percent 0.9 SD LS Mean -0.90 percent 0.10 SE LS Mean -2.6 mmHg 11.1 SD 56 53 YR
20.0 qd hba1c 12.0 9 c9t5 control Double-Blind True dapagliflozin SGLT2 20.0 MG/DAY ORAL QD TAB 59.0 59 Treated ANCOVA LOCF 12.0 WK HbA1c Mean 7.7 percent 0.9 SD LS Mean -0.55 percent 0.09 SE -0.73 -0.37 LS Mean 7.244 percent LS Mean -7.057 54.0 55.0 YR
similarity 100 100 100 20 44 50 100 17 0 33 50 100 40 100 100 67 100 100 100 67 100 100 100 100 100 100 50 100 75 100 0 0 100 50 0 0 0 100 100 0 0 100 100 100 100 33 33 100
10mg oncedaily hba1c 12 6 c7t6 test Double-Blind TRUE Dapagliflozin Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor 10 mg mg Oral Once Daily 56 56 ITT ANCOVA LOCF 12 WK HbA1c Mean 7.8 percent 1.0 SD LS Mean -0.90 percent 0.10 SE LS Mean -0.90 percent 0.10 SE 45 53 YR
10.0 qd hba1c 12.0 7 c7t6 control Double-Blind True dapagliflozin SGLT2 10.0 MG/DAY ORAL QD TAB 47.0 47 Treated ANCOVA LOCF 12.0 WK HbA1c Mean 8.0 percent 0.8 SD LS Mean -0.85 percent 0.11 SE -1.071 -0.629 LS Mean 6.944 percent LS Mean -10.906 53.0 54.0 YR
similarity 100 100 100 20 44 50 100 17 0 0 0 100 40 100 100 67 100 100 100 67 100 67 100 100 100 100 50 100 75 100 0 0 100 44 100 0 0 100 100 0 0 100 100 100 100 33 33 100
50 oncedaily hba1c 12 2 c5t2 test Double-Blind TRUE Dapagliflozin Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor 50 mg Oral Once Daily 57 57 38 ITT ANCOVA LOCF 12 WK HbA1c Mean 7.6 percent 0.8 SD LS Mean -0.90 percent LS Mean 48 54 YR
5.0 qd hba1c 12.0 5 c5t2 control Double-Blind True dapagliflozin SGLT2 5.0 MG/DAY ORAL QD TAB 58.0 58 Treated ANCOVA LOCF 12.0 WK HbA1c Mean 8.0 percent 0.9 SD LS Mean -0.72 percent 0.09 SE -0.9 -0.54 LS Mean 7.074 percent LS Mean -9.238 48.0 55.0 YR
similarity 100 100 100 20 40 50 100 17 0 33 50 0 40 100 100 67 100 100 100 33 100 67 100 100 100 100 50 100 0 0 0 0 100 0 0 100 100 100 100 0 0 100 100 100 100 67 33 100
2.5 oncedaily hba1c 12 1 c3t1 test Double-Blind TRUE Dapagliflozin Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor 2.5 mg Oral Once Daily 47 47 ITT ANCOVA LOCF 12 WK HbA1c Mean 8.0 percent 0.8 SD LS Mean -0.85 percent 0.11 LS Mean -0.85 percent 0.11 53 54 YR
qd hba1c 12.0 3 c3t1 control Double-Blind True dapagliflozin SGLT2 2.5 MG/DAY ORAL QD TAB 59.0 59 Treated ANCOVA LOCF 12.0 WK HbA1c Mean 7.6 percent 0.7 SD LS Mean -0.71 percent 0.09 SE -0.89 -0.53 LS Mean 7.084 percent LS Mean -9.11 49.0 55.0 YR
similarity 100 100 100 20 100 50 100 17 0 0 0 100 40 100 100 67 100 100 100 33 100 67 100 100 100 100 50 100 50 0 0 0 100 44 100 0 100 100 100 0 0 100 100 100 100 0 33 100
placebo oncedaily hba1c 12 3 c1t3 test Double-Blind TRUE Placebo Once-daily 59 59 ITT ANCOVA LOCF 12 WK HbA1c Mean 7.6 percent 0.7 SD Adjusted Mean -0.18 percent 0.10 SE Adjusted Mean -0.18 percent 0.10 SE 49 55 YR
0.0 qd hba1c 12.0 1 c1t3 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD TAB 54.0 54 Treated ANCOVA LOCF 12.0 WK HbA1c Mean 7.9 percent 0.9 SD LS Mean -0.18 percent 0.1 SE -0.38 0.02 LS Mean 7.614 percent LS Mean -2.31 56.0 53.0 YR
similarity 100 100 100 0 0 0 0 17 0 33 50 100 40 100 100 67 100 100 100 33 100 67 100 100 100 60 100 100 86 100 0 0 60 22 100 0 0 100 100 0 0 100 100 100 100 0 33 100
metformin 750 forcetitratedatweek2to1,500mg hba1c 12 4 c13t4 test Double-Blind TRUE Metformin Biguanide 750 mg Oral Force-titrated at week 2 to 1,500 mg XR 58 58 ITT ANCOVA LOCF 12 WK HbA1c Mean 8.0 percent 0.9 SD LS Mean -0.73 percent LS Mean -0.73 percent 48 55 YR
1500.0 qd hba1c 12.0 13 c13t4 control Double-Blind True metformin Biguanides 1500.0 MG/DAY ORAL QD TAB-XR 56.0 56 Treated ANCOVA LOCF 12.0 WK HbA1c Mean 7.6 percent 0.8 SD LS Mean -0.73 percent 0.1 SE -0.93 -0.53 LS Mean 7.064 percent LS Mean -9.367 48.0 54.0 YR
similarity 100 100 100 95 44 50 100 5 50 33 50 100 40 100 100 67 100 100 100 33 100 67 100 100 100 100 100 100 0 0 0 0 100 67 100 100 100 100 100 0 0 100 100 100 100 67 33 100
dapagliflozin 5mg oncedaily hba1c 12 0 c11t0 test Double-Blind TRUE Dapagliflozin Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor 5 mg mg Oral Once Daily 59 59 ITT ANCOVA LOCF 12 WK HbA1c Mean 7.7 percent 0.9 SD LS Mean -0.55 percent 0.09 LS Mean -0.55 percent 0.09 54 55 YR
50.0 qd hba1c 12.0 11 c11t0 control Double-Blind True dapagliflozin SGLT2 50.0 MG/DAY ORAL QD TAB 56.0 56 Treated ANCOVA LOCF 12.0 WK HbA1c Mean 7.8 percent 1.0 SD LS Mean -0.9 percent 0.1 SE -1.1 -0.7 LS Mean 6.894 percent LS Mean -11.548 45.0 53.0 YR
similarity 100 100 100 20 25 50 100 17 0 33 50 100 40 100 100 67 100 100 100 67 100 67 100 100 100 100 57 100 57 0 0 0 100 22 100 0 100 100 100 0 0 100 100 100 100 33 33 100
placebo 0.0 qd hba1c 0.0 0 control Double-Blind True placebo Placebo 0.0 MG/DAY ORAL QD TAB 54.0 54 Treated ANCOVA LOCF 0.0 WK HbA1c Mean 7.9 percent 0.9 SD LS Mean 0.0 percent Mean 7.9 percent 0.9 SD LS Mean 0.0 56.0 53.0 YR
metformin 750.0 qd hba1c 0.0 12 control Double-Blind True metformin Biguanides 750.0 MG/DAY ORAL QD TAB-XR 56.0 56 Treated ANCOVA LOCF 0.0 WK HbA1c Mean 7.6 percent 0.8 SD LS Mean 0.0 percent Mean 7.6 percent 0.8 SD LS Mean 0.0 48.0 54.0 YR
dapagliflozin 50.0 qd hba1c 0.0 10 control Double-Blind True dapagliflozin SGLT2 50.0 MG/DAY ORAL QD TAB 56.0 56 Treated ANCOVA LOCF 0.0 WK HbA1c Mean 7.8 percent 1.0 SD LS Mean 0.0 percent Mean 7.8 percent 1.0 SD LS Mean 0.0 45.0 53.0 YR
5.0 qd hba1c 0.0 4 control Double-Blind True dapagliflozin SGLT2 5.0 MG/DAY ORAL QD TAB 58.0 58 Treated ANCOVA LOCF 0.0 WK HbA1c Mean 8.0 percent 0.9 SD LS Mean 0.0 percent Mean 8.0 percent 0.9 SD LS Mean 0.0 48.0 55.0 YR
20.0 qd hba1c 0.0 8 control Double-Blind True dapagliflozin SGLT2 20.0 MG/DAY ORAL QD TAB 59.0 59 Treated ANCOVA LOCF 0.0 WK HbA1c Mean 7.7 percent 0.9 SD LS Mean 0.0 percent Mean 7.7 percent 0.9 SD LS Mean 0.0 54.0 55.0 YR
2.5 qd hba1c 0.0 2 control Double-Blind True dapagliflozin SGLT2 2.5 MG/DAY ORAL QD TAB 59.0 59 Treated ANCOVA LOCF 0.0 WK HbA1c Mean 7.6 percent 0.7 SD LS Mean 0.0 percent Mean 7.6 percent 0.7 SD LS Mean 0.0 49.0 55.0 YR
10.0 qd hba1c 0.0 6 control Double-Blind True dapagliflozin SGLT2 10.0 MG/DAY ORAL QD TAB 47.0 47 Treated ANCOVA LOCF 0.0 WK HbA1c Mean 8.0 percent 0.8 SD LS Mean 0.0 percent Mean 8.0 percent 0.8 SD LS Mean 0.0 53.0 54.0 YR

341_wilding_2013¶

Control rows matched by test output: 10 of 18

Literature data accuracy: 77.53%

Clinical data accuracy: 34.40%

Clinical data accuracy (drop unmatched): 61.92%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
placebo;canagliflozin100mg;canagliflozin300mg 100;300 oncedaily hba1c 52 4 c7t4 test Double-Blind TRUE Placebo;Canagliflozin 100 mg;Canagliflozin 300 mg Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor 100;300 mg Oral Once Daily 156;157;156 156 mITT ANCOVA LOCF 52 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean -0.13 percent LS Mean -0.13 percent 48.7;48.4;55.8 56.8;57.4;56.1 YR
canagliflozin 100 qam hba1c 0.0 7 c7t4 control Double-Blind True canagliflozin SGLT2 100 MG/DAY ORAL QAM CAP 31 mITT ANCOVA LOCF 0.0 WK HbA1c Mean 9.6 percent 0.4 SD LS Mean 0.0 percent Mean 9.6 percent 0.4 SD LS Mean 0.0
similarity 100 100 42 19 60 50 100 15 0 0 40 100 100 100 100 0 100 100 100 33 100 67 100 100 100 100 57 100 100 100 100 100 73 29 100 0 0 100 100 0 0 100 100 100 100 0 0 0
placebo;canagliflozin100mg;canagliflozin300mg 100;300 oncedaily hba1c 52 3 c4t3 test Double-Blind TRUE Placebo;Canagliflozin 100 mg;Canagliflozin 300 mg Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor 100;300 mg Oral Once Daily 156;157;156 150 mITT ANCOVA LOCF 52 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean -0.13 percent LS Mean -0.13 percent 48.7;48.4;55.8 56.8;57.4;56.1 YR
canagliflozin 100 qam hba1c 0.0 4 c4t3 control Double-Blind True canagliflozin SGLT2 100 MG/DAY ORAL QAM CAP 51 mITT ANCOVA LOCF 0.0 WK HbA1c Mean 8.4 percent 0.3 SD LS Mean 0.0 percent Mean 8.4 percent 0.3 SD LS Mean 0.0
similarity 100 100 42 19 60 50 100 15 0 0 40 100 100 100 100 0 100 100 100 67 100 67 100 100 100 100 57 100 100 100 100 100 73 29 100 0 0 100 100 0 0 100 100 100 100 0 0 0
placebo;canagliflozin100mg;canagliflozin300mg 100;300 oncedaily hba1c 26 7 c2t7 test Double-Blind TRUE Placebo;Canagliflozin 100 mg;Canagliflozin 300 mg Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor 100;300 mg Oral Once Daily 156;157;156 150 mITT ANCOVA LOCF 26 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean -0.13 percent LS Mean -0.13 percent 48.7;48.4;55.8 56.8;57.4;56.1 YR
canagliflozin 300 qam hba1c 0.0 2 c2t7 control Double-Blind True canagliflozin SGLT2 300 MG/DAY ORAL QAM CAP 74 mITT ANCOVA LOCF 0.0 WK HbA1c Mean 7.4 percent 0.3 SD LS Mean 0.0 percent Mean 7.4 percent 0.3 SD LS Mean 0.0
similarity 100 100 42 19 60 50 100 15 0 0 0 100 100 100 100 0 100 100 100 33 100 67 100 100 100 100 57 100 100 100 100 100 73 29 100 0 0 100 100 0 0 100 100 100 100 0 0 0
placebo;canagliflozin100mg;canagliflozin300mg 100;300 oncedaily hba1c 52 2 c1t2 test Double-Blind TRUE Placebo;Canagliflozin 100 mg;Canagliflozin 300 mg Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor 100;300 mg Oral Once Daily 156;157;156 150 mITT ANCOVA LOCF 52 WK HbA1c Mean 130.1 mmHg 13.7 SD LS Mean 0.1 mmHg 1.0 SE LS Mean 0.1 mmHg 1.0 SE 48.7;48.4;55.8 56.8;57.4;56.1 YR
canagliflozin 100 qam hba1c 0.0 1 c1t2 control Double-Blind True canagliflozin SGLT2 100 MG/DAY ORAL QAM CAP 73 mITT ANCOVA LOCF 0.0 WK HbA1c Mean 7.3 percent 0.4 SD LS Mean 0.0 percent Mean 7.3 percent 0.4 SD LS Mean 0.0
similarity 100 100 42 19 60 50 100 15 0 0 0 100 100 100 100 0 100 100 100 25 0 29 100 100 100 100 67 0 0 0 100 100 73 33 0 67 50 100 100 0 0 100 100 100 100 0 0 0
placebo;canagliflozin100mg;canagliflozin300mg 100;300 oncedaily hba1c 26 6 c17t6 test Double-Blind TRUE Placebo;Canagliflozin 100 mg;Canagliflozin 300 mg Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor 100;300 mg Oral Once Daily 156;157;156 150 mITT ANCOVA LOCF 26 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean -0.13 percent LS Mean -0.13 percent 48.7;48.4;55.8 56.8;57.4;56.1 YR
canagliflozin 300 qam hba1c 26.0 17 c17t6 control Double-Blind True canagliflozin SGLT2 300 MG/DAY ORAL QAM CAP 29 mITT LOCF 26.0 WK HbA1c Mean 9.6 percent 0.5 SD LS Mean -1.59 percent 0.24 SE -2.081 -1.099 LS Mean 7.978 percent LS Mean -16.618
similarity 100 100 42 19 60 50 100 15 0 0 0 100 100 0 100 67 100 100 100 33 100 67 100 100 100 100 25 100 0 0 0 0 100 22 100 100 100 100 100 0 0 100 100 100 100 0 0 0
placebo;canagliflozin100mg;canagliflozin300mg 100;300 oncedaily hba1c 26 5 c16t5 test Double-Blind TRUE Placebo;Canagliflozin 100 mg;Canagliflozin 300 mg Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor 100;300 mg Oral Once Daily 156;157;156 150 mITT ANCOVA LOCF 26 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean -0.13 percent LS Mean -0.13 percent 48.7;48.4;55.8 56.8;57.4;56.1 YR
canagliflozin 100 qam hba1c 26.0 16 c16t5 control Double-Blind True canagliflozin SGLT2 100 MG/DAY ORAL QAM CAP 31 mITT ANCOVA LOCF 26.0 WK HbA1c Mean 9.6 percent 0.4 SD LS Mean -1.55 percent 0.22 SE -1.999 -1.101 LS Mean 8.018 percent LS Mean -16.2
similarity 100 100 42 19 60 50 100 15 0 0 40 100 100 100 100 67 100 100 100 33 100 67 100 100 100 100 25 100 0 0 0 0 100 44 100 100 100 100 100 0 0 100 100 100 100 0 0 0
300 oncedaily hba1c 52 0 c14t0 test Double-Blind TRUE Canagliflozin Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor 300 mg Oral Once Daily 156 156 mITT Least Square Means LOCF 52 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean -0.97 percent -1.17 -0.77 55.8 56.1 YR
qam hba1c 26.0 14 c14t0 control Double-Blind True canagliflozin SGLT2 300 MG/DAY ORAL QAM CAP 49 mITT ANCOVA LOCF 26.0 WK HbA1c Mean 8.4 percent 0.3 SD LS Mean -1.3 percent 0.12 SE -1.541 -1.059 LS Mean 7.1 percent LS Mean -15.476
similarity 100 100 100 19 100 50 100 15 0 0 0 100 100 25 100 33 100 100 100 67 100 67 100 100 100 0 0 0 0 0 0 0 100 57 100 100 100 0 0 0 0 100 100 100 100 0 0 0
100 oncedaily hba1c 52 8 c13t8 test Double-Blind TRUE Canagliflozin Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor 100 mg Oral Once Daily 157 157 mITT Least Square Means LOCF 52 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean -0.75 percent -0.95 -0.55 48.4 57.4 YR
qam hba1c 26.0 13 c13t8 control Double-Blind True canagliflozin SGLT2 100 MG/DAY ORAL QAM CAP 51 mITT ANCOVA LOCF 26.0 WK HbA1c Mean 8.4 percent 0.3 SD LS Mean -1.02 percent 0.13 SE -1.281 -0.759 LS Mean 7.38 percent LS Mean -12.143
similarity 100 100 100 19 100 50 100 15 0 0 40 100 100 25 100 33 100 100 100 67 100 67 100 100 100 0 0 0 0 0 0 0 100 50 100 100 100 0 0 0 0 100 100 100 100 0 0 0
300 oncedaily hba1c 26 1 c11t1 test Double-Blind TRUE Canagliflozin Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor 300 mg Oral Once Daily 156 156 mITT Least Square Means LOCF 26 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean -1.06 percent LS Mean -1.06 percent 55.8 56.1 YR
qam hba1c 26.0 11 c11t1 control Double-Blind True canagliflozin SGLT2 300 MG/DAY ORAL QAM CAP 74 mITT ANCOVA LOCF 26.0 WK HbA1c Mean 7.4 percent 0.3 SD LS Mean -0.67 percent 0.09 SE -0.849 -0.491 LS Mean 6.697 percent LS Mean -9.095
similarity 100 100 100 19 100 50 100 15 0 0 0 100 100 25 100 67 100 100 100 33 100 67 100 100 100 100 50 100 0 0 0 0 100 44 100 100 100 100 100 0 0 100 100 100 100 0 0 0
100 oncedaily hba1c 26 9 c10t9 test Double-Blind TRUE Canagliflozin Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor 100 mg Oral Once Daily 157 157 mITT Least Square Means LOCF 26 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean -0.85 percent LS Mean -0.85 percent 48.4 57.4 YR
qam hba1c 26.0 10 c10t9 control Double-Blind True canagliflozin SGLT2 100 MG/DAY ORAL QAM CAP 73 mITT ANCOVA LOCF 26.0 WK HbA1c Mean 7.3 percent 0.4 SD LS Mean -0.47 percent 0.09 SE -0.649 -0.291 LS Mean 6.897 percent LS Mean -6.38
similarity 100 100 100 19 100 50 100 15 0 0 40 100 100 25 100 67 100 100 100 33 100 67 100 100 100 100 50 100 0 0 0 0 100 44 100 100 100 100 100 0 0 100 100 100 100 0 0 0
placebo 0 qam hba1c 26.0 15 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QAM CAP 28 mITT ANCOVA LOCF 26.0 WK HbA1c Mean 9.5 percent 0.7 SD LS Mean -0.44 percent 0.22 SE -0.891 0.011 LS Mean 9.128 percent LS Mean -4.599
12 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QAM CAP 48 mITT ANCOVA LOCF 26.0 WK HbA1c Mean 8.4 percent 0.3 SD LS Mean -0.12 percent 0.12 SE -0.361 0.121 LS Mean 8.28 percent LS Mean -1.429
9 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QAM CAP 74 mITT ANCOVA LOCF 26.0 WK HbA1c Mean 7.4 percent 0.3 SD LS Mean -0.02 percent 0.1 SE -0.219 0.179 LS Mean 7.347 percent LS Mean -0.271
0.0 6 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QAM CAP 28 mITT ANCOVA LOCF 0.0 WK HbA1c Mean 9.5 percent 0.7 SD LS Mean 0.0 percent Mean 9.5 percent 0.7 SD LS Mean 0.0
3 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QAM CAP 48 mITT ANCOVA LOCF 0.0 WK HbA1c Mean 8.4 percent 0.3 SD LS Mean 0.0 percent Mean 8.4 percent 0.3 SD LS Mean 0.0
0 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QAM CAP 74 mITT ANCOVA LOCF 0.0 WK HbA1c Mean 7.4 percent 0.3 SD LS Mean 0.0 percent Mean 7.4 percent 0.3 SD LS Mean 0.0
canagliflozin 300 qam hba1c 0.0 8 control Double-Blind True canagliflozin SGLT2 300 MG/DAY ORAL QAM CAP 29 mITT ANCOVA LOCF 0.0 WK HbA1c Mean 9.6 percent 0.5 SD LS Mean 0.0 percent Mean 9.6 percent 0.5 SD LS Mean 0.0
5 control Double-Blind True canagliflozin SGLT2 300 MG/DAY ORAL QAM CAP 49 mITT ANCOVA LOCF 0.0 WK HbA1c Mean 8.4 percent 0.3 SD LS Mean 0.0 percent Mean 8.4 percent 0.3 SD LS Mean 0.0

432_devineni_2012¶

Control rows matched by test output: 6 of 6

Literature data accuracy: 60.53%

Clinical data accuracy: 62.83%

Clinical data accuracy (drop unmatched): 62.83%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
canagliflozin 300 twicedaily hba1c 1 3 c5t3 test Double-Blind TRUE Canagliflozin SGLT2 inhibitor 300 mg Oral Twice Daily 10 10 FAS ANCOVA -1 days HbA1c Mean 8.42 percent 1.02 s.d. LSMean -0.92 percent -0.92 -0.17 30 42.7 YR
600 bid hba1c 3.8571429 5 c5t3 control Double-Blind True canagliflozin SGLT2 600 MG/DAY SC BID 10.0 10 CO 3.8571429 WK HbA1c Mean 8.42 percent 1.02 SD Mean -0.92 percent 0.66 SD -1.385 -0.455 Mean 7.5 percent Mean -10.926 30.0 42.7 YR
similarity 100 100 100 50 67 50 0 14 100 67 100 100 0 0 100 20 0 100 100 100 100 100 40 100 100 80 100 100 0 0 22 44 0 0 0 100 100 100 100 0 0 100 100 100 100 67 100 100
100 qd hba1c 27 4 c4t4 test Double-Blind TRUE Canagliflozin SGLT2 inhibitor 100 mg Oral QD 10 10 FAS ANCOVA 27 days HbA1c Mean 8.38 percent 0.88 SD LSMean -0.73 percent -0.74 -0.003 70 50.5 YR
600 bid hba1c 0.0 4 c4t4 control Double-Blind True canagliflozin SGLT2 600 MG/DAY SC BID 10.0 10 CO 0.0 WK HbA1c Mean 8.42 percent 1.02 SD Mean 0.0 percent Mean 8.42 percent 1.02 SD Mean 0.0 30.0 42.7 YR
similarity 100 100 100 50 67 50 0 40 100 67 100 100 0 0 100 0 0 100 100 50 100 50 100 100 100 80 57 100 100 100 0 0 0 0 0 0 0 100 100 0 0 100 100 100 100 33 25 100
300 twicedaily hba1c 27 2 c3t2 test Double-Blind TRUE Canagliflozin SGLT2 inhibitor 300 mg Oral Twice Daily 10 10 FAS ANCOVA 27 days HbA1c Mean 8.42 percent 1.02 s.d. LSMean -0.92 percent -0.92 -0.17 LSMean 30 42.7 YR
100 qam hba1c 3.8571429 3 c3t2 control Double-Blind True canagliflozin SGLT2 100 MG/DAY SC QAM 10.0 10 CO 3.8571429 WK HbA1c Mean 8.38 percent 0.88 SD Mean -0.73 percent 0.5 SD -1.082 -0.378 Mean 7.65 percent Mean -8.711 70.0 50.5 YR
similarity 100 100 100 50 67 50 0 14 100 67 100 100 0 0 100 18 0 100 100 50 100 50 40 100 100 80 50 100 0 0 44 67 80 0 0 100 100 100 100 0 0 100 100 100 100 33 25 100
qd hba1c 1 5 c2t5 test Double-Blind TRUE Canagliflozin SGLT2 inhibitor 100 mg Oral QD 10 10 FAS ANCOVA -1 days HbA1c Mean 8.38 percent 0.88 s.d. LSMean -0.73 percent -0.74 -0.003 70 50.5 YR
qam hba1c 0.0 2 c2t5 control Double-Blind True canagliflozin SGLT2 100 MG/DAY SC QAM 10.0 10 CO 0.0 WK HbA1c Mean 8.38 percent 0.88 SD Mean 0.0 percent Mean 8.38 percent 0.88 SD Mean 0.0 70.0 50.5 YR
similarity 100 100 100 50 100 50 0 40 100 67 100 100 0 0 100 0 0 100 100 100 100 100 40 100 100 80 57 100 100 100 0 0 0 0 0 0 0 100 100 0 0 100 100 100 100 67 100 100
placebo hba1c 27 1 c1t1 test Double-Blind TRUE Placebo 9 7 FAS ANCOVA 27 days HbA1c Mean 7.99 percent 0.52 SD LSMean -0.19 percent 56 52.8 YR
0 hba1c 3.8571429 1 c1t1 control Double-Blind True placebo Placebo 0 MG/DAY SC 7.0 7 CO 3.8571429 WK HbA1c Mean 7.99 percent 0.52 SD Mean -0.19 percent 0.49 SD -0.628 0.248 Mean 7.8 percent Mean -2.378 56.0 52.8 YR
similarity 100 100 100 0 0 0 0 100 100 0 100 100 0 0 100 18 0 100 100 100 100 100 100 100 100 80 100 100 0 0 0 0 0 0 0 100 100 100 100 0 0 100 100 100 100 67 100 100
hba1c 1 0 c0t0 test Double-Blind TRUE Placebo 9 7 FAS ANCOVA -1 HbA1c Mean 7.99 percent 0.52 SD LSMean -0.19 percent 56 52.8 YR
0 hba1c 0.0 0 c0t0 control Double-Blind True placebo Placebo 0 MG/DAY SC 7.0 7 CO 0.0 WK HbA1c Mean 7.99 percent 0.52 SD Mean 0.0 percent Mean 7.99 percent 0.52 SD Mean 0.0 56.0 52.8 YR
similarity 100 100 100 0 0 0 0 100 100 0 100 100 0 0 100 0 0 100 100 100 100 100 100 100 100 80 57 100 100 100 100 100 0 0 0 0 0 100 100 0 0 100 100 100 100 67 100 100

678_rosenstock_2015¶

Control rows matched by test output: 6 of 6

Literature data accuracy: 81.33%

Clinical data accuracy: 72.19%

Clinical data accuracy (drop unmatched): 72.19%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
empagliflozin 25 oncedaily hba1c 78 0 c5t0 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 25 mg Oral Once Daily 155 110 FAS-18 completers ANCOVA LOCF 78 WK HbA1c Mean 8.3 percent 0.1 SE Adjusted Mean -0.6 percent 0.1 SE -0.9 -0.4 Mean 7.6 percent 0.1 SE 58.8 YR
qd hba1c 78.0 5 c5t0 control Double-Blind True empagliflozin SGLT2 25 MG/DAY ORAL QD 155.0 110 FAS ANCOVA LOCF 78.0 WK HbA1c Mean 8.34 percent 0.08 SE Mean -0.68 percent 0.09 SE -0.858 -0.502 Mean 7.6 percent 0.1 SE 7.402 7.798 Mean -8.193 60.0 59.9 YR
similarity 100 100 100 50 100 50 100 17 100 75 100 100 30 100 100 67 100 100 100 86 100 57 100 100 100 47 86 100 57 100 50 50 100 100 100 100 100 0 0 0 0 100 100 100 100 0 50 100
oncedaily hba1c 18 3 c4t3 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 25 mg Oral Once Daily 155 117 FAS-18 completers ANCOVA LOCF 18 WK HbA1c Mean 8.3 percent 0.1 SE Adjusted Mean -0.7 percent 0.1 SE -0.9 -0.5 Mean 7.6 percent 0.1 SE 58.8 YR
qd hba1c 18.0 4 c4t3 control Double-Blind True empagliflozin SGLT2 25 MG/DAY ORAL QD 155.0 117 FAS ANCOVA LOCF 18.0 WK HbA1c Mean 8.34 percent 0.08 SE Mean -0.75 percent 0.08 SE -0.908 -0.592 Mean 7.6 percent 0.1 SE 7.402 7.798 Mean -9.036 60.0 59.9 YR
similarity 100 100 100 50 100 50 100 17 100 75 100 100 30 100 100 67 100 100 100 86 100 57 100 100 100 47 86 100 57 100 75 75 100 100 100 100 100 0 0 0 0 100 100 100 100 0 50 100
10 oncedaily hba1c 78 12 c3t12 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 10 mg Oral Once Daily 169 127 FAS-18 completers ANCOVA LOCF 78 WK HbA1c Mean 8.3 percent 0.1 SE Adjusted Mean -0.5 percent 0.1 SE -0.7 -0.2 7.8 percent 58.8 YR
qd hba1c 78.0 3 c3t12 control Double-Blind True empagliflozin SGLT2 10 MG/DAY ORAL QD 169.0 127 FAS ANCOVA LOCF 78.0 WK HbA1c Mean 8.26 percent 0.07 SE Mean -0.51 percent 0.09 SE -0.688 -0.332 Mean 7.8 percent 0.1 SE 7.602 7.998 Mean -6.145 55.0 58.6 YR
similarity 100 100 100 50 100 50 100 17 100 75 100 100 30 100 100 67 100 100 100 57 100 57 100 100 100 47 86 100 57 100 50 75 0 100 100 0 0 0 0 0 0 100 100 100 100 0 75 100
oncedaily hba1c 18 15 c2t15 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 10 mg Oral Once Daily 169 132 FAS-18 completers ANCOVA LOCF 18 WK HbA1c Mean 8.3 percent 0.1 SE Adjusted Mean -0.6 percent 0.1 SE -0.8 -0.4 Mean 7.7 percent 0.1 SE 58.8 YR
qd hba1c 18.0 2 c2t15 control Double-Blind True empagliflozin SGLT2 10 MG/DAY ORAL QD 169.0 132 FAS ANCOVA LOCF 18.0 WK HbA1c Mean 8.26 percent 0.07 SE Mean -0.58 percent 0.07 SE -0.718 -0.442 Mean 7.7 percent 0.1 SE 7.502 7.898 Mean -6.988 55.0 58.6 YR
similarity 100 100 100 50 100 50 100 17 100 75 100 100 30 100 100 67 100 100 100 57 100 57 100 100 100 47 57 100 57 100 75 75 100 100 100 100 100 0 0 0 0 100 100 100 100 0 75 100
placebo oncedaily hba1c 78 6 c1t6 test Double-Blind TRUE Placebo Once Daily 170 112 FAS-18 completers ANCOVA LOCF 78 WK HbA1c Mean 8.1 percent 0.1 SE Adjusted Mean 0.0 percent 0.1 SE Mean 8.1 percent 0.1 SE 58.8 YR
0 qd hba1c 78.0 1 c1t6 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD 170.0 112 FAS ANCOVA LOCF 78.0 WK HbA1c Mean 8.1 percent 0.07 SE Mean -0.05 percent 0.1 SE -0.248 0.148 Mean 8.1 percent 0.1 SE 7.902 8.298 Mean -0.617 53.0 58.1 YR
similarity 100 100 100 0 0 0 0 17 100 75 100 100 30 100 100 67 100 100 100 100 100 57 100 100 100 47 86 100 100 100 0 0 100 100 100 100 100 0 0 0 0 100 100 100 100 0 50 100
oncedaily hba1c 18 9 c0t9 test Double-Blind TRUE Placebo Once Daily 170 125 FAS-18 completers ANCOVA LOCF 18 WK HbA1c Mean 8.1 percent 0.1 SE Adjusted Mean 0.0 percent 0.1 SE 8.1 percent 58.8 YR
0 qd hba1c 18.0 0 c0t9 control Double-Blind True placebo Placebo 0 MG/DAY ORAL QD 170.0 125 FAS ANCOVA LOCF 18.0 WK HbA1c Mean 8.1 percent 0.07 SE Mean 0.03 percent 0.07 SE -0.109 0.169 Mean 8.1 percent 0.1 SE 7.902 8.298 Mean 0.37 53.0 58.1 YR
similarity 100 100 100 0 0 0 0 17 100 75 100 100 30 100 100 67 100 100 100 100 100 57 100 100 100 47 86 100 57 100 0 0 0 100 100 0 0 0 0 0 0 100 100 100 100 0 50 100
oncedaily hba1c 78 8 test Double-Blind TRUE Placebo Once Daily 170 112 FAS MMRM OC 78 WK HbA1c Mean 8.1 percent 0.1 SE Mean 0.0 percent 0.1 SE Mean 8.1 percent 0.1 SE 58.8 YR
7 test Double-Blind TRUE Placebo Once Daily 170 112 FAS-78 completers ANCOVA LOCF 78 WK HbA1c Mean 8.1 percent 0.1 SE Mean 0.0 percent 0.1 SE Mean 8.1 percent 0.1 SE 58.8 YR
18 11 test Double-Blind TRUE Placebo Once Daily 170 125 FAS MMRM OC 18 WK HbA1c Mean 8.1 percent 0.1 SE Adjusted Mean 0.0 percent 0.1 SE 8.1 percent 58.8 YR
10 test Double-Blind TRUE Placebo Once Daily 170 125 FAS-78 completers ANCOVA LOCF 18 WK HbA1c Mean 8.1 percent 0.1 SE Adjusted Mean 0.0 percent 0.1 SE 8.1 percent 0.1 SE 58.8 YR
empagliflozin 25 oncedaily hba1c 78 2 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 25 mg Oral Once Daily 155 110 FAS MMRM OC 78 WK HbA1c Mean 8.3 percent 0.1 SE LSMean -0.6 percent 0.1 SE -0.9 -0.4 LSMean 7.6 percent 58.8 YR
1 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 25 mg Oral Once Daily 155 110 FAS-78 completers ANCOVA LOCF 78 WK HbA1c Mean 8.3 percent 0.1 SE Mean -0.6 percent 0.1 SE -0.9 -0.4 Mean 7.6 percent 0.1 SE 58.8 YR
18 5 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 25 mg Oral Once Daily 155 117 FAS MMRM OC 18 WK HbA1c Mean 8.3 percent 0.1 SE Adjusted Mean -0.7 percent 0.1 SE Mean 7.6 percent 0.1 SE 58.8 YR
4 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 25 mg Oral Once Daily 155 117 FAS-78 completers ANCOVA LOCF 18 WK HbA1c Mean 8.3 percent 0.1 SE Adjusted Mean -0.7 percent 0.1 SE -0.9 -0.5 Mean 7.6 percent 0.1 SE 58.8 YR
10 oncedaily hba1c 78 14 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 10 mg Oral Once Daily 169 127 FAS MMRM OC 78 WK HbA1c Mean 8.3 percent 0.1 SE LSMean -0.5 percent 0.1 SE -0.7 -0.2 LSMean 7.8 percent 58.8 YR
13 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 10 mg Oral Once Daily 169 127 FAS-78 completers ANCOVA LOCF 78 WK HbA1c Mean 8.3 percent 0.1 SE Mean -0.5 percent 0.1 SE -0.7 -0.2 Mean 7.8 percent 0.1 SE 58.8 YR
18 17 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 10 mg Oral Once Daily 169 132 FAS MMRM OC 18 WK HbA1c Mean 8.3 percent 0.1 SE Adjusted Mean -0.6 percent 0.1 SE -0.8 -0.4 58.8 YR
16 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 10 mg Oral Once Daily 169 117 FAS-78 completers ANCOVA LOCF 18 WK HbA1c Mean 8.3 percent 0.1 SE Adjusted Mean -0.7 percent 0.1 SE -0.9 -0.5 7.6 percent 58.8 YR

566_fadini_2017¶

Control rows matched by test output: 2 of 4

Literature data accuracy: 63.60%

Clinical data accuracy: 36.63%

Clinical data accuracy (drop unmatched): 73.26%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
dapagliflozin 10 daily hba1c 12 0 c3t0 test Single-Blind TRUE Dapagliflozin SGLT2 inhibitor 10 mg Oral Daily 15 16 6 PP Least Square Means 12 WK HbA1c Mean 8.2 percent 0.2 SE LSMean -0.9 percent 0.2 SE LSMean 7.3 percent 0.4 SE 68.8 66.3 YR
qam hba1c 12.0 3 c3t0 control Single-Blind True dapagliflozin SGLT2 10 MG ORAL QAM TAB 17.0 17 CO Student T Test 12.0 WK HbA1c Mean 8.2 percent 0.2 SE Mean -0.9 percent 0.2 SE -1.322 -0.478 Mean 7.3 percent 0.4 SE 6.456 8.144 Mean -10.976 68.8 66.3 YR
similarity 100 100 100 50 100 100 100 25 0 33 50 0 0 38 100 67 100 100 100 100 100 100 100 100 100 80 100 100 100 100 0 0 80 100 100 100 100 0 0 0 0 100 100 100 100 100 100 100
placebo hba1c 12 1 c1t1 test Single-Blind TRUE Placebo 16 16 CO Paired Student's t test 12 WK HbA1c Mean 8.2 percent 0.2 SE Mean 0.4 percent 0.2 SE Mean 8.6 percent 0.4 SE 66.7 61.0 YR
0 qam hba1c 12.0 1 c1t1 control Single-Blind True placebo Placebo 0 MG ORAL QAM TAB 16.0 16 CO Student T Test 12.0 WK HbA1c Mean 8.2 percent 0.2 SE Mean 0.4 percent 0.2 SE -0.024 0.824 Mean 8.6 percent 0.4 SE 7.752 9.448 Mean 4.878 66.7 61.0 YR
similarity 100 100 100 0 0 0 0 0 0 67 100 100 100 76 100 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 0 100 100 100 100 100 0 0 0 0 100 100 100 100 100 100 100
0.0 0 control Single-Blind True placebo Placebo 0 MG ORAL QAM TAB 16.0 16 CO Student T Test 0.0 WK HbA1c Mean 8.2 percent 0.2 SE Mean 0.0 percent Mean 8.2 percent 0.2 SE Mean 0.0 66.7 61.0 YR
dapagliflozin 10 qam hba1c 0.0 2 control Single-Blind True dapagliflozin SGLT2 10 MG ORAL QAM TAB 17.0 17 CO Student T Test 0.0 WK HbA1c Mean 8.2 percent 0.2 SE Mean 0.0 percent Mean 8.2 percent 0.2 SE Mean 0.0 68.8 66.3 YR

705_roden_2015¶

Control rows matched by test output: 4 of 4

Literature data accuracy: 67.40%

Clinical data accuracy: 77.33%

Clinical data accuracy (drop unmatched): 77.33%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
sitagliptin 100 oncedaily hba1c 76 6 c3t6 test Double-Blind TRUE Sitagliptin DPP-4 inhibitor 100 mg Oral Once daily 223 223 FAS ANCOVA LOCF 76 WK HbA1c Mean 7.85 percent 0.79 SD Adjusted Mean -0.53 percent 0.06 SE Adjusted Mean 7.34 percent 0.06 SE 63.2 55.1 YR
qd hba1c 76.0 3 c3t6 control Double-Blind Extension True sitagliptin DPP4 100 MG/DAY ORAL QD TAB 223.0 223 FAS ANCOVA LOCF 76.0 WK HbA1c Mean 7.85 percent 0.79 SD LS Mean -0.53 percent 0.06 SE -0.648 -0.412 LS Mean 7.34 percent 0.06 SE 7.222 7.458 LS Mean -6.732 63.2 55.1 YR
similarity 71 100 100 32 100 50 100 17 0 75 100 100 100 100 100 67 100 100 100 100 100 100 100 100 100 60 100 100 100 100 0 0 60 100 100 100 100 0 0 0 0 100 100 100 100 100 100 100
empagliflozin 25mg oncedaily hba1c 76 0 c2t0 test Double-Blind TRUE Empagliflozin SGLT2 inhibitor 25mg mg Oral Once daily 224 224 FAS ANCOVA LOCF 76 WK HbA1c Mean 7.86 percent 0.85 SD Adjusted Mean -0.76 percent 0.06 SE -1.04 -0.73 Adjusted Mean 7.12 percent 0.06 SE 64.7 53.8 YR
25 qd hba1c 76.0 2 c2t0 control Double-Blind Extension True empagliflozin SGLT2 25 MG/DAY ORAL QD TAB 224.0 224 FAS ANCOVA LOCF 76.0 WK HbA1c Mean 7.86 percent 0.85 SD LS Mean -0.76 percent 0.06 SE -0.878 -0.642 LS Mean 7.12 percent 0.06 SE 7.002 7.238 LS Mean -9.654 64.7 53.8 YR
similarity 71 100 100 50 67 50 100 17 0 75 100 100 100 100 100 67 100 100 100 100 100 100 100 100 100 60 100 100 100 100 44 44 60 100 100 100 100 0 0 0 0 100 100 100 100 100 100 100
10 oncedaily hba1c 76 3 c1t3 test Double-Blind TRUE Empagliflozin SGLT2 inhibitor 10 mg Oral Once daily 224 224 FAS ANCOVA LOCF 76 WK HbA1c Mean 7.87 percent 0.88 SD Adjusted Mean -0.65 percent 0.06 SE -0.94 -0.63 Adjusted Mean 7.22 percent 0.06 SE 63.4 56.2 YR
qd hba1c 76.0 1 c1t3 control Double-Blind Extension True empagliflozin SGLT2 10 MG/DAY ORAL QD TAB 224.0 224 FAS ANCOVA LOCF 76.0 WK HbA1c Mean 7.87 percent 0.88 SD LS Mean -0.65 percent 0.06 SE -0.768 -0.532 LS Mean 7.22 percent 0.06 SE 7.102 7.338 LS Mean -8.256 63.4 56.2 YR
similarity 71 100 100 50 100 50 100 17 0 75 100 100 100 100 100 67 100 100 100 100 100 100 100 100 100 60 100 100 100 100 44 67 60 100 100 100 100 0 0 0 0 100 100 100 100 100 100 100
placebo oncedaily hba1c 76 7 c0t7 test Double-Blind TRUE Placebo Once daily 228 228 FAS ANCOVA LOCF 76 WK HbA1c Mean 7.91 percent 0.78 SD Adjusted Mean 0.13 percent 0.06 SE Adjusted Mean 8.01 percent 0.06 SE 53.9 54.9 YR
0 qd hba1c 76.0 0 c0t7 control Double-Blind Extension True placebo Placebo 0 MG/DAY ORAL QD TAB 228.0 228 FAS ANCOVA LOCF 76.0 WK HbA1c Mean 7.91 percent 0.78 SD LS Mean 0.13 percent 0.06 SE 0.012 0.248 LS Mean 8.01 percent 0.06 SE 7.892 8.128 LS Mean 1.651 53.9 54.9 YR
similarity 71 100 100 0 0 0 0 17 0 75 100 100 100 100 100 67 100 100 100 100 100 100 100 100 100 60 100 100 100 100 0 0 60 100 100 100 100 0 0 0 0 100 100 100 100 100 100 100
empagliflozin 25mg oncedaily hba1c 76 2 test Double-Blind TRUE Empagliflozin SGLT2 inhibitor 25mg mg Oral Once daily 224 224 FAS-completers MMRM OC 76 WK HbA1c Mean 7.86 percent 0.85 SD LS Mean -0.76 percent 0.06 SE -1.04 -0.73 LS Mean 7.12 percent 0.06 SE 64.7 53.8 YR
1 test Double-Blind TRUE Empagliflozin SGLT2 inhibitor 25mg mg Oral Once daily 224 224 FAS MMRM OC 76 WK HbA1c Mean 7.86 percent 0.85 SD LS Mean -0.76 percent -1.04 -0.73 LS Mean 7.12 percent 64.7 53.8 YR
10 oncedaily hba1c 76 5 test Double-Blind TRUE Empagliflozin SGLT2 inhibitor 10 mg Oral Once daily 224 224 FAS-completers MMRM OC 76 WK HbA1c Mean 7.87 percent 0.88 SD LS Mean -0.65 percent 0.06 SE -0.94 -0.63 LS Mean 7.22 percent 0.06 SE 63.4 56.2 YR
4 test Double-Blind TRUE Empagliflozin SGLT2 inhibitor 10 mg Oral Once daily 224 224 FAS MMRM OC 76 WK HbA1c Mean 7.87 percent 0.88 SD LS Mean -0.65 percent -0.94 -0.63 LS Mean 7.22 percent 63.4 56.2 YR

2069_hattori_2018¶

Control rows matched by test output: 2 of 4

Literature data accuracy: 73.60%

Clinical data accuracy: 40.70%

Clinical data accuracy (drop unmatched): 81.41%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
empagliflozin 10 oncedaily hba1c 12 0 c3t0 test Open-Label TRUE Empagliflozin Sodium-glucose cotransporter-2 (SGLT2) inhibitor 10 mg Oral Once daily 58 58 ITT 12 WK HbA1c Mean 7.37 percent 1.34 SD Mean -0.49 percent 1.1 SD Mean 6.97 percent 0.94 SD Mean -5.4 38-74 YR
qd hba1c 12.0 3 c3t0 control Open-Label True empagliflozin SGLT2 10 MG/DAY QD 58.0 58 12.0 WK HbA1c Mean 7.37 percent 1.34 SD Mean -0.49 percent 1.1 SD Mean 6.97 percent 0.94 SD Mean -5.4
similarity 100 100 100 20 100 50 0 17 100 67 100 100 0 100 100 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 0
oncedaily hba1c 0 1 c2t1 test Open-Label TRUE Empagliflozin Sodium-glucose cotransporter-2 (SGLT2) inhibitor 10 mg Oral Once daily 58 58 ITT 0 WK HbA1c Mean 7.37 percent 1.34 SD Mean -0.49 percent 1.1 SD Mean 6.97 percent 0.94 SD Mean -5.4 38-74 YR
qd hba1c 0.0 2 c2t1 control Open-Label True empagliflozin SGLT2 10 MG/DAY QD 58.0 58 0.0 WK HbA1c Mean 7.37 percent 1.34 SD Mean 0.0 percent Mean 7.37 percent 1.34 SD Mean 0.0
similarity 100 100 100 20 100 50 0 17 100 67 100 100 0 100 100 50 100 100 100 100 100 100 100 100 100 100 57 100 0 0 100 100 100 50 100 50 100 100 100 100 33 100 100 100 100 100 0 0
placebo 0 qd hba1c 12.0 1 control Open-Label True placebo Placebo 0 MG/DAY QD 51.0 51 12.0 WK HbA1c Mean 6.91 percent 0.61 SD Mean 0.07 percent 0.37 SD Mean 6.95 percent 0.58 SD Mean 0.5
0.0 0 control Open-Label True placebo Placebo 0 MG/DAY QD 51.0 51 0.0 WK HbA1c Mean 6.91 percent 0.61 SD Mean 0.0 percent Mean 6.91 percent 0.61 SD Mean 0.0

1027_kashiwagi_2015¶

Control rows matched by test output: 2 of 2

Literature data accuracy: 72.33%

Clinical data accuracy: 72.22%

Clinical data accuracy (drop unmatched): 72.22%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
ipragliflozin;placebo oncedaily;oncedaily hba1c 24 1 c1t1 test Double-Blind TRUE Ipragliflozin; Placebo SGLT2 inhibitor Oral; Oral Once daily; Once daily 112; 56 56 FAS ANCOVA LOCF 24 WK HbA1c Mean 8.38 percent 0.738 SD Mean -0.87 percent 0.655 SD -1.501 -1.095 Mean 7.38 percent 0.712 SD 58.9; 58.9 56.2; 57.7 years; years
ipragliflozin 50 qd hba1c 24.0 1 c1t1 control Double-Blind True ipragliflozin SGLT2 50 MG/DAY QD 112.0 112 FAS LOCF 24.0 WK HbA1c Mean 8.25 percent 0.719 SD Mean -0.87 percent 0.655 SD -0.993 -0.747 Mean 7.38 percent 0.712 SD 7.247 7.513 Mean -10.545 58.9 56.2 YR
similarity 100 100 76 50 0 0 0 9 100 55 0 100 100 0 100 67 100 100 100 50 100 60 100 100 100 100 100 100 100 100 20 40 100 100 100 100 100 0 0 0 0 100 100 100 100 62 62 31
placebo oncedaily hba1c 24 3 c0t3 test Double-Blind TRUE Placebo Once daily 56 56 FAS ANCOVA LOCF 24 WK HbA1c Mean 8.38 percent 0.738 SD Mean 0.38 percent 0.703 SD Mean 8.76 percent 0.912 SD 58.9 57.7 YR
0 qd hba1c 24.0 0 c0t3 control Double-Blind True placebo Placebo 0 MG/DAY QD 56.0 56 FAS LOCF 24.0 WK HbA1c Mean 8.38 percent 0.738 SD Mean 0.38 percent 0.703 SD 0.192 0.568 Mean 8.76 percent 0.912 SD 8.516 9.004 Mean 4.535 58.9 57.7 YR
similarity 100 100 100 0 0 0 100 17 100 67 100 100 100 0 100 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 0 100 100 100 100 100 0 0 0 0 100 100 100 100 100 100 100
oncedaily hba1c 0 2 test Double-Blind TRUE Placebo Once daily 56 56 FAS ANCOVA LOCF 0 HbA1c Mean 8.38 percent 0.738 SD Mean 0.38 percent 0.703 SD Mean 8.76 percent 0.912 SD 58.9 57.7 YR
ipragliflozin;placebo oncedaily;oncedaily hba1c 0 0 test Double-Blind TRUE Ipragliflozin; Placebo SGLT2 inhibitor Oral; Oral Once daily; Once daily 112; 56 56 FAS ANCOVA LOCF 0 HbA1c Mean 8.38 percent 0.738 SD Mean 0.38 percent 0.703 SD 58.9; 58.9 56.2; 57.7 years; years

1783_pratley_2018¶

Control rows matched by test output: 5 of 5

Literature data accuracy: 72.53%

Clinical data accuracy: 75.96%

Clinical data accuracy (drop unmatched): 75.96%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
ertugliflozin;sitagliptin 15;100 oncedaily;oncedaily hba1c 52 13 c4t13 test Double-Blind TRUE ertugliflozin;sitagliptin SGLT2 inhibitor;DPP-4 inhibitor 15;100 mg;mg Oral;Oral Once daily;Once daily 244 244 mITT Least Square Means MMRM 52 WK HbA1c Mean 8.6 percent 1.0 SD LSMean -1.4 percent -1.5 -1.3 LSMean 7.0 percent 6.9 7.1 51.6 55.1 YR
qd;qd hba1c 52.0 4 c4t13 control Double-Blind Extension True ertugliflozin;sitagliptin SGLT2;DPP4 15;100 MG/DAY;MG/DAY ORAL QD;QD TAB;TAB 244.0 244 Treated Constrained Longitudinal Data Analysis 52.0 WK HbA1c Mean 8.6 percent 1.0 SD LS Mean -1.4 percent 95%CI -1.5 -1.3 LS Mean 7.18 percent LS Mean -16.317 51.639 55.1 YR
similarity 71 100 100 44 100 56 62 23 0 75 100 100 36 29 0 67 100 100 100 100 100 100 100 100 100 92 100 100 100 0 100 100 92 57 100 100 100 0 0 0 0 100 100 100 100 80 100 100
5;100 oncedaily;oncedaily hba1c 52 10 c3t10 test Double-Blind TRUE ertugliflozin; sitagliptin SGLT2 inhibitor; DPP-4 inhibitor 5; 100 mg; mg Oral; Oral Once daily; Once daily 243 243 mITT Least Square Means MMRM 52 WK HbA1c Mean 8.6 percent 1.0 SD LSMean -1.4 percent -1.5 -1.2 LSMean 7.0 percent 7.0 7.0 50.6 55.2 YR
qd;qd hba1c 52.0 3 c3t10 control Double-Blind Extension True ertugliflozin;sitagliptin SGLT2;DPP4 5;100 MG/DAY;MG/DAY ORAL QD;QD TAB;TAB 243.0 243 Treated Constrained Longitudinal Data Analysis 52.0 WK HbA1c Mean 8.6 percent 1.0 SD LS Mean -1.4 percent 95%CI -1.5 -1.2 LS Mean 7.18 percent LS Mean -16.317 50.617 55.2 YR
similarity 71 100 100 44 100 56 62 23 0 75 100 100 36 29 0 67 100 100 100 100 100 100 100 100 100 92 100 100 100 0 100 100 92 57 100 100 100 0 0 0 0 100 100 100 100 80 100 100
ertugliflozin15mg 15 oncedaily hba1c 52 2 c2t2 test Double-Blind TRUE ertugliflozin 15 mg SGLT2 inhibitor 15 mg Oral Once daily 248 248 mITT Least Square Means MMRM 52 WK HbA1c Mean 8.6 percent 1.0 SD LS Mean -0.9 percent -1.1 -0.8 LS Mean 7.4 percent 7.4 7.4 54.0 55.3 YR
ertugliflozin 15 qd hba1c 52.0 2 c2t2 control Double-Blind Extension True ertugliflozin SGLT2 15 MG/DAY ORAL QD TAB 248.0 248 Treated Constrained Longitudinal Data Analysis 52.0 WK HbA1c Mean 8.6 percent 1.0 SD LS Mean -0.9 percent 95%CI -1.1 -0.8 LS Mean 7.68 percent LS Mean -10.49 54.032 55.3 YR
similarity 71 100 81 50 100 50 100 17 0 75 100 100 36 29 0 67 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 57 100 100 100 0 0 0 0 100 100 100 100 80 100 100
ertugliflozin5mg 5 oncedaily hba1c 52 5 c1t5 test Double-Blind TRUE ertugliflozin 5 mg SGLT2 inhibitor 5 mg Oral Once daily 250 250 mITT Least Square Means MMRM 52 WK HbA1c Mean 8.6 percent 1.0 SD LS Mean -1.0 percent -1.1 -0.8 LS Mean 7.4 percent 7.3 7.5 50.8 55.1 YR
ertugliflozin 5 qd hba1c 52.0 1 c1t5 control Double-Blind Extension True ertugliflozin SGLT2 5 MG/DAY ORAL QD TAB 250.0 250 Treated Constrained Longitudinal Data Analysis 52.0 WK HbA1c Mean 8.6 percent 1.0 SD LS Mean -1.0 percent 95%CI -1.1 -0.8 LS Mean 7.58 percent LS Mean -11.655 50.8 55.1 YR
similarity 71 100 84 50 100 50 100 17 0 75 100 100 36 29 0 67 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 57 100 100 100 0 0 0 0 100 100 100 100 100 100 100
sitagliptin 100 oncedaily hba1c 52 8 c0t8 test Double-Blind TRUE sitagliptin DPP-4 inhibitor 100 mg Oral Once daily 247 247 mITT Least Square Means MMRM 52 WK HbA1c Mean 8.5 percent 1.0 SD LS Mean -0.8 percent -1.0 -0.7 LS Mean 7.3 percent 62.3 54.8 YR
qd hba1c 52.0 0 c0t8 control Double-Blind Extension True sitagliptin DPP4 100 MG/DAY ORAL QD TAB 247.0 247 Treated Constrained Longitudinal Data Analysis 52.0 WK HbA1c Mean 8.5 percent 1.0 SD LS Mean -0.8 percent 95%CI -1.0 -0.7 LS Mean 7.78 percent LS Mean -9.324 62.348 54.8 YR
similarity 71 100 100 32 100 50 100 17 0 75 100 100 36 29 0 67 100 100 100 100 100 100 100 100 100 100 100 100 100 0 100 100 100 57 100 100 100 100 100 0 0 100 100 100 100 80 100 100
oncedaily hba1c 26 7 test Double-Blind TRUE sitagliptin DPP-4 inhibitor 100 mg Oral Once daily 247 247 mITT Least Square Means MMRM 26 WK HbA1c Mean 8.5 percent 1.0 SD LS Mean -1.1 percent -1.2 -0.9 Mean 7.3 percent 1.1 SD 62.3 54.8 YR
0 6 test Double-Blind TRUE sitagliptin DPP-4 inhibitor 100 mg Oral Once daily 247 247 mITT Least Square Means MMRM 0 HbA1c Mean 8.5 percent 1.0 SD LS Mean -1.1 percent -1.2 -0.9 62.3 54.8 YR
ertugliflozin;sitagliptin 5;100 oncedaily;oncedaily hba1c 26 9 test Double-Blind TRUE ertugliflozin; sitagliptin SGLT2 inhibitor; DPP-4 inhibitor 5; 100 mg; mg Oral; Oral Once daily; Once daily 243 243 mITT Least Square Means MMRM 26 WK HbA1c Mean 8.6 percent 1.0 SD LSMean -1.5 percent -1.6 -1.4 LSMean 7.0 percent 7.0 7.0 50.6 55.2 YR
15;100 oncedaily;oncedaily hba1c 26 12 test Double-Blind TRUE ertugliflozin;sitagliptin SGLT2 inhibitor;DPP-4 inhibitor 15;100 mg;mg Oral;Oral Once daily;Once daily 244 244 mITT Least Square Means MMRM 26 WK HbA1c Mean 8.6 percent 1.0 SD LSMean -1.5 percent -1.6 -1.4 LSMean 7.0 percent 6.9 7.1 51.6 55.1 YR
0 11 test Double-Blind TRUE ertugliflozin;sitagliptin SGLT2 inhibitor;DPP-4 inhibitor 15;100 mg;mg Oral;Oral Once daily;Once daily 244 244 mITT Least Square Means MMRM 0 HbA1c Mean 8.6 percent 1.0 SD LS Mean 51.6 55.1 YR
ertugliflozin5mg 5 oncedaily hba1c 26 4 test Double-Blind TRUE ertugliflozin 5 mg SGLT2 inhibitor 5 mg Oral Once daily 250 250 mITT Least Square Means MMRM 26 WK HbA1c Mean 8.6 percent 1.0 SD LS Mean -1.0 percent 95% CI -1.1 -0.9 Mean 7.4 percent 0.9 SD 50.8 55.1 YR
0 3 test Double-Blind TRUE ertugliflozin 5 mg SGLT2 inhibitor 5 mg Oral Once daily 250 250 mITT Least Square Means MMRM 0 HbA1c Mean 8.6 percent 1.0 SD LS Mean -1.0 percent -1.1 -0.9 50.8 55.1 YR
ertugliflozin15mg 15 oncedaily hba1c 26 1 test Double-Blind TRUE ertugliflozin 15 mg SGLT2 inhibitor 15 mg Oral Once daily 248 248 mITT Least Square Means MMRM 26 WK HbA1c Mean 8.6 percent 1.0 SD LS Mean -1.1 percent 95% CI -1.2 -1.0 Mean 7.4 percent 1.0 SD 54.0 55.3 YR
0 0 test Double-Blind TRUE ertugliflozin 15 mg SGLT2 inhibitor 15 mg Oral Once daily 248 248 mITT Least Square Means MMRM 0 HbA1c Mean 8.6 percent 1.0 SD LS Mean -1.1 percent 95% CI -1.2 -1.0 54.0 55.3 YR

79_rosenstock_2013¶

Control rows matched by test output: 9 of 14

Literature data accuracy: 72.60%

Clinical data accuracy: 44.62%

Clinical data accuracy (drop unmatched): 69.41%

Test Output vs. Control Output and their Similarity¶

                ARM.BLIND ARM.RANDFLG ARM.TRT ARM.TRTCLASS ARM.DOSE ARM.DOSEU ARM.ROUTE ARM.REGIMEN ARM.FORMULATION N.ARM N.ARM.STATANAL N.ARM.EVENT.SUBJ STATANAL.POP STATANAL.METHOD STATANAL.IMP.METHOD ARM.TIME1 ARM.TIME1U ENDPOINT BSL.STAT BSL.VAL BSL.VALU BSL.VAR BSL.VARU BSL.LCI BSL.UCI CHBSL.STAT CHBSL.VAL CHBSL.VALU CHBSL.VAR CHBSL.VARU CHBSL.LCI CHBSL.UCI RSP.STAT RSP.VAL RSP.VALU RSP.VAR RSP.VARU RSP.LCI RSP.UCI PCHBSL.STAT PCHBSL.VAL PCHBSL.VAR PCHBSL.VARU PCHBSL.LCI PCHBSL.UCI ARM.PCT.MALE ARM.AGE ARM.AGEU
ARM.TRT ARM.DOSE ARM.REGIMEN ENDPOINT ARM.TIME1 primary_key match_key sample                                                                                                
empagliflozin 25 qd hba1c 12 5 c9t5 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 25 mg Oral QD 70 70 FAS ANCOVA LOCF 12 WK HbA1c Mean 8.1 percent 0.8 SD LS Mean -0.55 percent -0.70 -0.40 47 59 YR
12.0 9 c9t5 control Double-Blind True empagliflozin SGLT2 25 MG/DAY QD 70.0 70 FAS ANCOVA LOCF 12.0 WK HbA1c Mean 8.1 percent 0.8 SD LS Mean -0.55 percent 95%CI -0.7 -0.4 Mean 7.421 percent LS Mean -6.9 52.857 58.7 YR
similarity 100 100 100 50 100 50 0 100 100 67 100 100 100 100 100 67 100 100 100 100 100 100 100 100 100 0 0 0 100 0 0 0 73 22 100 100 100 0 0 0 0 100 100 100 100 25 33 100
10 qd hba1c 12 3 c7t3 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 10 mg Oral QD 71 71 FAS Linear ANCOVA modified LOCF 12 WK HbA1c Mean 7.9 percent 0.7 SD LS Mean -0.56 percent 95% CI -0.71 -0.41 LS Mean -0.56 percent 95% CI -0.71 -0.41 41 60 YR
12.0 7 c7t3 control Double-Blind True empagliflozin SGLT2 10 MG/DAY QD 71.0 71 FAS ANCOVA LOCF 12.0 WK HbA1c Mean 7.9 percent 0.7 SD LS Mean -0.56 percent 95%CI -0.71 -0.41 Mean 7.411 percent LS Mean -7.025 46.479 59.0 YR
similarity 100 100 100 50 100 50 0 100 100 67 100 100 100 63 47 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 73 22 100 100 0 0 0 0 0 100 100 100 100 25 33 100
sitagliptin 100 qd hba1c 12 2 c6t2 test Open-Label TRUE sitagliptin DPP-4 inhibitor 100 mg Oral QD 71 71 Treated ANCOVA 12 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean -0.45 percent -0.65 -0.25 54 58 YR
empagliflozin 10 qd hba1c 0.0 6 c6t2 control Double-Blind True empagliflozin SGLT2 10 MG/DAY QD 71.0 71 FAS ANCOVA LOCF 0.0 WK HbA1c Mean 7.9 percent 0.7 SD LS Mean 0.0 percent Mean 7.9 percent 0.7 SD LS Mean 0.0 46.479 59.0 YR
similarity 45 100 50 10 80 50 0 100 100 67 100 100 20 100 0 0 100 100 100 33 100 67 100 100 100 0 0 0 100 100 100 100 73 29 100 0 0 0 0 0 0 100 100 100 100 25 33 100
5 qd hba1c 12 4 c5t4 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 5 mg Oral QD 71 71 FAS Linear ANCOVA modified LOCF 12 WK HbA1c Mean 8.0 percent 0.7 SD LS Mean -0.23 percent 95% CI -0.39 -0.08 41 60 YR
12.0 5 c5t4 control Double-Blind True empagliflozin SGLT2 5 MG/DAY QD 71.0 71 FAS ANCOVA LOCF 12.0 WK HbA1c Mean 8.0 percent 0.7 SD LS Mean -0.23 percent 95%CI -0.39 -0.08 Mean 7.741 percent LS Mean -2.885 40.845 59.7 YR
similarity 100 100 100 50 100 50 0 100 100 67 100 100 100 63 47 67 100 100 100 100 100 100 100 100 100 0 0 0 100 0 0 0 73 22 100 100 0 0 0 0 0 100 100 100 100 25 0 100
1 qd hba1c 12 6 c3t6 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 1 mg Oral QD 71 71 FAS Linear ANCOVA modified LOCF 12 WK HbA1c Mean 7.8 percent 0.7 SD LS Mean -0.09 percent 95% CI -0.24 0.07 58 57 YR
12.0 3 c3t6 control Double-Blind True empagliflozin SGLT2 1 MG/DAY QD 71.0 71 FAS ANCOVA LOCF 12.0 WK HbA1c Mean 7.8 percent 0.7 SD LS Mean -0.09 percent 95%CI -0.24 0.07 Mean 7.881 percent LS Mean -1.129 57.746 57.4 YR
similarity 100 100 100 50 100 50 0 100 100 67 100 100 100 63 47 67 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 0 0 0 100 100 100 100 0 0 100 100 100 100 25 67 100
placebo qd hba1c 12 7 c1t7 test Double-Blind TRUE Placebo QD 71 71 FAS linear ANCOVA modified LOCF 12 WK HbA1c Mean 8.0 percent 0.7 SD LS Mean 0.15 percent 0.00 0.30 LS Mean 0.15 percent 0.00 0.30 47 60 YR
0 qd hba1c 12.0 1 c1t7 control Double-Blind True placebo Placebo 0 MG/DAY QD 71.0 71 FAS ANCOVA LOCF 12.0 WK HbA1c Mean 8.0 percent 0.7 SD LS Mean 0.15 percent 95%CI 0.0 0.3 Mean 8.121 percent LS Mean 1.882 46.479 59.7 YR
similarity 100 100 100 0 0 0 100 100 100 67 100 100 100 63 47 67 100 100 100 100 100 100 100 100 100 100 100 100 100 0 86 86 73 22 100 100 100 0 0 0 0 100 100 100 100 50 0 100
sitagliptin 100 qd hba1c 12 0 c13t0 test Open-Label TRUE sitagliptin DPP-4 inhibitor 100 mg Oral QD 71 71 25 FAS Linear ANCOVA Modified LOCF 12 WK HbA1c Mean 8.1 percent 0.9 SD LSMean -0.45 percent -0.65 -0.25 LSMean 54 58 YR
12.0 13 c13t0 control Open-Label True sitagliptin DPP4 100 MG/DAY QD 71.0 71 FAS ANCOVA LOCF 12.0 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean -0.45 percent 95%CI -0.65 -0.25 Mean 7.521 percent LS Mean -5.645 53.521 57.6 YR
similarity 100 100 100 32 100 50 0 100 100 67 100 0 100 63 47 67 100 100 100 100 100 100 100 100 100 92 100 100 100 0 100 100 80 0 0 100 100 100 100 0 0 100 100 100 100 25 33 100
12 1 c12t1 test Open-Label TRUE sitagliptin DPP-4 inhibitor 100 mg Oral QD 71 71 24 FAS Logistic regression Classical LOCF 12 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean -0.45 percent -0.65 -0.25 54 58 YR
0.0 12 c12t1 control Open-Label True sitagliptin DPP4 100 MG/DAY QD 71.0 71 FAS ANCOVA LOCF 0.0 WK HbA1c Mean 8.1 percent 0.9 SD LS Mean 0.0 percent Mean 8.1 percent 0.9 SD LS Mean 0.0 53.521 57.6 YR
similarity 100 100 100 32 100 50 0 100 100 67 100 0 100 16 44 0 100 100 100 100 100 100 100 100 100 0 0 0 100 100 100 100 73 29 100 0 0 0 0 0 0 100 100 100 100 25 33 100
empagliflozin 50 qd hba1c 12 8 c11t8 test Double-Blind TRUE empagliflozin SGLT2 inhibitor 50 mg Oral QD 70 70 34 FAS Linear ANCOVA Modified LOCF 12 WK HbA1c Mean 8.1 percent 0.8 SD LS Mean -0.56 percent 95% CI -0.70 -0.40 53 59 YR
12.0 11 c11t8 control Double-Blind True empagliflozin SGLT2 50 MG/DAY QD 70.0 70 FAS ANCOVA LOCF 12.0 WK HbA1c Mean 7.9 percent 0.7 SD LS Mean -0.49 percent 95%CI -0.64 -0.33 Mean 7.481 percent LS Mean -6.147 55.714 55.9 YR
similarity 100 100 100 50 100 50 0 100 100 67 100 0 100 63 47 67 100 100 100 33 100 67 100 100 100 0 0 0 100 0 0 0 73 22 100 100 0 0 0 0 0 100 100 100 100 25 67 100
placebo 0 qd hba1c 0.0 0 control Double-Blind True placebo Placebo 0 MG/DAY QD 71.0 71 FAS ANCOVA LOCF 0.0 WK HbA1c Mean 8.0 percent 0.7 SD LS Mean 0.0 percent Mean 8.0 percent 0.7 SD LS Mean 0.0 46.479 59.7 YR
empagliflozin 50 qd hba1c 0.0 10 control Double-Blind True empagliflozin SGLT2 50 MG/DAY QD 70.0 70 FAS ANCOVA LOCF 0.0 WK HbA1c Mean 7.9 percent 0.7 SD LS Mean 0.0 percent Mean 7.9 percent 0.7 SD LS Mean 0.0 55.714 55.9 YR
5 qd hba1c 0.0 4 control Double-Blind True empagliflozin SGLT2 5 MG/DAY QD 71.0 71 FAS ANCOVA LOCF 0.0 WK HbA1c Mean 8.0 percent 0.7 SD LS Mean 0.0 percent Mean 8.0 percent 0.7 SD LS Mean 0.0 40.845 59.7 YR
25 qd hba1c 0.0 8 control Double-Blind True empagliflozin SGLT2 25 MG/DAY QD 70.0 70 FAS ANCOVA LOCF 0.0 WK HbA1c Mean 8.1 percent 0.8 SD LS Mean 0.0 percent Mean 8.1 percent 0.8 SD LS Mean 0.0 52.857 58.7 YR
1 qd hba1c 0.0 2 control Double-Blind True empagliflozin SGLT2 1 MG/DAY QD 71.0 71 FAS ANCOVA LOCF 0.0 WK HbA1c Mean 7.8 percent 0.7 SD LS Mean 0.0 percent Mean 7.8 percent 0.7 SD LS Mean 0.0 57.746 57.4 YR